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Introduction 9
INTRODUCTION
The technique of Isolated Limb Perfusion (ILP) was pioneered by Creech and Kre-
mentz at Tulane University in New Orleans 1 and first applied in a patient with 
extensive melanoma metastases on the lower limb. The principle idea was that direct 
administration of a chemotherapeutic agent to the area to be treated by intra-arterial 
infusion would sort out in the maximum effect. However, venous return should be 
blocked to prevent the agents from entering the systemic circulation. The method 
of ILP was thus developed to be able to achieve regional concentrations of chemo-
therapeutic agents that are 15 to 25 times higher than can be reached with systemic 
administration, but without the systemic side-effects 2.
A perfusion circuit is achieved by canulating the major artery and vein of a limb 
and connect these catheters to a pump oxygenator, thus creating extracorporeal 
circulation (figure 1). Further isolation of the limb from the corporeal circulation 
is guaranteed by the use of a tourniquet just proximal to the catheter tips. This 
revolutionary technique enables a locoregional therapy approach to tumours located 
in the extremity that fail other treatment options. Since the report of its effect in the 
treatment of melanoma in mice 3, and because of the favourable local toxicity profile 
of the drug, melphalan (L-phenylalanine mustard) is used as the standard chemo-
therapeutic agent in the ILP setting. Melphalan is commonly used in doses of 10 
mg/L perfused tissue for a leg and 13 mg/L for an arm 4. As cancer cells were known 
to be selectively susceptible to high temperatures, hyperthermia was introduced in 
the ILP setting 5. The now most commonly used technique of mild hyperthermia 
for ILP was described shortly hereafter 6. A new era in the treatment of extremity 
cancer began in 1988, when the cytokine Tumour Necrosis Factor-alpha (TNF) was 
introduced in ILP as not only tumour cells, but also the tumour vasculature, became 
target for therapy 7.
 
TNF was isolated as an endogenous factor, especially active in inflammation, with 
necrotizing ability on tumour cells 8. Later studies revealed that TNF has a dual 
mechanism of action: high-dose TNF has a direct cytotoxic impact to tumour cells 9, 
but more importantly the TNF effect on the so called tumour associated vasculature 
induces a rapid change in tumour morphology 10. These observations led to high ex-
pectations on this cytokine in anti-tumour therapy, but systemic application was very 
disappointing. TNF turned out to be a potent mediator in septic shock and therefore 
the systemic side-effects (acute drop in vascular resistance leading to low blood 
pressure rates, fever etc.) were the major factors hindering systemic application of 
this cytokine 11. The maximum tolerated dose of TNF in humans turned out to be 10 
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to 50 times lower than needed for anti-tumour effects in murine models 12, so that 
systemic, but also intralesional administration of TNF was not clinically applicable. 
2
Figure 1: Isola ed Limb Perfusion Circuit
However, the concept of ILP combines the advantages of the TNF anti-tumour activity with
the avoidance of systemic effects. The cytotoxic effects of TNF are known to be enhanced in
hyperthermic conditions 13 and with the addition of alkylating chemotherapeutics 14, both
prerequisites already existing in the ILP model. The antivascular effects of TNF (a
haemorrhagic necrosis of the tumour as a result of destruction of the tumour associated
vasculature) were demonstrated in both histopathologic and angiographic studies 15, 16. The
application of TNF in the ILP setting was further studied in the preclinical setting. It turned
out that for effective ILP a minimum duration of ILP of 30 minutes is required. The perfusion
temperature should be above 38˚C for maximum effect, but should not exceed 42˚C in order
to avoid unacceptable toxicity to the normal tissue 17. TNF was shown to act synergisticly
with melphalan by enhancing its uptake in tumour cells (but not in normal tissue) six fold 18.
Hypoxia, although enhancing the effect of melphalan activity and TNF activity alone, did not
further enhance the synergistic effect of the combination of TNF and melphalan 17. These
studies form the basis of the clinical application of TNF-based ILP in both melanoma and
sarcoma patients.
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Figure 1: Isolated Limb Perfusion Circuit
However, the concept of ILP combines the advantages of the TNF anti-tumour activity 
with the avoidance of systemic effects. The cytotoxic effects of TNF are known to be 
enhanced in hyperth rmic conditions 13 and with the addition of alkylating chemo-
therapeutics 14, both prerequisites already existing in the ILP model. The antivascular 
effects of TNF (a haemorrhagic necrosis of the tumour as a result of destruction of 
the tumour associated vasculature) were demonstrated in both histopathologic and 
angiographic studies 15, 16. The application of TNF in the ILP setting was further stud-
ied in the preclinical setting. It turned out that for effective ILP a minimum duration 
of ILP of 30 minutes is required. The perfusion temperature should be above 38˚C for 
maximum effect, but should not exceed 42˚C in order to avoid unacceptable toxic-
ity to the normal tissue 17. TNF was shown to act synergisticly with melphalan by 
enhancing its uptake in tumour cells (but not in normal tissue) six fold 18. Hypoxia, 
although enhancing the effect of melphalan activity and TNF activity alone, did not 
further enhance the synergistic effect of the combination of TNF and melphalan 17. 
These studies form the basis of the clinical application of TNF-based ILP in both 
melanoma and sarcoma patients. 
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ILP FOR MELANOMA
Since the introduction of the ILP principle, melphalan ILPs were performed with 
very satisfactory results in melanoma patients, taken into account the disappoint-
ing response rates of this tumour on systemic chemotherapy. However, since TNF 
is applied in ILP, it has been used increasingly in combination with melphalan for 
the treatment of melanoma in-transit metastases (IT-mets). An early report on TNF-
based ILPs from 4 centers in Europe showed a significant increase in CR rate up to 
90% compared to a 52% CR rate after ILPs in these centers with melphalan alone 19. 
Both clinical observations and an interim analysis of a randomised controlled trial 
performed in the USA 20 gave indications that the benefit of TNF as an adjunct to mel-
phalan is especially appreciable in patients with large lesions. The special indication 
for ILP with both TNF and melphalan (TM-ILP) is therefore the patient with bulky 
melanoma IT-mets or the patient that has failed prior ILP with melphalan alone.
In our institution, 100 consecutive TM-ILPs for melanoma were performed between 
1991 and 2003. Part I of this thesis describes the results of these 100 procedures. We 
determine prognostic factors for response, recurrence and survival and then focus 
on the very specific population of patients qualifying for a repeat ILP for recurrence 
of IT-mets after previous ILP, either with TNF and melphalan or with melphalan 
alone. 
ILP FOR SOFT TISSUE SARCOMA
Soft Tissue Sarcoma (STS) of the limb is the second major indication for TM-ILP. In 
contrast to high response rates in melanoma patients, the results of melphalan-alone 
perfusions in STS patients were uniformly disappointing 21, 22. The initial study of 
TNF in ILP however reported not only high response rates in melanoma patients, 
but also in 4 patients with advanced extremity STS 7. This led to multicenter studies 
evaluating response- and limb salvage rates using TNF-based ILPs with or without 
Interferon-gamma, showing consistently overall response rates of 75- 85% and limb 
salvage in a similar percentages of the patients 16, 23. These results led to the ap-
proval of TNF in Europe 24. At present, TNF-based ILP for extremity STS is used as 
induction biochemotherapy to obtain local control and to make limb-sparing surgery 
possible. 
The database of the Erasmus MC - Daniel den Hoed Cancer Center on TM-ILP for STS 
contains 217 procedures performed between 1991 and 2003 and is the largest single-
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institution database worldwide. In part II of this thesis, the outcome of the patients 
with locally advanced extremity STS is studied. We identify prognostic factors for 
response and (recurrence-free) survival and we explore the possible application 
of TM-ILP in specific STS patient categories that are typically difficult to treat with 
limb-sparing surgery: patients who present with multifocal STS and patients who are 
previously treated with high-dose radiotherapy on the affected limb. A third patient 
category is formed by patients with desmoid tumours or aggressive fibromatosis as 
this type of STS can cause locally disabling disease but does not have the propensity 
to develop systemic metastases. ILP can provide shrinkage of the tumours, which 
can make a resection possible and can thus provide long-lasting local control. 
GENERAL QUESTIONS IN ILP
The development of TM-ILP has led to several questions regarding the clinical use 
of this treatment modality. It is well accepted that patients with locally advanced 
disease of the limb, both melanoma and STS, are candidates for ILP, as the local 
situation in the extremity often prompts for treatment. On the other hand, both 
melanoma and STS are tumours with poor prognosis once the disease has spread 
systemically. This last patient category, staged as stage IV in the AJCC classifications, 
can however qualify for ILP as the local situation is disabling to an extent that the 
quality of life in the terminal life phase is severely threatened. This discussion is 
based both on patient-related arguments (whether the patient should be offered 
such an invasive treatment with possibly lethal systemic side-effects), but has also an 
economic part, since TM-ILP is a costly procedure. These last two issues can possibly 
be partly overcome by a reduction of TNF in TM-ILP. In part III of this thesis we give 
an answer to these clinical questions by retrospectively investigating our database on 
all TM-ILPs in Rotterdam. This will give the introduction to the general discussion on 
the indications and results of TNF-based Isolated Limb Perfusion. 
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PART I
TNF-based ILP for Melanoma Patients
I

CHAPTER 2
100 Consecutive Isolated Limb Perfusions 
With TNF-α and Melphalan in Melanoma 
Patients with Multiple In-Transit Metastases
Dirk J. Grünhagen MD1,Flavia Brunstein MD1, 
Wilfried J. Graveland MSc2, Albertus N. van Geel MD 
PhD1, Johannes H.W. de Wilt MD PhD1, Alexander 
M.M. Eggermont MD PhD1
Ann Surg. 2004 Dec;240(6):939-47
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ABSTRACT
Objective 
The aim of this study is to describe the experience with 100 TNF-based isolated limb 
perfusions (ILP) for locally advanced melanoma and to determine prognostic factors 
for response, time to local progression and survival.
Methods
One hundred TNF-based ILPs were performed between 1991 and 2003 in 87 patients 
for whom local control by surgery of in-transit melanoma metastases was impossible. 
In total, 62 iliac, 33 femoral and 5 axillary ILPs were performed in mild hyperthermic 
conditions with 2 to 4 mg of TNF and 10 to 13 mg melphalan/L limb volume.
Results
Overall response was 95%, with 69% complete response, 26% partial response and 
5% no change. Complete response rate differed significantly for patients with IIIA 
disease versus IIIAB and IV. Local and systemic toxicity was mild to moderate in 
almost all cases, with no treatment-related death and one treatment-related amputa-
tion. Five-year overall survival was 32%; local progression occurred in 55% after a 
median of 16 months. In complete response patients, 5-year survival was 42% with 
local progression in 52% at a median of 22 months. Response rate and survival were 
significantly influenced by stage of disease; (local progression free) survival was 
influenced by response rate.
Conclusions
TNF-based ILP results in excellent response rates in this patient population with un-
favourable characteristics. Response on ILP predicts outcome in patients and reflects 
aggressiveness of the tumour.
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INTRODUCTION
In-transit metastases (IT-mets) occur in approximately 5% to 8% of the patients with 
high-risk melanoma. The management of IT-mets remains a challenge because it is 
dictated by the biologic behaviour of melanoma, especially in terms of number and 
size of the lesions 1. Simple wide surgical excision is often possible if IT-mets are 
limited in size and number, but fails when interval periods between new lesions are 
short, when numerous or bulky lesions are present and when various treatment mo-
dalities, e.g. radiotherapy, have preceded surgery. Apart from local control, melanoma 
is virtually refractory to all systemic treatments. Therefore, various locoregional ap-
proaches have been proposed and investigated. Isolated limb perfusion, developed 
in 1958 by Creech and Krementz 2, is the most effective regional treatment modality, 
as it achieves tissue concentrations in the affected limb of the chemotherapeutic 
agents that are more than 20 times higher than what can be achieved systemically 3. 
Melphalan (L-phenylalanine mustard, L-PAM) has been used as standard drug over 
the years due to its efficacy and toxicity profile 4. Melphalan-based ILP for melanoma 
IT-metastases is associated with Complete Response (CR) rates of 40% to 50% and 
overall response rates of 75% to 80% 1. Hyperthermia may increase the response 
rates somewhat, but at the cost of increased locoregional toxicity. Large melanoma 
lesions are difficult to eradicate because of poor and inhomogeneous drug uptake as 
with soft tissue sarcomas. Therefore, ILP programs with melphalan alone have been 
abandoned for treating irresectable soft tissue sarcomas 5. The application of Tumour 
Necrosis Factor alpha (TNF) 6 changed this situation dramatically because very large 
tumours were now observed to respond very well 7, which led to successful multi-
center trials in Europe and the approval of TNF-α for the treatment of irresectable 
extremity soft tissue sarcomas 8. 
TNF has also been used increasingly in combination with melphalan for the treat-
ment of melanoma IT-mets in ILP. An early report on TNF-based ILPs from 4 centers 
in Europe showed a significant increase in CR rate up to 90% compared with a 52% 
CR rate after ILPs in these centers with melphalan alone 9. The success of TNF in the 
treatment of large soft tissue sarcomas made the investigators aware early on that 
TNF also improved results in particular in melanoma patients with bulky lesions. 
Importantly, this clinical observation of efficacy in large tumours has been explained 
by observations in our laboratory in the experimental isolated perfusion setting in 
rats with advanced limb tumours. In contrast to the poor drug uptake of melphalan 
after an ILP with melphalan alone by these large tumours, it was shown that TNF 
increased the uptake of melphalan selectively in the tumour by a factor 3 to 6 in 
comparison to an ILP with melphalan alone 10. 
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We report here on our experience with 100 TNF-based ILPs in patients with multiple 
melanoma IT-metastases. We have analysed the data in this large group to determine 
prognostic factors for response such as stage of disease, size and number of lesions, 
local recurrence-free interval, and efficacy after failing other treatments. 
PATIENTS AND METHODS
Patients
Between 1991 and 2003, 100 TNF and melphalan (TM)-ILPs were performed in 87 
patients with multiple in-transit melanoma metastases in the limb. Demographic 
data, disease presentation at time of ILP and ILP characteristics were obtained from 
a prospectively maintained database. Patients were staged according to the MD An-
derson staging system 11 and presented with stage IIIA disease in 45, stage IIIAB in 
41 and stage IV in 14 cases. In all cases, local control by simple surgical excision 
was impossible due to bulky disease, which is illustrated by the size of the tumours 
(48 < 40 mm, 52 ≥ 40 mm) and the number of lesions (<10 lesions in 43 patients, 
10-50 lesions in 32 and >50 lesions in 25 patients). Besides surgical excision of 
resectable tumours, 59 patients did not undergo other treatment modalities prior 
to ILP, whereas 41 patients were previously treated with systemic chemotherapy, 
radiotherapy, ILP with any chemotherapeutic, immunotherapy or a combination of 
the above-mentioned modalities. Patient and tumour characteristics are summarized 
in table 1.
Treatment
All patients underwent an ILP via the axillary (n=5), iliac (n=62) or femoral (n=33) 
approach. The method of ILP is described in detail previously 8. In short: isolation 
of the limb is achieved by clamping and canulation of the major artery and vein, 
connection to an oxygenated extracorporeal circuit, ligation of collateral vessels and 
application of a tourniquet proximal to the site of perfusion. Once tissue tempera-
ture has reached 38°C, recombinant TNF (Boehringer Ingelheim GmbH, Ingelheim/
Rhein, Germany) is administered via the arterial line in a dose of 2 to 4 mg. Tissue 
temperatures are stabilized between 38°C and 39.5°C and leakage monitoring is 
performed by using a precordial scintillation probe to detect leakage of radiolabelled 
albumen injected to the perfusion circuit 12. After 30 minutes, melphalan (L-PAM, 
Alkeran, Wellcome Ltd., London, UK) is added to the perfusate in a dose of 10 mg/L 
for leg and 13 mg/L for arm perfusions. In 23 ILPs, performed between 1991 and 
1994, interferon γ (IFN) was added to the schedule according to trial prescriptions 
consisting of the subcutaneous injection of 0.2 mg IFN on days –2 and –1 prior to 
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the ILP and the injection of 0.2 mg IFN during the ILP procedure into the arterial 
line prior to the administration of TNF. Median dose of melphalan was 89.2 mg 
(mean 94.5, range 39-140), median dose of TNF was 4 mg (mean 3.69, range 2-4) 
and all 23 IFN-ILPs were performed with 0.2 mg IFN. At the end of the perfusion 
period, a washout procedure using 2-4 L of a dextrane and/or electrolyte solution is 
performed. In patients undergoing an iliac perfusion, an iliac lymph node dissection 
is performed; an axillary lymph node dissection is performed in patients undergoing 
an axillary ILP. In patients with palpable nodal disease in the groin an ilio-inguinal 
lymph node dissection is performed in the same operative session as the ILP but 
before executing the ILP.
Evaluation of response and toxicity
Acute local toxicity of the ILP procedure was classified according to Wieberdink et 
al. 13 in the following manner: (I) no reaction; (II) slight erythema or edema; (III) 
considerable erythema or edema with some blistering, slightly disturbed motility 
Table 1
Patient and tumour characteristics of 87 patients undergoing 100 TM-ILPs
Characteristics No. of patients
Sex Female 60 (69%)
Male 27 (31%)
Age (years), median+range 62 (25-90)
Stage IIIA 45
IIIAB 41
IV 14
Location Arm 5
Leg 95
No. of tumours <10 43
10-50 32
>50 25
Size of largest lesion (mm) <40 mm 48
≥ 40 mm 52
Prior treatment None 59
XRT 4
CT 8
ILP 21
Immuno 3
Combination 5
TM-ILP=isolated limb perfusion with tumour necrosis factor and melphalan XRT=radiotherapy, CT=chemotherapy, ILP=isolated limb 
perfusion, Immuno=immunotherapy
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permissible; (IV) extensive epidermolysis or obvious damage to the deep tissues, 
causing definite functional disturbance; and threatening or manifest compartmental 
syndrome, and (V) reaction that may necessitate amputation. Response evaluation 
was performed 2 to 4 weeks and 8 weeks after ILP by clinical examination, and after 
that at 3-month regular intervals for the first 2 years and at longer intervals hereafter. 
Response rates were reported according to WHO criteria 14, in which complete re-
sponse (CR) is the complete disappearance of all lesions and no new areas of disease 
appearing within the field of ILP. Partial response (PR) is defined as a reduction of 
50-99% of the total tumour size; no change (NC) is recorded if <50% of the total 
tumour size responds. 
Recurrence of tumour within the extremity after a CR, or progression of the le-
sions and the appearance of new lesions after a PR or after NC, is reported as local 
progression. 
Statistical evaluation
Overall survival (OS) and time to local/systemic progression (TTLP/TTSP) were de-
fined as time from ILP to death, local progression and systemic progression respec-
tively and estimates were made using the method of Kaplan and Meier 15. Disease 
free survival (DFS) is defined as time from CR to local progression, systemic progres-
sion or death, whichever occurs first. We evaluated the prognostic value of some 
baseline factors for these three endpoints (TTLP/TTSP and OS) with Cox regression. 
The hazard ratio belonging to each factor in table 3 is defined as the hazard of the 
second category divided by the hazard in the first category. We also evaluated the 
Table 2
Local toxicity
Wieberdink12 Grade I Grade II Grade III Grade IV Grade V
15% 54% 27% 3% 1%
Systemic toxicity
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Neurologic* 93% 7% 0% 0% 0%
Liver* 98% 0% 2% 0% 0%
Renal* 99% 0% 1% 0% 0%
Haematologic* 99% 0% 0% 0% 1%
<38°C 38-39°C 39-40°C >40°C, <24 hrs >40°C, >24 hrs
Temp 37% 26% 31% 6% 0%
Absent Present
Shock& 98% 2%
Hrs=hours, *= WHO criteria13, &= support of vasopressors needed
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prognostic value of some baseline factors on achievement of CR using logistic re-
gression. The odds ratio of each factor is the odds of CR achievement in the second 
category divided by the odds of CR achievement in the first category. The prognostic 
factors that we included were: sex, age, site of tumour, stage of disease, size of larg-
est lesion and number of lesions. This list represents all previously reported studies 
on prognostic factors after ILP 16-21. After univariate analysis, all these factors were 
included in a multivariate model. We used a stepwise backward algorithm in order 
to exclude factors without prognostic value with a significance level of 5%. After 
obtaining the final model, we evaluated the additional prognostic value of complete 
response after perfusion. However, it must be noted that a prognostic model with 
response on perfusion applies only to patients after perfusion, whereas the model 
without response on perfusion can also be applied to patients before perfusion. All 
tests were done at a significance level of 5%.
RESULTS
Sixty female and 27 male patients with a median age of 62 years (mean 61, range 
25-90) had multiple IT-mets in upper (n=5) or lower (n=95) extremity. A TM-ILP 
was performed to achieve local control in all 87 patients; 26 ILPs were performed 
in patients who had undergone one or multiple ILPs previously during the course 
Table 3
Univariate analysis of clinical prognostic factors for CR achievement, local progression and survival
Variable CR Local progression Survival
OR (p-value) HR (p-value) HR (p-value)
Sex (female* vs. male) 0.56 (0.20) 1.04 (0.91) 1.89 (0.02)
Age (≤ 60* vs. >60) 0.74 (0.50) 1.56 (0.11) 1.49 (0.11)
Location of lesions (three strata: Lower 
arm/leg* vs. Upper arm/leg1 vs. Total limb2)
0.68 (0.49)1   1.66 
(0.35)2 0.82 (0.62)1  0.80 (0.49)2 1.04 (0.92)1  0.87 (0.64)2
Stage of disease (three strata: IIIA* vs. IIIAB1 
vs. IV2)
0.37 (0.05)1   0.16 
(0.006)2 1.54 (0.13)1  0.78 (0.69)2
1.96 (0.01)1  9.78 
(<0.001)2
Size of largest lesion (Ø<4 cm* vs. ≥ 4 cm) 0.58 (0.21) 1.08 (0.78) 2.01 (0.005)
Number of lesions (<10* vs. ≥ 10) 0.64 (0.31) 2.85 (0.001) 0.96 (0.86)
IFN (no* vs. yes) 1.84 (0.27) 0.82 (0.52) 0.58 (0.08)
Prior ILP treatment (no* vs. yes) 1.30 (0.60) 1.34 (0.31) 0.57 (0.06)
Date of perfusion (1st 50 ILPs* vs. 2nd 50) 0.35 (0.02) 1.86 (0.02) 1.62 (0.07)
CR achieved (no* vs. yes) n.a. 0.25 (<0.001) 0.27 (<0.001)
*=reference group, CR=complete response, OR=Odds Ratio, HR=Hazard Ratio, IFN=interferon gamma, n.a.=not applicable
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of their disease either in our institution (n=13, TM-ILPs) or in the referring hospital 
(n=13). In total, 100 TNF-based ILPs +/- IFN were performed in our institution. 
Leakage and toxicity
There was no or minor leakage of the drugs in 93 ILPs (median leakage 0%). Eight 
ILPs had leakage percentages of 10% to 32%. Toxicity in these 8 cases was limited 
to transient hypotension in 2 patients for which vasopressor support was given; in 
1 patient a grade IV leucopenia was observed that lasted only for 1 day and that 
did not need any type of intervention. Local toxicity after ILP was mild to moder-
ate (Wieberdink grade II-III) in 81%. A Wieberdink I (no reaction) was seen after 
15 procedures and in 3 patients a grade IV local toxicity occurred, with the need 
of performing a fasciotomy in 1 patient. One patient with IT-mets in the lower leg 
experienced extensive rhabdomyolysis of the upper leg necessitating an amputation. 
This reaction was classified as Wieberdink grade V (table 2).
Response rates and limb function
The overall response rate was 95%, with 69 CRs (69%), 26 PRs (26%) and 5 NCs (5%). 
The proportion of patients reaching CR presenting with stage IIIA disease (82%) 
differed from those presenting with stage IIIAB (63%) and stage IV disease (43%) 
(table 3). These differences showed a significant correlation between CR and stage 
of disease (IIIA vs. IIIAB, p=0.053; IIIA vs. IV, p=0.004; IIIAB vs. IV, p=0.184). Limb 
function was assessed in all 87 patients and was unaffected with respect to standard 
daily activities in 84 of them. One case of moderate function loss was recorded, and 
two amputations had to be performed: one because of a Wieberdink grade V local 
toxicity (see above) and 1 because of severe arteriosclerosis, which requested a 
below-knee amputation more than 1 year after the ILP.
Local progression
Local progression occurred after 55 ILPs (55%), at a median time of 16 months. 
Median TTLP of patients after CR was 22 months versus 6 months for patients after 
PR or NC (p<0.001) (figure 1). There was more rapid progression of disease in pa-
tients with a high (≥10) number of IT-mets (p=<0.001), consistent in both uni- and 
multivariate analysis (tables 3+4, figure 2). No difference in TTLP was observed for 
stage IIIA vs. stage IIIAB patients (p=0.12)
Systemic progression
During follow-up, systemic progression occurred after 71 ILPs. Median time to sys-
temic progression (TTSP) was 14 months and differed significantly between stage 
IIIA (55 months) and stage IIIAB (9 months, p<0.001) patients (figure 3). Other prog-
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nostic factors for systemic progression included sex (p<0.001), size of the largest le-
sion (p<0.001), prior ILP treatment (p=0.003) and ILP response (p<0.001). Prognostic 
factors for systemic progression were consistent with prognostic factors for survival
Survival
The overall actuarial 5-year survival rate was 32% (±5, SE); median survival was 25 
months. Survival was influenced by stage of disease, sex, size of the largest tumour 
and previous ILP-treatment (table 3). After multivariate analysis, stage of disease and 
Figure 1: Time to local progression (TTLP) by response on ILP 
X-axis: time in months, Y-axis: cumulative proportion, ILP=isolated limb perfusion, CR=complete response, PR/NC=partial response/no change
Figure 2: Time to local progression (TTLP) by no. of lesions 
X-axis: time in months, Y-axis: cumulative proportion
Time to local progression(TTLP) by response on ILP 
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age of the patient remained prognostic variables for survival. (Table 4, figure 4). 
Disease free survival was estimated for stage IIIA/IIIAB patients. At three years, DFS 
was 16% and was significantly different between stage IIIA (32%) and IIIAB (0%, 
p=0.008) patients.
When the achievement of CR after ILP was added to the prognostic factor analysis 
in the multivariate model, it showed to be of significance in TTLP (p<0.001) without 
influencing the prognostic value of number of lesions (p=0.001). For survival, the 
Figure 3: Time to systemic progression (TTSP) by stage of disease
X-axis: time in months, Y-axis: cumulative proportion, IIIA=stage IIIA disease, IIIAB=stage IIIAB disease, IV=stage IV disease
Time to systemic progression(TTSP) by stage of disease 
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Figure 4: Overall survival by stage of disease
X-axis: time in months, Y-axis: cumulative proportion, IIIA=stage IIIA disease, IIIAB=stage IIIAB disease, IV=stage IV disease
Overall survival by stage of disease 
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achievement of CR is of significant prognostic value, reducing the impact of age 
of the patients. Five-year overall survival for patients with a CR after ILP was 42% 
versus 5% for PR/NC-patients (p=<0.001) (Figure 5). Because stage of disease itself is 
a prognostic factor for response, the effect of response was evaluated for each stage 
of disease (table 5) and remained significant, especially in stage IIIA patients.
Influence of IFN, prior ILP treatment and tumour bulk
IFN-γ: No significant difference in CR-rate was found between patients receiving a 
TM-ILP with or without IFN (78% vs. 66% respectively, p=0.274). Neither could an 
Table 4
Multivariate analysis of clinical prognostic factors for CR achievement, local progression and survival prior to ILP
Endpoint Variable N Haz ratio p 95% CI
CR Stage of disease IIIA* 45 1
IIIAB 41 0.375 0.053 0.139-1.013
IV 14 0.162 0.006 0.044-0.598
Local progression Number of lesions <10* 43 1
≥ 10 57 2.854 0.001 1.539-5.293
Survival Stage of disease IIIA* 45 1
IIIAB 41 2.005 0.011 1.174-3.423
IV 14 11.654 <0.001 4.640-29.272
Age (years) ≤ 60* 47 1
>60 53 1.738 0.033 1.047-2.887
CR=complete response, ILP=isolated limb perfusion, Haz ratio=hazard ratio, CI=confidence interval, *=reference group
Figure 5: Overall survival by response on ILP
X-axis: time in months, Y-axis: cumulative proportion, ILP=isolated limb perfusion, CR=complete response, PR/NC=partial response/no change
Overall survival by response on ILP 
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additive effect of IFN be detected for TTLP (p=0.521) or for survival corrected for 
stage of disease (p=0.149). 
Prior ILP: Prior ILP treatment, a typical indication for a repeat ILP with TNF, had no effect 
on CR-rate (p=0.601) or TTLP (p=0.312). The 26 patients who received multiple ILPs had 
a 5-year survival of 44% versus 28% for patients receiving a single treatment (p=0.059). 
Tumour bulk: Because the experience with TNF-based ILP in soft tissue sarcomas 
clearly indicated that the addition of TNF induced impressive responses in large 
tumours in contrast to the experience with melphalan alone, we gradually changed 
our inclusion criteria for a TNF-based ILP and decided only to offer this treatment to 
patients with bulky disease or to patients that had failed previous perfusion(s). For 
Table 5
Influence of response rate on survival after ILP
Stage of disease CR N Haz ratio p
IIIA yes* 37 1
no 8 5.016 <0.001
IIIAB yes 26 2.189
no 15 4.130 0.115
IV yes 6 8.158
no 8 41.035 0.041
CR=complete response, Haz ratio=hazard ratio
Table 6
Influence of tumour bulk and stage of disease
1st 50 ILPs 2nd 50 ILPs p
Size of largest lesion (Ø) <4 cm 60% 36%
≥ 4 cm 40% 64% 0,016
Number of lesions <10 50% 36%
10 to 50 34% 30%
>50 16% 34% 0,105
Stage of disease IIIA 60% 30%
IIIAB 36% 46%
IV 4% 24% 0,002
CR rate 80% 58% 0,017
TTLP (median, months) 20 8 0,021
Survival (median, months) 45 21 0,066
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this reason, we retrospectively analysed the results of the first 50 ILPs versus the last 
50. The tumour burden and stage of disease of the latter group differed significantly 
from the first (table 6). Both CR-rate (80% vs. 58%; p=0.017) and TTLP (20 months 
vs. 8 months; p=0.021) were significantly lower in the last 50 ILPs. Survival was also 
shorter in the latter group (45 vs. 21 months), but this difference just failed to reach 
statistical significance (p=0.066). 
DISCUSSION
We report here on 100 TNF-based ILPs in melanoma patients out of a total of 350 
TNF-based ILPs that we performed in our institution during the period from 1991 
through July 2003. In patients with melanoma IT-mets, the procedure is associated 
with a close to 100% response rate in a patient population that has significantly 
shifted towards more bulky disease and pre-treatments over the years. This pa-
tient population is considerably less likely to respond to treatment than the patient 
population of “all patients that present with IT-mets”, that we used to elect for a 
melphalan-only ILP in the past, even when IT-mets were limited in number and size. 
This single institution experience further underscores that in the expert setting, the 
procedure is very safe. TNF can be used in high doses without a single case of treat-
ment-related mortality; there were no cases of grade 4 systemic toxicity except for a 
single case in which significant leakage occurred and leucocytes dropped below 1.0 
for a single day. In such a setting, there is no need for other than standard cardio-
vascular monitoring peroperatively, no need for standard use of vasopressors, or for 
standardly having patients in the intensive care unit postoperatively 22. 
The present series shows a CR rate of 69%, which is within the range of CR rates 
reported in previously published smaller series 6, 18, 23-25. We identified stage of disease 
as a prognostic factor for response with the most prominent difference in IIIA versus 
IIIAB/IV patients, which is in line with the literature on melphalan-based ILP 16-19. 
This probably reflects a difference in aggressiveness of melanoma biology in these 
patient categories, further exemplified by significant differences in survival. This hy-
pothesis is sustained by the observation that during the course of melanoma progres-
sion, the ability of melanoma cells to express so-called death receptors diminishes 
26. TNF receptor and TNF-related Apoptosis Inducing Ligand (TRAIL), two examples 
of these receptors, play key roles in the acquired resistance of melanoma cells to 
undergo TNF-mediated apoptosis: whereas early-phase melanoma appears to utilize 
TNF pathways to undergo programmed cell death, late-phase melanoma does not 27. 
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Response on treatment therefore is an indicator of the tumour phenotype, which 
itself is of influence on patient survival. 
Potentially it may also reflect a difference in immunocompetence between these 
patient categories that differ greatly because the absence of presence of lymph node 
metastases and/or visceral metastases. In our laboratory, we showed an attenuation 
of tumour response to ILP in leukocyte depleted rats 28, which corresponds well to 
the report on the role of an early and rapid invasion of tumour lesions after a TNF-
based ILP by neutrophils 29. Furthermore, we reported on the observation in tumour 
lesions in patients after ILP that eosinophils and macrophages (“melanophages”) 
play an important role in the delayed-type reaction to TM-ILP 30.
 
Results of ILP treatment are often presented in overall response rates. Our prognostic 
factor analysis shows that especially the CR rate is of imminent importance, since it 
significantly affects both TTLP and survival. In fact, the marked difference in TTLP 
between CR and PR/NC patients identifies the period that the patient is without any 
need of locoregional treatment. We therefore specifically analysed the group of pa-
tients with IIIA/IIIAB disease and a PR after ILP, since these patients progress rapidly 
in the limb and therefore might need repeat locoregional treatment. Of these 23 
patients, however, only 5 patients lived for more than 9 months without presenting 
distant metastases, and they received additional treatment (among which, 2 repeat 
ILPs). This indicates that response on ILP selects those patients with more aggressive 
nature of disease, which is sustained by the prognostic influence of response rate 
on overall survival, especially when corrected for stage of disease. The 42% 5-year 
survival rate in CR patients, which make up the large majority of patients (69%), is 
quite substantial and compares favourably with most commonly reported survival 
rates for this patient category (23-47%) 31. This underscores the importance of the 
treatment and shows that it is a worthwhile intervention.
Patient selection
Since the introduction of TNF in the ILP setting, it has been discussed which patient 
subgroup would profit the most from addition of this cytokine 32. The early experi-
ence of 4 European centers showed that the treatment of all patients with IT-mets, 
irrespective of number of tumours or size of the lesions, increased the complete 
response rate from 52% to 91% 9. Yet the notion that the clearest benefit was seen 
in the patients population with bulky tumours that previously was known to be 
very poorly responsive to melphalan-based ILP was already obvious through our 
experiences in the multicenter trials in sarcoma patients since 1991, and it affected 
over the years the patient selection in our institution. We managed patients with 
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small tumours and a small number of tumours increasingly by repeated excisions 
and vaccine protocols and offered TNF-based ILP more and more exclusively to pa-
tients with a high tumour burden. In this patient category with highly unfavourable 
characteristics, analysed separately as 2nd 50 ILPs in our series, CR rate was still 58%. 
This is still superior to the response rate in the historical group of patients treated 
with melphalan alone without such unfavourable patient selection 9, and it is similar 
to the observations in the United States. In an interim analysis of a randomised trial 
by Fraker et al., TNF-based ILP showed to be of significant benefit in patients with 
a high tumour load, increasing the CR rate from 19% for melphalan-ILP to 58% in 
TM (+IFN)-ILP 33. Moreover, Rossi et al. reported recently in a series of 20 melanoma 
patients with a high tumour burden a CR rate of 70% after TNF-based ILP 34. We 
demonstrate in this series of patients that the median of TTLP of 16 months exceeds 
the median of TTSP of 14 months in the overall patient population. It underscores 
that systemic metastases present frequently in the stage IIIA and IIIAB populations 
and that an ILP should be reserved for patients who run out of simple management 
options such as excision of few lesions or participation in non-toxic vaccination 
protocols for (multiple) small lesions that do not present clear local morbidity. Those 
patients without local morbidity that still progress systemically can thus be spared 
the ILP intervention. Moreover, in case these patients respond to a vaccine, they 
most likely will do so also at systemic disease sites at the cost of little toxicity and 
no surgical intervention. This policy shift has occurred over the 12 year period 
described here and has led to a patient population with significantly more advanced 
disease locally in the second bracket of 50 ILPs (after 1996). It is important to realize 
that even in this patient population, the CR rate of 58% is still higher than the 52% 
CR rate in our prior experience with melphalan alone in patients with clearly less 
extensive disease 9.
A second indication for TM-ILP is failure after previous ILP-therapy 35. In the present 
study, 26 ILPs were performed for recurrences in the limb after previous ILP treat-
ment (13 ILPs after prior ILP elsewhere, 13 repeat TM-ILPs in our institution). The 
overall response rate of repeat ILP was 96% (CR 73%, PR 23%, NC 3%). This did not 
differ from the primary ILPs in our series and no increased toxicity was observed, as 
opposed to previous reports on the outcome of repeat melphalan-based ILP 36. This 
observation underscores the efficacy of a TNF-based ILP in the repeat-ILP setting and 
thereby its indication.
Toxicity
Local toxicity after TNF-based ILP in our series was moderate to severe (grade III-IV) 
in 31 ILPs (31%), which compares with reported percentages in TNF or melphalan-
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based ILP 37. A reintervention by amputation or fasciotomy occurred in only two 
patients. Local toxicity is reported to be directly correlated with the incidence of 
long-term morbidity (tissue fibrosis, muscle atrophy and limb malfunction 38). In 
our patient population however, the rate of limb function loss was markedly low, 
even in the 27 patients older than 75 years and in the 26 patients with multiple ILP 
treatments. 
Systemic toxicity is directly correlated with leakage of the chemotherapeutics to 
the systemic circulation 8, 22, 39, 40. In the present situation of leakage-free ILPs, the 
systemic toxicity is mostly limited to fever in the first 24 hours postoperatively, which 
can be easily avoided by the immediate postoperative application of indomethacin 
and/or paracetamol. Furthermore, the patients commonly show a period of 6 to 10 
hours of a slightly elevated circulation due to a drop in peripheral resistance, which 
is compensated by a mild tachycardia and a small drop in blood pressure, easily 
managed by a generous intravenous fluid infusion policy, and does not require 
the standard use of vasopressors. The feared systemic adverse reaction of TNF - a 
systemic inflammatory response syndrome with a major drop in blood pressure that 
requires the administration of vasopressors - was not observed in any of our pa-
tients. Only in two patients, both with substantial leakage during the ILP, the blood 
pressure drop lead to the administration of vasopressors at a mild dose of 3-6µg/kg 
for a maximum duration of 36 hours. The absence of any major toxicity is due to a 
number of factors: first, adequate leakage control in virtually all patients; second, 
and this is of crucial importance, we have a policy of ample hydration of the patient 
during ILP and for the first 12-24 hours after ILP. This policy assures that all of our 
patients have adequate diuresis to keep the period of high circulating TNF levels 
post-ILP as short as possible 22. Eight ILPs in our series had a leakage percentage 
above 10% (up to 32%), but in only one patient this lead to a systemic reaction by el-
evated liver enzymes, elevated urea and leucopenia, all easily managed with normal 
conservative measures. We do not use and do not advocate therefore the standard 
use of Swann-Ganz catheters, vasopressors or post-operative stay in the intensive 
care. In our experience, neither systemic nor local toxicity is significantly enhanced 
in TNF-based ILP compared with melphalan-based ILPs. 
In conclusion, our results demonstrate the very high efficacy of TNF-based ILP in 
melanoma patients both in terms of local control of disease and of survival. Outcome 
is influenced by stage of disease, reflecting the aggressiveness of the melanoma. 
Complete response to ILP selects within each stage of disease those patients with 
relatively favourable characteristics. In our experience, the use of TNF increases the 
CR rate, especially in patients with high tumour burden and in those having failed 
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previous therapy. Local and systemic safety profile of the TNF-based ILP is so good 
that in the expert setting, a TNF-based ILP does not need a standard approach that 
differs from a melphalan-based ILP. The procedure should be considered in all cases 
of limb-threatening tumours or situations where simple surgical procedures to obtain 
local control fail. Currently, the procedure is the most efficacious one to obtain local 
control and achieve limb salvage in such conditions 41. 
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ABSTRACT
Background
Isolated limb perfusion (ILP) is an effective treatment modality for multiple in-transit 
melanoma metastases confined to the limb. Recurrences after ILP, however, occur in 
approximately 50% of patients and are a challenge for further treatment. The efficacy 
of repeat ILPs to prolong local control in this patient category is evaluated in this 
article.
Methods
We used a prospective database in a tertiary referral center. Out of 100 ILPs with 
Tumour Necrosis Factor-α (TNF) and melphalan (TM-ILPs) in melanoma patients 
between March 1991 and July 2003, 25 repeat ILP procedures were performed in 21 
patients in whom prior ILP treatment failed. All patients had bulky and/or numerous 
lesions and were treated with mild hyperthermic TM-ILP using 2 to 4 mg TNF and 10 
to 13 mg/L of limb volume for the leg and arm, respectively.
Results
The complete response rate was 76%, a partial response occurred in 20% and no 
change was recorded in 4%. There was no difference in the complete response rate 
or local toxicity between first and repeat perfusions. Local recurrence occurred in 
72%; the median time to local progression was 14 months. The five-year survival rate 
was 47%, which compares favourably with known survival rates of stage III A/AB 
patients. The median follow-up of the patients was 26 months.
Conclusions
Patients who experience treatment failure after previous ILP treatment respond very 
well to repeat perfusion, and prolonged local control can thus be obtained. The 
subgroup of patients qualifying for repeat ILP represents a relatively favourable 
biological behaviour of the melanoma.
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INTRODUCTION
Recurrent melanoma of the limb remains a treatment challenge. Many options, from 
simple surgical excision to intralesional injections with cytokines to isolated limb 
perfusion (ILP), have been proposed. Depending on the size and number of the 
lesions, each modality is more or less suitable 1. ILP for melanoma has demonstrated 
to be very effective in patients with multiple metastases for which surgical excision 
is impossible. Melphalan-based ILP is associated with complete response (CR) rates 
of 40% to 50% and overall response rates of 75% to 80%. When Tumour Necrosis 
Factor-α (TNF) was introduced in the isolated limb perfusion model by Lejeune 
and Lienard in 1988 2, CR rates of 80% to 90% were reported. The first report on 
the European multicenter experience with TNF-based ILP in melanoma patients re-
vealed that a significant increase in CR rates was observed in the four participating 
centers: 91% with TNF and melphalan (TM)-ILPs compared with a 52% CR rate for 
melphalan-only-ILPs 3. By this treatment, disease control in the limb can be obtained 
in patient categories with a poor prognosis quo ad vitam 4. However, local progres-
sion in the limb after ILP with melphalan has been reported to develop in 46% to 
54% of patients, and this rate was 55% in our own experience in 100 TM-ILPs, with 
predominantly high numbers of metastases, bulky disease, or both 5. For this patient 
category, treatment options are limited. Some patients, however, qualify for re-treat-
ment of the limb when treatment fails only locally without evidence of systemic 
metastases. Particularly for these patients repeat ILP might provide prolonged local 
control 6-8. The use of TNF in the repeat ILP is hypothesized to improve response 
rates in patients who do not respond or respond insufficiently to melphalan-only-
ILPs, but definitive prove is still lacking 7. 
In this article, we report on 25 TM-ILPs for locally recurrent melanoma in patients 
who experienced treatment failure with previous ILP treatment, both with and with-
out TNF. Special attention is given to local and systemic progression after repeat ILP 
and on the locoregional toxicity of the repeat procedure.
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PATIENTS AND METHODS
Patients
Out of 100 TNF-based ILPs in 87 patients performed in our institution between 1991 
and July 2003, 25 ILPs in 21 patients were repeat ILPs because of failure of previous ILP 
treatment for extensive in-transit melanoma metastases. Of these 25 ILPs, 12 were per-
formed after failure of melphalan-based ILPs performed in referring hospitals, one was 
performed after a TM-ILP elsewhere, and 12 ILPs were second (n=10) or third (n=2) 
TNF-based perfusions performed in our own institution. Tumour stage was assessed 
according to the MD Anderson staging system: 7 stage IIIA patients (only in-transit 
metastases; no lymph node metastases or distant metastases), 15 IIIAB patients (both 
in-transit metastases and lymph node metastases, but no distant metastases) and 3 stage 
IV patients (IV: in-transit metastases and distant metastases). At the time of a second 
perfusion in our institution, progression of tumour stage had occurred in six patients. 
Local control of the in-transit recurrences by surgery was impossible due to numerous 
lesions (>10 lesions in 21 ILPs) and/or size of the lesions (>40 mm in 12 ILPs). Patient 
and tumour characteristics of the 25 repeat ILPs in 21 patients are listed in table 1.
Table 1
Patient and tumour characteristics of 21 patients undergoing 25 repeat TM-ILPs
Sex Female 15
Male 6
Age (years), mean+range 60 (25-83)
Stage IIIA 7
IIIAB 15
IV 3
Stage shift IIIA à IIIAB 4
IIIAB à IV 1
IIIA à IV 1
No. of tumours <10 4
10-50 9
>50 12
Size of largest lesion (mm) <40 mm 13
>40 mm 12
Prior treatment None 20
(apart from ILP) XRT 1
CT 2
Immuno 1
XRT + CT 1
ILP = isolated limb perfusion, XRT = radiotherapy, CT = systemic chemotherapy, Immuno = immunotherapy
Repeat ILP for Melanoma 41
Treatment
All patients underwent an ILP of the lower extremity by an iliac (n=15), femoral 
(n=6) or popliteal (n=4) approach. The method of ILP has been described in detail 
previously 9,10. In short, isolation of the limb is achieved by clamping and canulation 
of the major artery and vein, connection to an oxygenated extracorporeal circuit, 
ligation of collateral vessels and application of a tourniquet proximal to the site of 
perfusion. Once tissue temperature has reached 38°C, recombinant TNF (Boehringer 
Ingelheim GmbH, Ingelheim/Rhein, Germany) is administered via the arterial line in 
a dose of 2-4 mg (mean 3.6 mg). Tissue temperatures are stabilized between 38°C 
and 39.5°C, and leakage monitoring is performed by using a precordial scintillation 
probe to detect leakage of radiolabelled albumen injected to the perfusion circuit 
11. After 30 minutes, melphalan (L-PAM, Alkeran, Burroughs Welcome, London, UK) 
is added to the perfusate in a dose of 10 mg/L for leg perfusions and 13 mg/L for 
arm perfusions. In six ILPs, performed between 1991 and 1994, interferon γ (IFN) 
was added to the schedule according to trial prescriptions, which consisted of the 
subcutaneous injection of 0.2 mg IFN on days –2 and –1 prior to the ILP and the 
injection of 0.2 mg IFN during the ILP procedure into the arterial line prior to the 
administration of TNF. The median dose of melphalan was 100 mg (mean 92.6, range 
40-140), and all six IFN-ILPs were performed with 0.2 mg IFN. At the end of the 
perfusion period, a washout procedure using 2 to 4 L of a dextrane and/or electro-
lyte solution is performed. In patients undergoing an iliac perfusion, an iliac lymph 
node dissection is routinely performed. In patients with palpable nodal disease in 
the groin, an ilio-inguinal lymph node dissection is performed in the same operative 
session as the ILP: the iliac lymph node dissection prior to the ILP and the inguinal 
lymph node dissection immediately after the ILP.
Evaluation of response and toxicity
Acute local toxicity of the ILP procedure was classified according to Wieberdink et 
al. 12: (grade I) no reaction, (grade II) slight erythema or edema, (grade III) consid-
erable erythema or edema with some blistering, slightly disturbed motility permis-
sible, (grade IV) extensive epidermolysis or obvious damage to the deep tissues, 
causing definite functional disturbance, and threatening or manifest compartmental 
syndrome, and (grade V) reaction that may necessitate amputation. Response evalu-
ation was performed 4, 8 and 12 weeks after ILP by clinical examination, thereafter 
at regular 3-month intervals for the first 2 years and subsequently at longer intervals. 
Response rates were reported according to World Health Organisation criteria 13, in 
which CR is the complete disappearance of all lesions and no new areas of disease 
appearing within the field of ILP. Partial response (PR) was defined as a reduction 
of 50-99% of the total tumour size; no change (NC) was recorded if <50% of the 
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total tumour size responds. Recurrence of tumour within the extremity after a CR, or 
progression of the lesions and the appearance of new lesions after a PR or after NC, 
was reported as local progression. 
Statistical evaluation
Estimates of survival and local/systemic progression were made using the Kaplan-
Meier method and differences were evaluated using the log-rank test. P-values <0.05 
were considered to be significant.
RESULTS
Of the 25 repeat ILPs performed in our institution, 19 (76%) resulted in a CR. With 
an additional 5 ILPs with a PR, total response rate was 96%. One patient (patient 
number 12) showed regression of the lesions of 20-25%, which was recorded as NC. 
There was no difference in the CR rate between repeat ILPs after prior treatment 
elsewhere (83%) and repeat TM-ILPs in our institution (69%; p=0.36). In the 12 
patients who received multiple TM-ILPs in our institution, no difference in response 
rate was detected between first (70%) and second or third ILP (75%; p=0.58). Re-
sponse rates for the different patient categories analysed are listed in table 2. Median 
time between first and repeat ILP was 25 months (range 3-76 months). 
The median leakage of the repeat ILPs was 0% (range 0%-13%), leading to absence 
of severe (grade IV) systemic toxicity (table 3). Local toxicity was mild to moderate 
in all cases with Wieberdink grade I in 12%, grade II in 60% and grade III in 28% of 
the ILPs, and not a singe case of grade IV toxicity. No increase in local toxicity was 
observed in the patients receiving multiple TM-ILPs (table 4). 
Table 2
Response Rates
Overall Repeat Prior M-ILP TM-ILP repeats
N=100 N=25 N=13 N=12
CR 69/100=69% 19/25=76% 10/12=83% 9/13=69%
PR 26/100=26% 5/25=20% 2/12=17% 3/13=23%
NC 5/100=5% 1/25=4% 1/13=8%
Overall 94% 96% 100% 92%
M-ILP = melphalan-only isolated limb perfusion, TM-ILP = isolated limb perfusion with TNF and melphalan, CR = complete response, PR = 
partial response, NC = no change
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Compared with our total database of TM-ILP for melanoma, consisting of 100 ILPs, 
CR rate of repeat perfusions did not differ significantly from the CR rate of patients 
undergoing only one ILP (76% vs. 68%, p=0.61). Local progression occurred after 
18 repeat ILPs (72%). The median time to local progression (TTLP) was 14 months 
for repeat perfusions vs. 16 months for the overall population and 18 months for 
single ILPs (p=0.40; figure 1). Sixteen patients developed systemic metastases dur-
ing the course of follow-up; 3 already had stage IV at time of repeat ILP. Time to 
systemic progression (TTSP) did not differ between patients receiving single (12 
months) and multiple ILPs (15 months; p=0.27) 5. In 3 patients (patients 1,2 and 5), 
repeat ILP (plus resection of a local recurrence on the lateral side of the proximal 
thigh in patient 1) contributed to sustained local control of disease in the leg. No 
systemic progression was observed in these patients during follow-up of 91, 129 and 
Table 3: Local and systemic toxicity
Local toxicity
Wieberdink Grade I Grade II Grade III Grade IV Grade V
12% 60% 28%
Systemic toxicity
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Neurologic* 96% 4%
Liver* 100% 0%
Renal* 100% 0%
Haematologic* 96% 4%
<38°C 38-39°C 39-40°C >40°C, <24 hrs >40°C, >24 hrs
Temp 36% 24% 32% 8%
Absent Present
Shock& 100% 0%
Hrs = hours, * = WHO criteria, & = support of vasopressors needed
Figure 1 
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Figure 1: Time to local progression (TTLP) for repeat versus single isolated limb perfusions (ILPs).
X-axis: time in months counted from the last procedure
Y-axis: cumulative percentage
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72 months, respectively. The 21 patients who received multiple ILPs had a 5-year 
survival of 47%, compared with 28% for patients who received a single treatment 
(p=0.05; figure 2). The median follow-up was 26 months.
DISCUSSION
These results show that in a selected patient population of patients with local pro-
gression after previous ILP treatment, repeat TM-ILP is associated with excellent 
response rates (96%). The CR rate after TM-ILP was 76%, which compares favour-
ably with the CR rate of single ILPs in our institution. This is in line with the scarce 
literature on the efficacy of repeat ILPs 6-8 and is indicative of the fact that a rather 
favourable group of patients, mostly patients with stage IIIA disease only and with a 
good response to the first ILP, are considered for repeat ILPs when they recur with 
in-transit metastases. The 5-year survival rate of 47% reported in this study compares 
favourably with recently published survival rates of patients with locally advanced 
melanoma (23%-47% 4) and is again an indication of relatively mild biologic behav-
iour of the melanoma in this patient population.
The mechanism of recurrence after previous ILP treatment remains speculative. It is 
a common finding that in patients after a CR to the first perfusion, the new recurrent 
in-transit metastases arise at locations different from the original lesions that went 
into a CR after the initial ILP. Hypothetically this indicates that larger, well-vascular-
ized lesions are completely eradicated but that dormant, (relatively) non-vascular-
ized lesions are not eradicated by an ILP, because of inadequate drug exposure 14.
Figure 2 
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Figure 2: Overall survival for repeat versus single isolated limb perfusions (ILPs).
X-axis: time in months counted from the last procedure
Y-axis: cumulative percentage
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Patient selection for repeat ILP treatment is determined by the time to local progres-
sion after initial ILP and the absence of systemic metastases, unless the bulkiness 
of the disease is directly limb-threatening. Rapid disease progression after ILP is 
an indicator for aggressive disease and is therefore a relative contraindication for 
repeat ILP treatment, as the expected response rates are low 15. The median interval 
between initial ILP treatment and repeat TM-ILP of 25 months, as indicated in table 
4, is markedly longer than the median time to local progression both in this study 
after repeat ILP (14 months) and in our total database of 100 ILPs (16 months). In 
three patients (patients 13, 20 and 21) repeat TM-ILP was performed 3 to 5 months 
after failure of ILP with other chemotherapeutics in order to obtain sufficient re-
sponse, and it resulted in 1 PR and 2 CRs. This shows that failure to respond to a 
melphalan-only ILP can be overcome by adding TNF, which in tumour models has 
been shown to enhance the uptake of melphalan by the tumour 16, 17. This is in line 
with the observation that melphalan-only ILPs in soft tissue sarcoma patients are very 
poor, whereas TM-ILPs are associated with high response rates 3. For our melanoma 
population we can conclude that, apart from the three patients with rapid failures 
after a melphalan-only ILP, the melanoma of patients qualifying for repeat treatment 
is relatively indolent. This observation is sustained by the significant difference in 
overall survival between repeat and single ILPs. 
Whether to consider a patient for repeat ILP should be influenced by the stage of 
disease at first ILP. We found in our experience with 100 TM-ILPs that curves of TTLP 
and TTSP virtually overlap in stage IIIAB disease, whereas in patients with stage 
IIIA disease, the median TTSP was 55 months at a median TTLP of 18 months. This 
difference makes patients with stage IIIA disease with local progression much better 
candidates for repeat ILP than those with stage IIIAB disease 5.
We found toxicity after repeat TM-ILPs to be mild to moderate in all procedures. 
Compared with the first ILP, repeat TM-ILP did not increase local toxicity, in contrast 
to a previous report using melphalan alone 6. In this report, however, more intensive 
schedules were used for the repeat ILP (higher tissue temperatures and ILPs at short 
intervals 6. Other, smaller, studies do not report on increased local or systemic toxic-
ity 7, 8. On the basis of these data, we state that the use of mild hyperthermic TM-ILP 
for repeat perfusion is safe. The median leakage to the systemic compartment was 
0% in these 25 repeat ILPs, just like in our overall experience with TM-ILP in over 
350 patients. TM-ILP is a safe procedure, provided that adequate leakage monitor-
ing is ensured and postoperative fluid management is generous to deal adequately 
with the TNF-mediated transient decrease in the peripheral vascular resistance after 
ILP 18, 19. Moreover, the safety of the procedure is such that, in our opinion, there 
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should be no age limit. Especially in limb-threatening disease, limb salvage is of 
prime importance and this treatment should not be withheld from the elderly as we 
have demonstrated in our extensive experience in patients >75 years old 20.
In conclusion, repeat TM-ILP is a valuable treatment option in patients with local 
progression after previous ILP treatment. In patients with bulky or numerous lesions 
that cannot be managed with surgery, repeat TM-ILP provides excellent disease con-
trol. Especially patients with recurrences after ILP for stage IIIA disease and patients 
with a long interval between initial and repeat ILP, who constitute a subcategory of 
melanoma patients with relatively favourable characteristics, profit from this treat-
ment. Moreover, patients with no response or rapid progression after a melphalan-
only ILP can still respond with a CR to a TM-ILP. 
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ABSTRACT
Background
The treatment of melanoma in-transit metastases (IT-mets) can vary widely and is 
dependent on the size and the number of the lesions. When multiple, large lesions 
exist, Isolated Limb Perfusion (ILP) has established itself as an attractive treatment 
option with high response rates. 
Methods
Review on the various methods of treatment of melanoma in-transit metastases, with 
a focus on Isolated Limb Perfusion. A Medline based literature search was performed 
for articles relating to this topic. Additional original papers were obtained from cita-
tions in those identified by the initial search. Indications and results are discussed 
and the extra value of Tumour Necrosis Factor (TNF) is evaluated.
Results
ILP with melphalan results in complete response rates of 40% to 82% and showed 
to be 54% in a large retrospective meta-analysis. The addition of TNF can improve 
these completes response rates (59%-85%) and although no data from randomised 
controlled trials are available, it seems of particular value in large, bulky lesions or 
in patients with recurrent disease after previous ILP.
Conclusions
TNF-based ILP has earned a permanent place in the treatment of patients with mela-
noma IT-mets. In patients with a high tumour burden, TNF-based ILP is the most 
efficacious procedure to obtain local control and to achieve limb salvage.
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INTRODUCTION
Melanoma is the cancer type with the largest increase in incidence over the last 
decade, with estimated new cases in the USA increasing from <45.000 in 1999 1 to 
nearly 60.000 in 2005 2. In The Netherlands, a recent calculation of the predicted 
incidence of melanoma reveals an increase of 99% from 2000 to 2015 3. The prog-
nosis of melanoma patients varies widely and depends on the stage of disease 4. In-
transit metastases (IT-mets) of melanoma occur in 5-8% of high-risk patients and are 
categorised as stage IIIB or stage IIIC disease according to the most recent staging 
system of the American Joint Committee on Cancer (AJCC) 5. IT-mets are cutaneous 
or subcutaneous deposits of melanoma between the primary melanoma site and 
the regional lymph node basin occurring in the course of lymphatic drainage. They 
reflect a disseminated stage of disease with corresponding 5-year survival rates of 25-
30%, depending on associated lymph node metastases 4. Besides the unfavourable 
prognosis, the occurrence of IT-mets forms a great discomfort for the patients, espe-
cially if numerous large lesions exist with ulceration of the tumours. The treatment 
of in-transit metastases of melanoma is therefore a challenge and is mainly dictated 
by the biology of the tumours in terms of size and number. 
TREATMENT OPTIONS 
Surgical excisions of IT-mets is chosen when size and number permits this approach. 
It must be realized that amputation is seldom if ever indicated and does not improve 
survival. 6. Surgery should be radical, but no excisional margin is proven beneficial 
for these metastases, contrary to primary melanoma. The possibility of repeated 
excisions is completely dictated by the location, the size and for practical reasons 
the number of the lesions. 
When numerous small lesions exist, local ablation by carbon dioxide laser therapy 
can be useful as it minimizes the injury of surrounding tissue and permits to treat 
multiple lesions in one session. Drawbacks are healing by secondary intention that 
can be lengthy and painful. Although initial results were reported to be adequate 7, 
the recurrence rate showed to be very high (7/15 patients with a local recurrence, 
disease-free interval 2-7 weeks) in another report 8. This, together with the inability 
of the technique to treat lesions >1 cm in diameter, has limited the use of CO2 laser 
ablation to a very specific patient population.
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Various other topical therapeutic options for IT-mets are studied over the last de-
cades. Bacille Calmette-Guérin (BCG), Corynebacterium parvum, interferon (IFN) 
and interleukin-2 (IL-2) all were used to augment the autoimmune response, known 
to be existent in melanoma. Although a measurable antibody response could usually 
be achieved, this did not lead to satisfactory response rates. As multiple therapeutic 
sessions are needed and the injections are not free of toxicity, the use of intralesional 
therapy is largely abandoned and replaced by alternatives such as isolated limb 
perfusion. Truncal lesions however can be treated with one of these modalities. At 
present, electrochemotherapy (the use of bleomycin in combination with the ap-
plication of electric current over cutaneous or subcutaneous lesions) has produced 
some promising results 9-11, but is not considered standard therapy.
Immunotherapy through vaccination is based on the same premise of augmenting 
the immune response to melanoma cells. Patients with IT-mets are attractive for these 
experimental protocols as the tumour material needed for vaccine development is 
easily accruable and subsequent biopsies for monitoring the vaccination effects can 
be taken from the residual lesions. Results of vaccination protocols however are up 
to know insufficient 12-14 and therefore vaccination is strictly experimental.
Although melanoma cells are relatively resistant to radiation, radiotherapy can be 
a useful treatment modality for obtaining local control in cutaneous melanoma at 
sites that would otherwise require complex surgical procedures. In gross disease in 
a relatively small total area, radiotherapy has proven to be effective in providing 
local control (in approximately 50% 15, 16), which might even be increased by adding 
hyperthermia in centres with the expertise and equipment 17. 
Systemic chemotherapy for metastatic melanoma has shown to be very disappoint-
ing due to the resistance of the tumour to cytotoxic drugs. Currently, no treatment 
schedule has proven to be superior in a randomised trial to the currently used 
dacarbazine (DTIC), especially in terms of local control combined with acceptable 
toxicity, which should be the aim of therapy in patients with melanoma IT-mets. As 
DTIC provides response rates of <20% with a median duration of response of 5-6 
months 18, it should not be used for treatment of melanoma patients other than AJCC 
stage IV. Intra-arterial infusions of chemotherapeutic agents have been tried in order 
to achieve acceptable results without the complex setting of isolated limb perfusion. 
The initial results were rather disappointing with an overall response rate of 37% 19, 
but could be improved when a tourniquet was used for better occlusion 20. 
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ISOLATED LIMB PERFUSION
The technique of Isolated Limb Perfusion was pioneered by Creech and Krementz at 
Tulane University in New Orleans in 1958 21 in order to achieve regional concentra-
tions of chemotherapeutic agents that are 15 to 25 times higher than can be reached 
with systemic administration, but without the systemic side-effects 22. Isolation of 
the blood circulation of the limb is achieved by clamping and canulation of the 
major artery and vein, connection to an oxygenated extracorporeal circuit, ligation 
of collateral vessels and application of a tourniquet proximal to the site of perfusion. 
The drugs can be introduced to the perfusion circuit once this isolation is secured. 
Melphalan (L-phenylalanine mustard) is the standard drug for reasons of its favour-
able local toxicity profile and its efficacy. Melphalan is commonly used in doses of 10 
mg/L perfused tissue for a leg and 13 mg/L for an arm 23. Tissue temperatures are sta-
bilized and leakage monitoring is performed by using a precordial scintillation probe 
to detect leakage of radiolabelled albumen injected to the perfusion circuit 24. Leak-
age monitoring is mandatory, especially when Tumour Necrosis Factor-alpha (TNF) 
is used in high doses. At the end of the 1 to 1.5 hour perfusion period, a washout 
procedure using an electrolyte solution is performed. In patients undergoing an iliac 
or axillary perfusion, the corresponding lymph node basin is dissected. In patients 
with palpable nodal disease in the groin an ilio-inguinal lymph node dissection is 
performed in the same operative session as the ILP but prior to executing the ILP. 
Response of the tumours on ILP is reported according to WHO criteria 25, in which 
complete response (CR) is the complete disappearance of all lesions and no new 
areas of disease appearing within the field of ILP. Partial response (PR) is defined as 
a reduction of 50-99% of the total tumour size; no change (NC) is recorded if <50% 
of the total tumour size responds. Acute local toxicity of the ILP procedure is classi-
fied according to Wieberdink et al. 26: (I) no reaction, (II) slight erythema or edema, 
(III) considerable erythema or edema with some blistering, slightly disturbed motility 
permissible, (IV) extensive epidermolysis or obvious damage to the deep tissues, 
causing definite functional disturbance, and threatening or manifest compartmental 
syndrome, and (V) reaction that may necessitate amputation.
ISOLATED LIMB PERFUSION FOR MELANOMA 
Since the introduction of ILP almost half a century ago, many modifications have 
been applied in order to improve tumour response on ILP. These modifications have 
led to an improved insight in the optimal temperature, the optimal drugs and the 
optimal indications for the procedure.
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Hyperthermia
Temperature of the perfused tissue is important in more than one way: the tempera-
ture of the skin has to be warmed during perfusion in order to prevent vasoconstric-
tion in the cutis and subcutis. Especially in superficial IT-mets, application of a warm 
water mattress can improve the local drug delivery as the uptake of the drug by in-
transit metastases in vivo has proven to be two times higher at 39.5°C than at 37°C 27. 
The second reason for hyperthermia is the idiosyncratic sensitivity of tumour cells to 
heat. Moreover, hyperthermia can improve the uptake of the drug in tumour cells, 
especially at temperatures >41°C 28, 29. Normothermic ILP-schedules, known to lead 
to an overall response rate of 65% 30 (table 1), are now largely abandoned for the 
Table 1: The efficacy of melphalan-based ILPs
Efficacy of Melphalan-ILP
ILP strategy Procedures Results Reference
N CR% PR% OR%
Med 
mts Year Author #
Normothermia
37-38°C 58 41 24 65 6 1994 Klaase 30
Mild hyperthermia
39-40°C 23 65 26 91 ns 1983 Lejeune 37
22 82 18 100 ns 1985 Minor 38
67 ns ns 78 ns 1990 Skene 39
35 60 34 94 ns 1990 Kettelhack 40
103 52 25 77 14 1995 Lejeune 41
103 76 23 99 10 1996 Lingam 42
Borderline true hyperthermia
40-41°C 32 56 25 81 ns 1985 Vaglini 33
26 81 0 81 ns 1985 Storm 34
85 40 42 82 ns 1995 Bryant 35
105 73 13 86 10 1997 Thompson 36
True hyperthermia
41.5-43°C 11 64 27 91 >6 1992 Kroon 32
128 46 40 86 ns 1998 Di Filippo 31
Isolated limb infusion (ILI)
37-38°C 128 41 44 85 16 2002 Lindner 49
Double perfusion schedules
Double ILP, NT 42 76 14 90 5 1993 Klaase 52
Double ILP, THT 17 65 29 94 ns 2003 Noorda 53
Double ILI 47 41 47 88 18 2004 Lindner 51
ILP = isolated limb perfusion, CR = complete response, PR = partial response, OR = overall response (= CR+PR), Med mts = median duration 
of response in months, ns = not stated, ILI = isolated limb infusion, NT = normothermia, HT = hyperthermia
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above-mentioned reasons. However, hyperthermia is associated with increased local 
toxicity. Tissue temperatures of 41.5-43°C during ILP can yield high response rates 31, 
but the local toxicity of these procedures led to major complications and even ampu-
tation of the perfused limb 32 (table 1). The use of true hyperthermia should therefore 
be avoided. The range from 39-41°C can be divided in mild hyperthermia (39-40°C) 
and borderline true hyperthermia (40-41°C). The latter is associated with high overall 
response rates of about 80%, but also with significant toxicity 33-36 (table 1). These 
observations make that mild hyperthermia for ILP is used as a compromise between 
response and toxicity 37-42 (table 1). 
Failure of prophylactic ILP and ILP with other chemotherapeutics
The efficacy of melphalan ILP in eliminating melanoma IT-mets in the limb combined 
with the concept that melanoma IT-mets commonly arise from primarily clinically 
undetectable lymphogenic tumour deposits present at the time of primary treat-
ment, give rise to the premise that prophylactic ILP of high-risk melanoma patients 
can prevent locoregional recurrence in the limb and might even influence survival. 
The first retrospective studies on this subject indeed showed improved outcome of 
patients with a high-risk primary melanoma after ILP treatment 43. Although several 
retrospective studies have since confirmed these results, it was not until 1998 that the 
shortcoming of retrospective studies could be clearly demonstrated in the first well-
designed prospective randomised trial on prophylactic ILP. This large, multicenter 
trial with 832 evaluable patients and a median follow-up of 6.4 years showed that 
although a small effect on locoregional recurrence could be observed (reduction of 
IT-mets development from 6.6 to 3.3%, reduction of regional lymph node metastases 
from 16.7 to 12.6%), there was no benefit on time to systemic metastases or on 
survival. As the procedure was accompanied by considerable morbidity and costs, 
the authors conclude that prophylactic ILP cannot be recommended as an adjunct to 
standard surgical excision in high-risk primary melanoma patients 44. 
The same discussion can be held upon the issue of prophylactic ILP after excision 
of symptomatic IT-mets. Theoretically, more benefit of a prophylactic procedure can 
be expected because of the fact that in these patients, the melanoma has already 
shown a propensity to develop locoregional recurrences. Although retrospective 
studies point out in the direction of improved locoregional control and even survival, 
the single randomised phase III trial on this subject with 69 patients and a mean 
follow-up of 39 months showed no impact on overall 5-year survival of prophylactic 
ILP (44% vs. 39% for surgical excision only), despite a slightly improved disease-
free interval. For the same reasons as mentioned above, the authors of this study 
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conclude that routine use of prophylactic ILP in melanoma patients with IT-mets is 
not to be recommended 45.
Several attempts have been made to improve the response on ILP by using other cy-
tostatic drugs than melphalan. Commonly used drugs in the treatment of systemically 
metastasised melanoma, either alone or in a combination schedule, are dacarbazine 
and cisplatinum. Therefore, amongst others, these drugs were tested in the ILP-set-
ting but no drug or drug combination used for melanoma patients has proven to 
achieve results superior to melphalan 23, 46. 
Technical modifications: Isolated Limb Infusion and double perfusion schedules
Isolated Limb Infusion (ILI) was designed by Thompson et al. in 1994 as a simplifica-
tion of the ILP procedure 47. The procedure is comparable with ILP, but the catheters 
are placed percutaneously via the contralateral groin using the common Seldinger 
technique under radiological imaging. The catheter tips are placed (for ILI of the 
lower limb) in the popliteal artery and vein just proximal to the knee, which at the 
same time is one of the main disadvantages of ILI: only lesions at the distal two 
thirds of the limb are effectively treated in contrast to ILP that can treat lesions all 
the way up to the groin. After general anaesthesia and systemic heparinisation, a 
pneumatic tourniquet is positioned at the desired level and temperature probes are 
placed. ILI is currently performed with melphalan (5-10 mg/L limb tissue) and acti-
nomycin D (50-100 µg/L limb tissue) added to 400ml of heparinised saline that has 
been warmed to 40°C. The chemotherapeutics are infused into the isolated limb via 
the arterial catheter and subsequently continuously circulated by withdrawing blood 
from the venous catheter and re-infuse it with a syringe arterially. A blood warmer is 
incorporated in the circuit to warm the infusate to 41°C before it is re-infused. This 
procedure is repeated for 30 minutes, after which the limb is flushed with saline, the 
tourniquet deflated and the catheters removed. Reported response rates of ILI are 
comparable to ILP with melphalan only 48. In a prospective study of 128 patients, 
ILI showed to be able to achieve a CR-rate of 41% and a PR-rate of 44% 49 (table 1). 
Thus, ILI is a minimally invasive procedure with less complex precaution measures 
in the operation room than ILP and with significant cost-reduction. It is effective, 
easily repeatable and more widely applicable than ILP and can therefore be the 
standard treatment for a certain high-risk patient population with distal IT-mets 50.
Another modification of the ILP-procedure has been the use of a double perfusion 
schedule. The premise that repeated administration of chemotherapeutic agents is 
more effective than single use, is adopted from the systemic chemotherapy situation 
and is based on the idea that residual tumour cells after the first treatment may be 
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eliminated and that partially damaged tumour cell after first exposure may be more 
vulnerable to chemotherapy on repeated exposures. Double perfusion schedules 
were tested both for ILI and ILP. In ILI, the double infusion protocol (median interval 
between the treatments 4.2 weeks) did not improve CR-rate, OR-rate or duration 
of response 51. In the ILP situation, the double perfusion schedule (interval 3-4 
weeks, 2nd perfusion with reduced melphalan dose, normothermic ILP) led to higher 
CR-rates than single-ILP 52, but the median duration of response was not altered. 
Fractioning of melphalan administration and the use of true hyperthermia have been 
used in a double perfusion schedule where a true hyperthermic perfusion with no 
chemotherapeutic agents was followed by a normothermic melphalan-ILP one week 
later. The achieved response rates with this protocol are high, probably due to the 
synergistic effect of hyperthermia and melphalan, whereas due to the fractioning, no 
increased toxicity was observed compared to single ILP 53.
TUMOUR NECROSIS FACTOR-ALPHA 
Probably the most influential adjustment of ILP has been the introduction of Tumour 
Necrosis Factor-alpha (TNF) by Lejeune and Lienard in 1988. TNF was isolated as 
an endogenous factor, especially active in inflammation, with necrotising ability on 
tumour cells 54. Later studies revealed that TNF has a dual mechanism of action: the 
direct cytotoxic impact of high-dose TNF to tumour cells certainly plays a role in 
anti-tumour activity 55, but more importantly the TNF effect on the so called tumour 
associated vasculature induces a rapid change in tumour morphology characterised 
by haemorrhagic necrosis 56. These observations led to high expectations on this 
cytokine in anti-tumour therapy, but systemic application, amongst others in mela-
noma patients 57, was very disappointing. TNF turned out to be a potent mediator 
in septic shock and therefore the systemic side-effects (acute drop in vascular resis-
tance leading to low blood pressure rates, fever etc.) were the major factors hinder-
ing systemic application of this cytokine 58. The maximum tolerated dose of TNF in 
humans turned out to be 10 to 50 times lower than needed for anti-tumour effects in 
murine models 59, so that systemic, but also intralesional administration of TNF was 
not clinically applicable. The concept of ILP combines the advantages of the TNF 
anti-tumour activity with the avoidance of systemic effects. Moreover, the cytotoxic 
effects of TNF are known to be enhanced in hyperthermic conditions 60 and with the 
addition of alkylating chemotherapeutics 61, both prerequisites already existing in the 
ILP model. The re-introduction of TNF in anti-cancer therapy by application in the 
ILP protocol combined optimal activity with minimal toxicity 62.
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TNF as a synergetic mediator in ILP
The mechanism of action of TNF in ILP has extensively been studied in a pre-clini-
cal rat model, mainly in a sarcoma bearing rat model as used in our laboratory 63, 
but recently also in a rat model with human melanoma xenograft 64. A very small 
direct cytotoxic effect of TNF was observed in osteosarcoma bearing rats 65, but far 
more important are the indirect effects of TNF. It was demonstrated that addition 
of high-dose TNF to the perfusate results in a 4 to 6 fold increase in uptake of 
the cytostatic drug by tumour cells. This increased uptake was tumour-specific (no 
increased uptake in normal tissue), thus emphasizing the selective action of TNF 
on the tumour-associated vasculature 66, 67. Moreover, the TNF-effect on the tumour 
vasculature induced microvascular damage by loss of endothelial cohesion 68 leading 
to haemorrhagic necrosis. This might result in a delayed effect of TNF to tumour 
regression 69. Speculations exist on a third role of TNF in its synergistic working 
mechanism: exposure to TNF might lead to an immediate drop in interstitial pressure 
in the tumour 70. 
Important lessons from the laboratory are that the temperature of the perfusate, 
analogous to the situation in melphalan-only ILPs, is of imminent importance. We 
demonstrated that true hyperthermia (42-43°C), though resulting in slightly improved 
response rates, was associated with very severe damage to the normal tissues, requir-
ing amputation of the limbs. ILP at room temperature resulted in complete loss of 
anti-tumour activity. Therefore, mild hyperthermia seems essential in TNF-based ILP 
(TM-ILP) for obtaining optimal response with minimal toxicity 71. Although hypoxia 
and acidosis are known to increase the response rates in melphalan-only ILPs 64, we 
could not demonstrate a beneficial effect of hypoxia in TM-ILP 71. 
The dose of TNF in ILP to exert its optimal effect was studied in the rat model. In 
a de-escalation study, it was shown that a fivefold reduction of the standard used 
50 µg to 10 µg did not alter the response rates significantly. Further reduction to 2 
µg, however, resulted in complete loss of additional benefit of TNF over melphalan 
alone 71. Both in vitro and in vivo studies report of a synergistic activity of Interferon-
γ (IFN) on TNF 72, 73 by increasing the number of TNF-receptors on malignant cells. 
In our rat ILP model, response rates were only slightly better (IFN added to TM-ILP 
resulted in an increase in CR rate of 23% and in Overall Response of 16%, results not 
significant), but at the cost of increased toxicity 74. Both the question of TNF dose 
and IFN addition were tested in the clinical situation and discussed later.
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CLINICAL APPLICATION OF TNF-BASED ILP
After the initial report of the clinical application of TNF setting by Lienard 62, many 
studies have been performed that all report excellent response rates of melanoma 
IT-mets on TM-ILP 62, 75-82 (table 2). These results seem far better than the results 
obtained with melphalan-only ILP, as the response rates of these studies are all su-
perior to the response on melphalan-ILP, which showed to be around 54% in a large 
meta-analysis of retrospective series 46. The early experience of 4 European centres 
showed that addition of TNF to the ILP schedule in patients with IT-mets, irrespective 
of number of tumours or size of the lesions, increased the complete response rate to 
91% 83. Recently, the American College of Surgeons Oncology Group (ACOSOG) ran-
domised phase III trial of ILP with melphalan, with or without TNF, in patients with 
localised advanced extremity melanoma was prematurely closed to patient accrual as 
an interim analysis showed that response on TM-ILP was not significantly better than 
the response achieved the melphalan alone arm. The only reported results of this 
trial from an earlier interim-analysis revealed that although overall no beneficial ef-
fect of TNF could be established, in a subgroup of patients with bulky melanoma the 
CR rate on TM-ILP was 58% compared with 19% for melphalan-only ILPs 84. These 
observations were recently sustained by Rossi et al. who found a 70% CR-rate (and 
25% PR) in a homogeneous group of bulky melanoma patients treated with (low TNF 
dose) TM-ILP 80. The tumour bulk of the melanoma IT-mets can indeed be crucial 
Table 2: The efficacy of TNF-based ILPs
Efficacy of TNF and melphalan (+interferon) ILP
ILP strategy Procedures Results Reference
N CR% PR% OR% Med 
mts
Year Author #
Mild hyperthermia
39-40°C 19 89 11 100 >8 1992 Lienard 62
44 90 10 100 >18 1993 Lejeune 75
11 64 0 64 ns 1994 Vaglini 76
58 88 12 100 26 1995 Eggermont 77
26 76 16 92 ns 1996 Fraker 78
64 73 22 95 14 1999 Lienard 79
* 20 70 25 100 10 2004 Rossi 80
90 59 ns ns 16 2004 Noorda 81
100 69 26 95 16 2004 Grünhagen 82
TNF = tumour necrosis factor, ILP = isolated limb perfusion, CR = complete response, PR = partial response, OR = overall response (= CR+PR), 
Med mts = median duration of response in months, ns = not stated
 *: low-dose TNF: 1 mg
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in appraising the TNF effect, as these large, sarcoma-like lesions benefit the most 
from the destruction of tumour associated vasculature by TNF. The inhomogeneous 
drug uptake of Soft Tissue Sarcomas was once the reason for abandoning melpha-
lan-ILP as a treatment option for these irresectable tumours 85. The application of 
TNF changed this situation dramatically as very large tumours were now observed 
to respond very well 86, which led to successful multicenter trials in Europe and the 
approval of TNF-α for the treatment of irresectable extremity soft tissue sarcomas 87. 
Unfortunately, TNF is not clinically available in North America because the patent 
and licensing rights are in the hand of a different company and thus the registration 
file has not been presented to the FDA. Based on the presently available evidence, 
we recommend the use of TNF in ILP for bulky melanoma IT-mets 82.
The role of IFN and the optimal TNF dose
Most of the TM-ILP studies include at least a number of patients in whom IFN was 
added to the perfusion schedule. It consists of the subcutaneous injection of 0,2 mg 
IFN on days –2 and –1 prior to the ILP and the injection of 0.2 mg IFN during the 
ILP procedure into the arterial line prior to the administration of TNF and is based 
on the presumed synergy between TNF and IFN. Its role has been evaluated in a 
randomised phase II trial that showed only a marginal improvement of outcome for 
the combination with TNF 79, which is in line with the above-mentioned preclinical 
studies. 
The optimal TNF dose in ILP for the synergistic effect with melphalan has never 
been properly determined. However, both preclinical 71 and clinical studies 80, 88, 89 
suggest that TNF dose reduction to 1 mg might be as effective as the now standard 
used TNF dose of 3 mg for arm- and 4 mg for leg-ILPs. We recently performed a 
retrospective, non-randomised study of 64 ILPs performed with reduced-dose TNF 
(16 melanoma ILPs) demonstrating no effect of TNF dose reduction on response, 
disease free survival or overall survival 90. This suggests that the presently standard 
TNF dose might be higher than necessary to achieve maximum synergy between 
TNF and melphalan.
Prognosis after TM-ILP
Although TM-ILP can achieve excellent response rates in patients with melanoma 
IT-mets, the nature of the disease determines that the patients in this very unfavour-
able population often experience local recurrence of disease in the limb. Reported 
recurrence rates after ILP are around 50% 36, 82, 91, 92 and as mentioned in table 2, occur 
after a median time of 1-1.5 years after ILP. The prognostic factor for local recurrence 
in the limb is the total number of IT-mets present at the time of ILP 82. The 5 years 
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survival of patients after TM-ILP was 32% in our series and was only influenced 
by stage of disease and age of the patient 82. An important observation is that after 
an initial CR to ILP, melanoma recurrences were usually not at the site of tumour 
deposits that had been clinically apparent at the time of ILP but at other sites in the 
same limb 36. This indicates that ILP is effective in tumour deposits large enough to 
have own tumour associated vasculature, but fails to be active against single tumour 
cell deposits. This might be the explanation for the failure of prophylactic ILP and 
the high recurrence rate after therapeutic ILP and gives support to the anti-vascular 
tumour activity of TNF. The management of limb recurrences after ILP is essentially 
the same as for IT-mets in general: local excision if technically feasible, but repeat 
ILP in extensive disease 92. Response rates of repeat ILP are comparable to those 
achieved after single perfusion 93-95 and thus, repeat ILP can provide prolonged lo-
cal control in this patient category. We recently found that the 5-year survival rate 
after repeat ILP in our institution is 47% 95, which compares favourably to known 
survival percentages of patients with melanoma IT-mets 5 and might be indicative of 
a relatively favourable biologic behaviour of the melanoma in patients that qualify 
for a repeat ILP procedure. A repeat ILP procedure can thus be worthwhile and is 
indicated both for recurrences after previous TM-ILP and after failure of ILP with 
other chemotherapeutics 94.
Although we know that the prognosis for melanoma patients with stage IV disease 
(systemic metastases present) is inevitably fatal, usually within one year, some pa-
tients have such disabling local disease in the limb that ILP can be considered. The 
response percentages of ILP in stage IV disease are significantly lower than generally 
achieved with TM-ILP 79, 82, 91, presumably due to the aggressive biologic behaviour 
of the tumour in these disseminated patients. Nevertheless, local control of the limb 
is the goal of treatment in these patients during the short remaining life period. This 
can be provided by TM-ILP, which makes this procedure a valuable palliative treat-
ment option in stage IV melanoma patients 96, 97.
TM-ILP is a safe procedure
Whether TNF increases local toxicity compared to a melphalan-only ILP is still under 
debate. Initial reports explicitly state that no increased local toxicity was observed 
in a triple drug (TNF, melphalan, IFN) regimen 62, 98. However, in a TNF dose escala-
tion study with TNF doses up to 6 mg, Fraker et al. report that local toxicity was 
significantly related with TNF dose 78. The authors speculate that the reason for 
this observation is the increased uptake of melphalan in the tissue, as experimental 
ILPs with TNF only, did not reveal local toxicity at all. Melphalan dose (total dose, 
peak concentration, concentration at equilibrium and area under curve) is a major 
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determinant of acute local toxicity 99, 100. The one study specifically addressing the 
local toxicity of TM-ILP, showed a significant increase of local toxicity with TNF 
compared to melphalan-only ILPs 101. The confounding factor here however was 
that the patients in that study participating in the TNF-ILP protocol were, due to trial 
prescriptions, exposed to higher temperatures during melphalan circulation. This 
difference might be partly the explanation of the observed difference in toxicity. 
Minimizing local toxicity is essential as it has shown to be directly correlated with 
the incidence of long-term morbidity (tissue fibrosis, muscle atrophy and limb mal-
function) 102. At present, TM-ILP is performed under mild hyperthermic conditions 
with gradual administration of melphalan instead of bolus injection. No difference in 
acute local toxicity, nor in long-term morbidity exist between TM-ILP and melpha-
lan-only perfusions 81.
Systemic toxicity is directly correlated with leakage of the chemotherapeutics to the 
systemic circulation 87, 103-105. In the present situation of leakage-free ILPs, the systemic 
toxicity is mostly limited to fever in the first 24 hours postoperatively, which can 
be easily avoided by the immediate postoperative application of indomethacin and 
/ or paracetamol. Furthermore the patients commonly show a period of 6-10 hours 
of a slightly elevated circulation due to a drop in peripheral resistance, which is 
compensated by a mild tachycardia and a small drop in blood pressure. Essential 
in the management of this circulatory change is a policy of ample hydration of the 
patient during ILP and for the first 12-24 hours after ILP. This policy assures to have 
adequate diuresis in all patients in order to keep the period of high circulating TNF 
levels post-ILP as short as possible 103. Standard use of vasopressors is not recom-
mended. A further reduction of systemic toxicity by reducing the TNF dose could 
not be demonstrated 90.
TM-ILP is a safe procedure, both in terms of local and systemic side effects. It can be 
easily performed in elderly people 106, 107 and can be repeated if necessary without 
increasing toxicity 94, 95.
CONCLUSION 
TNF-based ILP has earned a permanent place in the treatment of patients with 
melanoma IT-mets, albeit for a selected patient population. Patients with only few, 
small IT-mets should be treated locally: radical surgery if feasible, carbon dioxide 
laser therapy if necessary. ILP with melphalan has proven to be effective in patients 
with multiple IT-mets. If lesions are small and it is not likely that tumour-associated 
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vasculature has been formed, the additional effect of TNF is on theoretical ground 
negligible. In these cases, especially if lesions are located on the distal two-thirds of 
the limb, ILI is a very good alternative. In patients with high tumour burden however, 
TM-ILP seems superior to any other technique. Although a costly procedure, it can be 
performed safely and leads to excellent response rates in patients with limb-threaten-
ing and socially disabling disease. At present, TM-ILP is the most efficacious proce-
dure to obtain local control and achieve limb salvage in this patient category 108.
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ABSTRACT
Background
Extensive and mutilating surgery is often required for locally advanced Soft Tissue 
Sarcoma (STS) of the limb. As it has become apparent that amputation for STS does 
not improve survival rates, the interest in limb-preserving approaches has increased. 
Isolated Limb Perfusion (ILP) with TNF and melphalan is successful in providing lo-
cal tumour control and enables limb-preserving surgery in a majority of cases. Here 
we report on the mature largest single-institution experience with 217 consecutive 
ILPs for STS of the extremity.
Methods
Prospectively maintained database at a tertiary referral center. From July 1991 – July 
2003, 217 ILPs were performed in 197 patients with locally advanced STS of the ex-
tremity. ILPs were performed at mild hyperthermic conditions with 1 to 4 mg of TNF 
and 10 to 13 mg/L limb-volume melphalan for leg and arm perfusions, respectively.
Results
Overall response rate was 75%. Limb salvage was achieved in 87% of the perfused 
limbs. Median survival post-ILP was 57 months and prognostic factors for survival 
were Trojani grade of the tumour and ILP for single versus multiple STS. The pro-
cedure could be performed safely with a peri-operative mortality of 0.5% in all 
patients with no age-limit (median age 54 years, range 12-91 years). Systemic and 
locoregional toxicity were modest and easily manageable.
Conclusions
TNF+M-based ILP can provide limb salvage in a significant percentage of patients 
with locally advanced STS and has therefore gained a permanent place in the multi-
modality treatment of STS.
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INTRODUCTION
In the United States, 8680 new cases of Soft Tissue Sarcomas (STS) are diagnosed 
annually, and approximately 60% of these tumours occur in the extremity 1. Although 
the propensity of the tumour to develop systemic metastases is the primary cause of 
the high disease-specific mortality rate (up to 50%), the extremity tumours are often 
large at time of presentation, causing a local management problem 1. The local situa-
tion in the limb may require extensive and mutilating surgery (±radiotherapy), which 
can cause severe disability of the limb, while in some 10% of cases amputation may 
be inevitable. With the emergence of evidence that amputative surgery does not 
improve survival 2-4, the tendency to perform more and more limb-preserving surgery 
has led to the exploration of Isolated Limb Perfusion (ILP) as a procedure enabling 
limb salvage at time of surgery in cases of primarily unresectable STS. 
ILP was fist described by Creech et al in 1958 5 and is since then primarily used with 
melphalan as the cytostatic drug in patients with melanoma in-transit metastases. In 
contrast to high response rates in melanoma patients, the results in STS patients were 
uniformly disappointing 6, 7. The introduction of Tumour Necrosis Factor-α (TNF) 
in ILP by Lejeune and Lienard changed this situation dramatically as they reported 
not only high response rates in 13 melanoma patients, but also in 4 patients with 
advanced extremity STS 8. This led to multicenter studies evaluating response and 
limb salvage rates using TNF-based ILPs with or without Interferon-gamma, show-
ing consistently overall response rates of 75% to 85% and limb salvage in a similar 
percentages of the patients 9, 10. These results led to the approval of TNF in Europe 11. 
At present, TNF-based ILP for extremity STS is used as induction biochemotherapy 
to obtain local control and to make limb-sparing surgery possible. Here we report 
on the mature results of the largest single center experience of 217 consecutive ILPs 
with TNF and melphalan (TM-ILPs) for locally advanced STS.
PATIENTS AND METHODS
Patients
From July 1991 – July 2003, 217 TM-ILPs were performed in 197 patients for locally 
advanced STS. Fourteen patients underwent a second ILP after recurrence of the 
tumour in the limb; 2 patients had 3 ILP procedures. In 4 patients (1 with Stewart-
Treves lymphangiosarcoma, 2 with Kaposi sarcoma and 1 with neurofibrosarcoma), 
a second ILP procedure was performed on the other leg because of bilateral disease. 
Thus, a total of 201 limbs were treated with an ILP. There were 101 men and 96 
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Table 1: Patient and tumour characteristics of 217 TM-ILPs in 197 patients
Patient and tumour characteristics of 217 TM-ILPs in 197 patients
N %
Gender female 108 50 
male 109 50 
Age ≤ 50 93 43
> 50 124 57
Size < 5 cm 67 31
5 – 10 cm 58 27
> 10 cm 92 42
Trojani Grade 1 41 19
2 60 28
3 116 53
Site upper arm 31 14
lower arm 29 13
upper leg 108 50
lower leg 49 23
Histology Liposarcoma 31 14
Synovial Sarcoma 34 16
MFH 34 16
Leiomyosarcoma 18 8
Desmoid/Agg Fibro 12 6
St-T/Kaposi sarcoma 23 11
Other (16 tumour types) 65 30
Primary/recurrent primary 132 61
recurrent 85 39
Previous treatment None 161 74
XRT 34 16
CT 21 10
ILP 11 5
Single/multiple single 153 71
multiple 64 29
Post- ILP treatment None 145 67%
XRT 59 27%
CT 10 5%
XRT + CT 3 1%
TM-ILP = isolated limb perfusion with TNF and melphalan, MFH = malignant fibrous histiocytoma, Agg Fibro = aggressive fibromatosis, St-T = 
Stewart-Treves lymphangiosarcoma, XRT = radiotherapy, CT = chemotherapy
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women with a median age at time of ILP of 54 years (range 12-91 years). Patient and 
tumour characteristics are summarized in table 1. All patients were candidates for 
amputation of the limb as resection of the tumour was impossible, or only possible 
at the cost of severe functional morbidity, due to either fixation of the tumour to neu-
rovascular structures or bone, multifocality of the tumour or location of the tumour 
in a previously irradiated area without the possibility to perform a complete radical 
resection. Median follow-up of all patients was 22 (range 0.1-130) months.
Treatment
Patients underwent an ILP via the axillary (N=25), brachial (N=35), iliac (N=94), 
femoral (N=38) or popliteal (N=25) approach. ILP technique has been described pre-
viously 9, 10. Briefly, recombinant human TNF (Boehringer Ingelheim GmbH, Ingel-
heim/Rhein, Germany) and the cytostatic drug melphalan (L-PAM, Alkeran, Burroughs 
Wellcome Ltd., London, UK), obtained as a sterile powder, were dissolved aseptically 
using solvent and diluents (Burroughs Wellcome Ltd., London, UK). Isolation of the 
blood circuit of a limb was achieved by clamping and canulation of the major artery 
and vein, connection to an oxygenated extracorporeal circuit, and application of a 
tourniquet to compress the remaining collateral vessels. TNF was injected as a bolus 
into the arterial line provided limb tissue temperature had reached 38°C. Melphalan 
was administered after 30 minutes at limb temperatures between 38 and 39.5°C. The 
administration of melphalan changed during the studied period from injection as a 
bolus (1991-1996) to infusion by pump over a period of 20 minutes (1996-present), 
because of reports that melphalan peak concentration is correlated with regional 
toxicity 12. ILP consisted of a 90-minutes perfusion with 1 to 3 mg (arm) or 1 to 4 
mg (leg) TNF, and a 10-mg/l (leg) or 13-mg/l (arm) volume of melphalan at mild 
hyperthermia (tissue temperatures of maximally 39.5°C in the leg and 38.5°C in the 
arm). Median dose of melphalan was 70 mg (mean 73.3, range 0-160); median dose 
of TNF was 4 mg (mean 3.5, range 1-4). In the first 25 ILPs, performed between 1991 
and 1994, interferon γ (IFN) was added to the schedule according to trial prescrip-
tions consisting of the subcutaneous injection of 0,2 mg IFN on days –2 and –1 prior 
to the ILP and the injection of 0.2 mg IFN during the ILP procedure into the arterial 
line prior to the administration of TNF. During the procedure, continuous leakage 
monitoring was performed by using a precordial scintillation probe to detect leakage 
of radiolabelled albumen injected into the perfusion circuit. At the end of the ILP, the 
limb was washed out with at least 1 L (arm) up to 4 L (iliac perfusion) of physiologic 
saline solution and 6% dextran 70 (Macrodex Pharmacia, Uppsala, Sweden). ILPs 
were performed under general anaesthesia and normally took 2.5 to 4 hours. Median 
hospital stay of the patients was 8 days (mean 12, range 2-136).
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Response evaluation and toxicity
Clinical response evaluation was performed 2, 4, 8 and 12 weeks after ILP and 
hereafter every 3 months for the first year both by clinical examination and by MRI 
(after 4-6, 8-12 weeks after ILP and hereafter every 3-6 months) 13, and reported 
according to WHO-criteria. In 130 patients, histological response could be assessed 
and in these patients response rates were adjusted if the pathological response 
(complete response (CR) if 100% necrosis, partial response (PR) if 50-99% necrosis 
and no change (NC) if <50% necrosis) differed from clinical response. New lesions or 
growth of the tumour at first response evaluation is reported as progressive disease 
(PD), and if occurring during follow-up as local progression.
Acute local toxicity of the ILP procedure was classified according to Wieberdink et 
al. 14: (I) no reaction, (II) slight erythema or edema, (III) considerable erythema or 
edema with some blistering, slightly disturbed motility permissible, (IV) extensive 
epidermolysis or obvious damage to the deep tissues, causing definite functional 
disturbance, and threatening or manifest compartmental syndrome, and (V) reaction 
that may necessitate amputation. Systemic toxicity is reported according to WHO 
criteria.
Statistical evaluation
Overall survival (OS) and time to local/systemic progression (TTLP/TTSP) were 
defined as time from ILP to death, local progression and systemic progression re-
spectively and estimates were made using the method of Kaplan and Meier. We 
evaluated the prognostic value of some baseline categories on overall response (CR 
or PR) achievement, using the Fisher’s exact test for univariate analysis and logistic 
regression for multivariate analysis. Logrank test and Cox regression were used for 
TTLP, TTSP and OS. Based on previous reports on prognostic factors in patients with 
extremity STS 15, 16, we chose to evaluate gender and age of the patient, size, Trojani 
grade 17 and histology of the tumours and presentation with recurrent disease at time 
of ILP. We added previous irradiation therapy and presence of multifocal tumours to 
these baseline categories, as these conditions are often present when ILP treatment is 
considered. After univariate analysis all these factors were included in a multivariate 
model. We used a stepwise backward algorithm in order to exclude factors without 
prognostic value starting with the factor with the highest p-value, until p<0.05. All 
tests were done at a significance level of 5%.
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RESULTS
Tumour response 
Of 217 TM-ILPs for STS, a clinical complete response was obtained in 38 ILPs (18%), 
PR in 111 ILPs (51%), NC in 62 (29%) and PD in 4 (2%) ILPs. Clinical response was 
not assessed in 2 patients (1%, 1 patient died shortly after ILP, 1 reason unknown). In 
130 patients (60%), ILP had made a complete resection of the tumours possible (71% 
in patients with single tumours, 34% in patients with multiple tumours, figure 1). In 
these patients (and in a minority of patients, especially with multiple sarcomas, in 
whom a core biopsy was performed to assess histological response), final outcome 
was adjusted according to the necrosis percentage found on histological evaluation. 
Final outcome therefore was: 56 CR (26%), 106 PR (49%), 49 NC (23%) and 5 PD 
(2%), resulting in an overall response percentage of 75%. One patient died 3 days 
after ILP so final response to ILP could not be assessed. On univariate analysis, the 
presence of multiple tumours (p=0.006) and ILP for Stewart-Treves lymphangiosar-
coma or Kaposi sarcoma (p=0.002), were both related with a significantly better re-
sponse rate (table 2). Only the latter remained statistically significant in multivariate 
analysis. There were no histological tumour types that did not, or significantly worse, 
respond to ILP. After ILP (± tumour resection), 72 patients received adjuvant therapy 
consisting of radiotherapy in 59 patients, systemic chemotherapy in 10 patients and 
a combination of both in 3 patients.
Table 2: Univariate analysis of clinical prognostic factors for CR/PR achievement, local progression, systemic progression and 
survival
Univariate analysis of clinical prognostic factors for CR/PR achievement, local progression, systemic progression 
and survival
Variable CR/PR Local progression Systemic 
progression
Survival
Gender NS NS NS NS
Age NS NS NS NS
Size of the tumour NS p<0.001 NS NS
Trojani grade NS NS p=0.001 p=0.020
Histology p=0.041* p<0.001 p=0.006 NS
Primary / Recurrent NS p=0.009 NS NS
Previous XRT NS p=0.011 NS NS
Single / Multiple 
tumours p=0.006 p<0.001 NS NS
CR = complete response, PR = partial response, XRT = radiotherapy, NS = not significant
* Overall, histology is a borderline significant prognostic factor for response (p=0.041), but Stewart-Treves lymphangiosarcoma / Kaposi 
sarcoma is associated with higher response rates (p=0.002, see text)
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Limb function
Limb function of the 201 perfused limbs was assessed in 194 cases (97%) and was 
without functional loss in 145 limbs (72%), mildly disturbed in 14 (7%) and severely 
diminished leading to the use of crutches in 9 limbs (4%). An amputation could not 
be avoided in 26 perfused limbs (13%). Fifteen patients had an insufficient clinical 
response (PD/NC) and underwent immediate amputation. Notably, histological ex-
amination of the amputated limb showed PR in 3 of these patients. Nine amputations 
had to be performed due to rapid progression (2-9 months) after ILP: 5 after PR and 
4 after CR. One patient with a histological PR but with sufficient local control of a 
synovial sarcoma of the lower leg developed a late local progression after 36 months 
necessitating amputation. One other patient had to undergo a late amputation: de-
layed resection of a 100% necrotic malignant fibrous histiocytoma of the lower leg 
caused osteomyelitis because of a period of inadequate soft tissue coverage of the 
bone resulting in a pathological fracture 17 months after ILP. Two patients had to 
undergo leg amputation during the follow-up period due to pre-existing vascular 
disease. Although the ILP-procedure might have altered the course of the vascular 
disease in these patients, these amputations are not considered Wieberdink V local 
toxicity or tumour-related amputations for analysis in this study.
Leakage and toxicity
Leakage of TNF and melphalan, as is reflected by the leakage of radioactively la-
belled albumen to the systemic circulation, was absent or minor (<10%) in 192 ILPs 
(88%). Median leakage was 0%, mean 2.6%. Six procedures were complicated by 
significant leakage of >20% (21-23-25-29-34-64%), but no serious systemic toxicity 
occurred in these patients and none of the patients required intensive-care stay of 
more than 24 hours. The 64% leakage in 1 ILP was attributable to snapping of the 
tourniquet 35 minutes after administration of TNF, just after adding melphalan to the 
perfusate. All other high-leakage ILPs were terminated when leakage exceeded 20%, 
but melphalan circulation time was at least 45 minutes in all these cases.
Local toxicity of the procedure was absent or mild (Wieberdink I-II) in 165 cases 
(76%), Wieberdink III in 45 patients and Wieberdink IV in only 4 patients. No treat-
ment-related amputation had to be performed. In 3 patients local toxicity could not 
be assessed (1 rapid amputation due to PD, 1 rapid death and 1 reason unknown). 
Systemic toxicity was restricted to a transient rise in core temperature >40˚C in 8 
patients, lasting over 24 hours in 1 patient. No toxic shock-like syndrome neces-
sitating the use of vasopressors occurred. One patient, a 91-year old patient with 
significant arteriosclerosis and an excessively large high-grade liposarcoma of the 
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leg, developed a thrombosis of the mesenteric artery and died 3 days post-ILP (peri-
operative mortality 0.5%).
Local progression
Local progression of STS in the limb was observed after 57 ILPs (26%). If progression 
occurred, median time to local progression was 8.9 (range 1-54) months. Of these 
local failures, 28 occurred after resection of the tumour remnants post-ILP and are 
therefore true local recurrences (28 in 130 resections: 22%). Twenty-nine patients 
developed new lesions after ILP, or late regrowth of the known lesion(s), but in these 
patients the tumour was not resected after ILP (29 in 87 cases: 33%). The implications 
on local control of the management of the tumours post-ILP (resection, post-ILP ir-
radiation) are outlined in figure 1.
Univariate prognostic factors for developing a local recurrence included size and 
histology of the tumour, ILP for recurrent STS, previous radiotherapy and the pres-
ence of multiple tumours. Prognostic factors for local progression after multivari-
ate analysis were: tumour type (synovial sarcoma, malignant fibrous histiocytoma, 
leiomyosarcoma and Stewart-Treves/Kaposi associated with higher local recurrence 
rates) and multiple sarcomas at presentation (p<0.001). Prognostic factors are listed 
in tables 2 and 3.
Figure 1: Flow-chart of management after ILP and its implications on local control
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Figure 1: Flow-chart of management after ILP and its implications on local control
ILP = isolated limb perfusion; XRT = radiotherapy; Loc Rec = local recurrence
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Systemic progression 
We observed systemic metastases after ILP in 92 patients (42%). In those patients 
who developed systemic metastases, they became manifest after a median period of 
4.6 (range 0-80) months. Notably, 34 patients (16%) had stage IV disease (metastases 
present) at time of ILP. On univariate analysis, Trojani grade (p=0.001) and histol-
ogy (p=0.006) were significant prognostic factors for the development of systemic 
metastases. On multivariate analysis, age of the patient, size, grade and histology 
of the tumour and the presence of multiple tumours all were significant prognostic 
factors (tables 2 and 3). 
Survival
Overall, 5-years actuarial survival rate was 49%; median survival was 57 months. 
Survival after ILP for extremity STS is shown in figure 2. The prognostic factor for 
overall survival after ILP was Trojani grade (both on uni- and multivariate analysis, 
figure 2 b). Despite the fact that patients with multiple tumours had lower, but not 
Table 3: Multivariate analysis on local progression, systemic progression and survival
Multivariate analysis on local progression, systemic progression and survival
Variable Local progression Systemic progression Survival
HR p HR p HR p
Age ≤ 50 1
> 50 0.6 0.039
Size of the tumour ≤ 5 cm 1
5 – 10 cm 1.5 NS
≥ 5 cm 2.4 0.005
Trojani grade 1 1 1
2 2.1 NS 2.5 NS
3 3.2 0.030 3.6 0.003
Histology Lipo 0.8 NS 0.5 NS
Synovial 4.9 0.002 1.4 NS
MFH 5.0 0.001 0.7 NS
Leio 4.6 0.004 0.7 NS
Desmo 0.7 NS 0.0 *
St-T / Kaposi 2.9 0.036 0.2 0.005
Other 1 1
Single / multiple single 1 1 1
multiple 4.6 <0.001 2.4 0.001 1.7 0.015
* = Perfect prediction: no systemic progression in desmoid tumours
HR = hazard ratio, Lipo = liposarcoma, Synovial = synovial sarcoma, MFH = malignant fibrous histiocytoma, Leio = leiomyosarcoma, Desmo = 
desmoid/aggressive fibromatosis, St-T = Stewart-Treves lymphangiosarcoma, up = upper, low = lower, NS = not significant
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statistically significant lower, survival rates than patients with single tumours (53% vs. 
39% at 5 years, p=0.152), this factor showed to be significant on multivariate analysis 
(p=0.015, tables 2 and 3, figure 2 c).
a) Total (X-axis: time in months; Y-axis: cumulative percentage)
Figure 2: Overall survival, total (a), by Trojani grade (b) and by single/multiple (c) 
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DISCUSSION
The currently presented study of 217 TM-ILPs in a single center setting shows that 
limb salvage can be achieved in a large percentage of patients by combining induc-
tion biochemotherapy with marginal resection of the tumour. Even by ILP alone, sig-
nificant tumour response rates can be obtained providing long-lasting local control 
in patients with large extremity STS and a limited life expectancy.
Response and limb function
The overall response rate in this series of 75% is in range with previous reports on 
TM-ILPs for STS with response rates varying from 63% to 91% 9, 10, 18-20. With only 26 
amputations in 201 perfused limbs, the limb salvage rate was 87%, which compares 
to smaller series reported in the literature. This is in fact an important observation, 
as we know that a large proportion of the patients will eventually develop systemic 
metastases and succumb to their disease. However, the local problem of a large 
tumour in the extremity can be managed with ILP, even if no resection is performed 
or if response is not complete. As TNF acts on tumour associated vasculature by 
destroying the vessels 21 and increasing the uptake of melphalan in the tumour in the 
preclinical tumour models 22, one could expect that response rates would be better 
in well-vasularised (high-grade) and large tumours. We could not demonstrate such 
a preferential effect in this study, nor could we identify a negative effect in tumours 
that lack extensive vascularisation. The only prognostic factors for response were 
ILP for multiple tumours and ILP for Stewart-Treves lymphangiosarcoma or Kaposi 
sarcoma. As these factors are highly related, only the latter remained statistically 
significant on multivariate analysis. We know from previous reports that response 
rates in these tumours indeed are very high (87-100% 23, 24), presumably as these are 
small and highly vasularised tumours, and therefore we speculated that the clinical 
situation in these tumours more resembles the melanoma- than the STS-situation 25. 
Progression and survival
Local tumour recurrence in this study occurred in 26%, which again is in range with 
results from the literature on ILP, ranging from 11% to 45% 9, 10, 18-20. This is slightly 
higher than the 10% to 20% local recurrence rate reported in the literature for all STS 
of the extremity 26-28, supposedly because a large percentage of the patients qualify-
ing for ILP presents with recurrent disease (39% in this study), which is a known 
adverse prognostic factor for local recurrence 29. Systemic metastases developed in 
42% of the patients and the actuarial 5-years overall survival rate was 49%. We could 
determine Trojani grade and leiomyosarcoma and synovial sarcoma as prognostic 
factors for systemic recurrence and Trojani grade as prognostic factor for survival, 
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which is virtually equal with known data 15, 16. The fact that size of the tumour is not 
a prognostic factor for survival in our study, but on multivariate analysis presentation 
with multiple tumours is, reflects the high number of patients presenting with small 
but numerous tumours who specifically are candidates for ILP as primary resection 
is not feasible in these patients. 
ILP with consecutive limb-sparing surgery is considered to be the alternative for 
amputation in this study population. This is based on the insight that limb-preserving 
surgery is equal to amputation in terms of survival 2-4, although the local recurrence 
rate of 10% to 20% 26-28 after limb-sparing resection is obviously higher than when an 
amputation is performed. There still is a debate whether local recurrence of STS is a 
determinant of overall survival, with studies that do not find a statistically significant 
effect 2, 29 and studies that do 27, 30. Although the authors of the latter studies argue 
that patients who develop a local recurrence need aggressive treatment, a study 
from Memorial Sloan-Kettering Cancer Center showed that even in a patient category 
presenting with recurrent disease, amputation only improves local control but not 
survival 31. We therefore claim that ILP is justified as a treatment option allowing 
limb-preservation in both primary and recurrent STS. 
As ILP was applied to make limb-sparing surgery possible in the majority of patients 
in this study, its effect should be compared to other neo-adjuvant treatment regi-
mens. The impact of induction systemic chemotherapy on the resectability of STS 
was recently studied at the MD Anderson Cancer Center 32. Although a response 
of the tumour was observed in 43% of the patients, only 13% of the population 
(consisting of 65% extremity STS and 35% retroperitoneal STS patients) showed a 
radiographically documented response sufficient to reduce the extent of the opera-
tion. Notably, none of the extremity STS patients scheduled for amputation could 
be treated with limb-sparing surgery after neo-adjuvant systemic chemotherapy 32. 
These results are sustained by a randomised study on neo-adjuvant chemotherapy 
for “high-risk” adult STS (150 patients, 82% extremity STS). In none of the 9 patients 
scheduled for amputation in this study, neo-adjuvant chemotherapy could provide 
limb salvage 33. Systemically administered chemotherapy does have the advantage 
of a possible systemic effect on distant (micro-)metastases, although a large meta-
analysis of doxorubicin-based adjuvant chemotherapy only showed a reduction in 
time to recurrence (both local and distal), but no significant effect on survival 34. ILP 
with doxorubicin or melphalan alone in advanced STS has failed to demonstrate 
adequate activity in studies performed in the Netherlands 35 and in a recent study 
performed at MD Anderson 36 and is not recommended. Presumably the poor drug 
uptake in large tumours without the use of TNF is the cause of this failure 11, 37. 
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Preoperative radiotherapy also has the possible advantage of reducing the tumour to 
a size making resection possible. To our knowledge, no data on this issue exist to 
date. Preoperative radiotherapy has shown in a randomised trial to be as effective as 
postoperative irradiation in terms of progression-free survival, but is associated with 
higher wound-complication rates 38. Chemoradiotherapy, a combination of preopera-
tive (intra-arterial or intravenous) chemotherapy and radiotherapy, has shown to 
provide excellent local control rates and improved overall survival with acceptable 
toxicity both in small exploring studies 39 and in a comparison with a historical con-
trol group 40. However, this treatment option remains investigational and the results 
of randomised trials are awaited. Moreover, to compare chemoradiotherapy with 
ILP is difficult, as the tumours are primarily resectable in the first, whereas they are 
generally not in the second.
As TM-ILP can be of particular value in the palliative treatment of patients with 
metastatic disease and a rapidly growing tumour threatening the limb, it is of emi-
nent importance that the procedure is safe and without severe side effects. Systemic 
toxicity is directly correlated with leakage of TNF (and melphalan) to the systemic 
circulation 41-43. In the present time of leakage-free ILPs, it should not be necessary to 
use vasopressors in order to keep the blood pressure at adequate levels to counter-
act the systemic inflammatory response syndrome that can occur when significant 
levels of TNF reach the systemic circulation. Ample hydration and adequate diuresis 
in order to keep the levels of circulating TNF after ILP low, should prevent systemic 
toxicity even in high-leakage ILPs 43. The procedure can be safely performed in 
patients with advanced age 44 and the median hospital stay of 8 days shows that the 
procedure is relatively mild to undergo. This is also underlined by the peri-operative 
mortality-rate of 0.5%.
The results obtained in the 217 consecutive TM-ILPs described here, underline that 
TNF-based isolated limb perfusion can play a major role in the treatment of limb-
threatening extremity STS. TM-ILP can provide excellent local control and a high rate 
of limb salvage. Therefore, TNF+M-based-ILP has gained a permanent place in the 
multimodality treatment of locally advanced extremity STS and is currently available 
in some 40 referral centers in Europe.
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ABSTRACT
Background
Treatment for extremity soft tissue sarcoma (STS) shifted in recent years from am-
putation to local wide excision combined with irradiation. For multiple sarcomas, 
this limb-sparing approach is often not possible. To avoid amputations, isolated limb 
perfusion (ILP) with tumour necrosis factor-α (TNF) and melphalan is an attractive 
treatment option for patients with multiple extremity sarcomas.
Methods
We investigated a prospective database at a tertiary referral institute. From July 1991 
to July 2003, out of 217 ILPs, 64 ILPs were performed for either multifocal primary 
sarcomas or multiple sarcoma recurrences in 53 patients. All ILPs were performed 
under mild hyperthermic conditions by using 1 to 4 mg TNF and 10 to 13 mg/L limb 
volume for leg and arm perfusions, respectively.
Results
The overall response was 88%, with 42% complete response, 45% partial response, 
11% no change and 2% progressive disease. This response rate is significantly better 
than our experience in 153 locally advanced single STS cases (88% vs. 69%). The 
toxicity of the procedure was mild to moderate in almost all cases; no treatment-
related amputation had to be performed. The time to local recurrence was 29 months 
and differed significantly between multiple primary and multiple recurrent STS. The 
5-year survival rate was 39%. Limb salvage was achieved in 45 (82%) of 55 treated 
limbs.
Conclusions
In a group of patients who are uniformly candidate for amputation, ILP can achieve 
limb salvage in approximately four out of five patients. Because this treatment op-
tion provides excellent local control, it should be considered before an amputation 
is planned.
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INTRODUCTION
Of the 7800 new cases of soft tissue sarcoma (STS) diagnosed in the USA each 
year, approximately 4700 occur in the extremities 1. Tumours are often large at 
the time of diagnosis. Treatment options for locally advanced extremity STS may 
consist of an amputation or an extensive limb-sparing surgical procedure followed 
by radiation therapy. This combination may mutilate and compromise limb function 
considerably. Since the application of tumour necrosis factor (TNF)-α in combina-
tion with melphalan in the isolated limb perfusion (ILP) setting, a new limb-salvage 
strategy has emerged. Multicenter trials in Europe have established high response 
rates and limb salvage rates in the management of limb-threatening STS, which led 
to the approval of TNF for this indication in Europe 2, 3. Subsequent single center 
reports on TNF-based (TM-)ILP have reported response rates varying from 63-92 % 
and limb-salvage rates ranging from 58% to 85% 4-8; this is very much in line with the 
76% response rate and 71% limb-salvage rate as achieved in the multicenter pivotal 
trials setting 9. 
Multiple sarcomas in the extremities are very rare and are usually uniformly treated 
by amputation of the limb 10, 11. Reports on the surgical management of these patients 
are scarce because surgical options are usually limited to amputation of the limb. 
Limb salvage has come to the forefront in the management of all patients with ex-
tremity STS in light of the data that have shown that this approach has not influenced 
survival outcome adversely 12-14. Because amputations are very rarely performed 
for patients with melanoma in-transit metastases, we have adopted a limb-salvage 
approach in patients with multiple sarcomas by using TM-ILP. In this report, we 
describe our unique experience with 64 TM-ILPs in the management of in 53 patients 
with multiple limb sarcomas.
PATIENTS AND METHODS
Patients
Out of 217 TM-ILPs for STS performed in the Daniel den Hoed Cancer Center be-
tween 1991 and July 2003, 64 ILPs were performed on 53 patients with multifocal 
sarcoma. Two patients, one patient with Kaposi sarcoma and one patient with Stew-
art-Treves lymphangiosarcoma, underwent ILPs on both legs, thus making the total 
number of limbs 55. There were 29 women and 24 men with a median age of 61 
years (range 20-88 years). Nine ILPs (14%) were performed in patients with stage IV 
disease (systemic metastases were present). Histological subtyping of the tumours 
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and classification of tumour grade according to Trojani 15 et al. are listed in table 1. 
In total, 28 ILPs were performed on patients with multifocal primary STS, and 36 
ILPs were performed for multiple recurrent STS. A patient was regarded as having 
multifocal primary STS when presenting with multifocal disease without previous 
surgical resection of STS in the limb. Multiple recurrent STS was defined as the 
occurrence of multifocal recurrences of STS after previous surgery (with or without 
irradiation) for the primary tumour. Recurrences of Kaposi sarcoma and Stewart-
Treves lymphangiosarcoma were also considered multifocal primary tumours when 
they “recurred” after ILP, because of the nature of the disease dictated that no prior 
complete surgical resections had preceded ILP. Twenty-six patients had undergone 
other previous treatments for their STS. These treatments consisted of irradiation 
(n=11), systemic chemotherapy (n=4), isolated limb perfusion (n=8, [7 in our in-
stitution, 1 elsewhere]), a combination of irradiation and systemic chemotherapy 
(n=1) and a combination of ILP and irradiation (n=2). All patients were candidates 
for amputation because primary surgical resection was impossible because of the 
multifocality of the tumours. 
Table 1
Tumour characteristics of 64 TM-ILPs for multiple STS
Histology type
Multifoc 
Primary
Multiple 
Recurrent Grade 1 Grade 2 Grade 3 Total
Liposarcoma 1 1 0 1 1 2
Synoviosarcoma 1 4 1 3 1 5
MFH 0 7 0 2 5 7
Leiomyosarcoma 1 5 0 0 6 6
Angiosarcoma 2 3 2 1 2 5
Fibrosarcoma 0 1 1 0 0 1
Clear cell sarcoma 0 4 0 1 3 4
Neurogenic sarcoma 0 1 0 1 0 1
Hemangiopericytoma 1 2 1 0 2 3
Osteosarcoma 0 1 0 0 1 1
Kaposi sarcoma 5 (3) 0 (2)* 4 1 0 5
Extraskeletal Ewing sarcoma 1 0 0 0 1 1
Stewart-Treves 16 (7) 0 (9)* 7 9 0 15
Aggressive fibromatosis/Desmoid 0 7 7 0 0 7
Total 28 36 23 19 22 64
*= Kaposi sarcomas and Stewart Treves lymphangiosarcomas are considered primary sarcomas for evaluation (explained in text).
MFH = malignant fibrous histiocytoma, Multifoc = multifocal
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Treatment
Patients underwent an ILP via the axillary (n=13), brachial (n=4), iliac (n=28), femoral 
(n=14) or popliteal (n=5) approach. ILP technique has been described previously 2, 3. 
Briefly, recombinant human TNF (Boehringer Ingelheim GmbH, Ingelheim/Rhein, 
Germany) and the cytostatic drug melphalan (L-PAM, Alkeran, Burroughs Wellcome 
Ltd., London, UK), obtained as a sterile powder, were dissolved aseptically using 
solvent and diluents (Burroughs Wellcome Ltd., London, UK). ILPs were performed 
under general anaesthesia and normally took 2.5 to 4 hours. Isolation of the blood 
circuit of a limb was achieved by clamping and canulation of the major artery and 
vein, connection to an oxygenated extracorporeal circuit, and application of a tour-
niquet to compress the remaining collateral vessels. ILP consisted of a 90-minutes 
perfusion with 1 to 3 mg (arm) or 3-4 mg (leg) TNF, and a 10 mg/L (leg) or 13 mg/L 
(arm) volume of melphalan at mild hyperthermia (tissue temperatures of maximally 
39.5°C in the leg and 38.5°C in the arm). Median dose of melphalan was 60 mg 
(mean 68.7 mg, range 14-140 mg); median dose of TNF was 4 mg (mean 3.3 mg, 
range 1-4 mg). TNF was injected as a bolus into the arterial line provided limb tissue 
temperature had reached 38°C. Melphalan was administered after 30 minutes at limb 
temperatures between 38 and 39.5°C. During the procedure, continuous leakage 
monitoring was performed by using a precordial scintillation probe to detect leakage 
of radiolabelled albumen injected to the perfusion circuit. At the end of the ILP, the 
limb was washed out with at least 1 L (arm) up to 4 L (iliac perfusion) of physiologic 
saline solution and 6% dextran 70 (Macrodex; Pharmacia, Uppsala, Sweden).
Response evaluation and toxicity
Clinical response evaluation was performed 2, 4, 8 and 12 weeks after ILP and 
thereafter every 3 months for the first year both by clinical examination and by 
magnetic resonance imaging (4-6 and 8-12 weeks after ILP and thereafter every 3-6 
months) 16, 17, and reported according to World Health Organisation (WHO) criteria. 
Histological response could be assessed in 22 cases after a median interval of 3 
months (range 1-17 months) and was obtained in 14 cases by a biopsy of respond-
ing lesions and in 8 patients by evaluation of the resection specimen of tumour 
remnants that had become resectable. In these patients, the final outcome was ad-
justed if the pathological response (necrosis percentage: complete response (CR) if 
100% necrosis, partial response (PR) if 50-99% necrosis and no change (NC) if <50% 
necrosis) differed from the clinical response. Of the eight patients with completely 
resected disease, seven received adjuvant radiotherapy after resection because of 
high tumour grade or narrow resection margins. Other post-ILP treatment consisted 
of radiotherapy (n=2) or chemotherapy (n=4).
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Acute local toxicity of the ILP procedure was classified according to Wieberdink et 
al. 18: grade I, no reaction; grade II, slight erythema or edema; grade III, consider-
able erythema or edema with some blistering, slightly disturbed motility permis-
sible; grade IV, extensive epidermolysis or obvious damage to the deep tissues, 
causing definite functional disturbance and threatening or manifest compartmental 
syndrome; and grade V, reaction that may necessitate amputation. Systemic toxicity 
wass reported according to WHO criteria.
Statistical evaluation
Estimates of overall survival (OS) and time to local or systemic progression (TTLP 
and TTSP, respectively) were made according to the method of Kaplan and Meier. 
The 64 multiple ILPs were compared with the group of single-sarcoma ILPs in our 
ILP database, and multifocal primary sarcomas were compared with multiple recur-
rences of STS because of the expected difference in behaviour, both by using the 
log-rank test. As desmoid tumours and aggressive fibomatosis are tumour types 
known to be locally aggressive but to have benign systemic behaviour, survival and 
progression were separately calculated with exclusion of these tumour types. Com-
parison between two groups was tested using the Fisher’s exact test or the Wilcoxon 
trend test if appropriate. P-values <0.05 were considered statistically significant. 
RESULTS
Response
A clinical CR after ILP in 64 patients with multiple sarcomas was observed in 38%. 
PR occurred in 47%, NC in 14% and progressive disease in 2%. In eight patients with 
a limited number of tumours (n=2-5), the post-ILP response was nearly complete, 
and this made the tumour remnants resectable. In five patients, no more vital tumour 
Table 2
Response rates
 All multiples Multifocal primary STS Multiple recurrent STS 
N=64 N=28 N=36
CR 42% 61% 28%
PR 45% 36% 53%
NC 11% 4% 17%
PD 2% 3%
Overall 87% 96% 81%
STS = soft tissue sarcoma, CR = complete response, PR = partial response, NC = no change, PD = progressive disease
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cells were found in the resected tumour remnants. In another 14 responding patients 
a biopsy of (some of) the lesions was performed for response assessment, mainly 
to distinguish between PR and CR. Of these 14, 9 had >50% to 100% necrosis. The 
final outcome, therefore, was: 42% CR, 45% PR, 11% NC and 2% progressive disease. 
Compared with our ILP experience in single STS, the outcome of TM-ILP in multiple 
sarcomas is significantly better (total response rate 88% vs. 69%, p=0.005). There was 
no statistically significant difference in overall response among high-, intermediate- 
and low-grade tumours (trend test p=0.402). Response rates of multiple STS were 
analysed separately for multifocal primary sarcoma and multiple recurrences and 
were shown to be 96% in multiple primary tumours and 81% in multiple recurrences 
(p=0.070). Response rates for each group are listed in table 2.
Progression and survival
The local recurrence rate was 45% (29 local recurrences in 64 ILPs); the median TTLP 
was 29 months. This was significantly lower than TTLP after ILP for single sarcomas 
(median TTLP >129 months, p<0.001, figure 1). For the patients who developed Figure 1 
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a local recurrence, the median time to this event was 8 months (vs. 13 months in 
single sarcoma patients, p=0.074). No significant difference in TTLP could be de-
tected between multifocal primary (20 months) and multiple recurrent (39 months) 
STS (p=0.605). Systemic progression occurred in 28 patients; the median TTSP was 
67 months. There was no statistically significant difference in TTSP for multiple 
versus single STS (p=0.711) or for multifocal primary versus multiple recurrent STS 
(p=0.105). Actuarial 5-year (OS) after ILP for multiple STS was 39% (figure 2), which 
is lower than but not significantly different from the 53% 5-year survival rate for 
single STS (p=0.152). No significant difference in OS could be detected for multifo-
cal primary versus multiple recurrent STS (p=0.164). However, analysis excluding 
aggressive fibromatosis/desmoid tumours (all seven multiple recurrent STS) revealed 
a significant difference in both TTSP (p=0.021) and OS (p=0.030) between multifocal 
primary and multiple recurrent STS. Median follow-up of the patients in this study 
was 22.2 months (range 0.2-129 months).
Toxicity and limb function
Local toxicity was mild (grade I-II) to moderate (grade III) in all ILPs. Systemic toxic-
ity was absent or mild: only one patient had a fever >40°C for >24 hours (table 3). 
Limb function of the 55 limbs was available in 53 cases and was perfect in 38 limbs, 
mildly disturbed in 4 cases and moderately disturbed leading to the use of crutches 
in 1 patient. An amputation could not be avoided in 10 perfused limbs, thus leading 
to a limb salvage percentage of 82%.
Table 3: Local and systemic toxicity
Local toxicity
Wieberdink Grade I Grade II Grade III Grade IV Grade V
12 37 15
Systemic toxicity
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Neurologic* 60 4
Liver* 64
Renal* 64
Haematologic* 63 1
<38°C 38-39°C 39-40°C >40°C, <24 hrs >40°C, >24 hrs
Temperature 32 22 9 0 1
Absent Present
Shock& 64
Hrs = hours, * = WHO criteria, & = support of vasopressors needed
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DISCUSSION
Our experience with TNF-based ILP for limb salvage in the treatment of multiple 
STS of the extremities is the largest experience reported to date and demonstrates 
the efficacy of this approach. In patients with multifocal limb-threatening STS, ILP 
with TNF and melphalan can prevent amputation in the vast majority of the perfused 
limbs. Response rates are excellent and local control is obtained for a median of 29 
months.
The overall response rate of 88% of multiple sarcomas in this study compares to 
previously reported response rates in the literature of 63% to 91% with TNF and 
melphalan 2, 4, 6, 8, and is considerably better than that reported in ILP with only che-
motherapeutics 19-22. The overall response rate is in line with the results obtained by 
TM-ILP in a small series of 13 patients reported by Lev-Chelouche et al. 23.
Compared with our own experience in 153 single-STS ILPs, the overall response 
rate was significantly better. This can be attributed mainly to the high CR rate in 
multifocal primary STS of 61%. Because the nature of multifocal primary STS such 
as Kaposi sarcoma and Stewart-Treves lymphangiosarcoma is comparable to mela-
noma in terms of the number of lesions and the approach of post-ILP resection, we 
compared the response rates of multiple primary STS with our experience in 100 
TNF-ILPs for melanoma 24. The CR rate in melanoma (69%) is markedly higher than 
can be achieved in all STS patients (single and multiple tumours combined), but the 
CR rate of 61% in our series of multifocal primary STS was virtually the same as the 
high CR rate in melanoma. Also, the overall response rates in melanoma (95%) and 
in multifocal primary STS (96%) were practically identical. Moreover, the relatively 
short TTLP in multifocal primary STS of 20 months also compares to our melanoma 
experience (median TTLP 16 months). The behaviour of the tumours and the re-
sponse on ILP of multifocal primary STS therefore matches more with melanoma 
than with single sarcomas, and this is further supported by the previously reported 
excellent response rates after ILP of 100% for Kaposi sarcoma 25 and 87% for Stewart-
Treves lymphangiosarcoma 26. 
Desmoid tumours and aggressive fibromatosis in this study all presented as multiple 
recurrences of STS after previous surgical resections. Recurrent STS is a known ad-
verse prognostic factor for both systemic recurrence and disease-specific survival 14. 
However, in desmoid tumours, systemic metastases do not occur 27. Excluding these 
tumour types in progression and survival analysis in this study indeed revealed a worse 
outcome for multiple recurrent STS compared with multifocal primary tumours.
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The local recurrence rate of 45% is very high in comparison to previously reported 
data in single STS, both after surgery 28 (19%) and after ILP 2,3 (22%). Because a large 
proportion of the presently studied patient presented with recurrent disease, which 
is known to be an independent adverse prognostic factor for local recurrence 14, this 
high local recurrence rate is to be expected. Still, local control of disease could be 
achieved for a significant period (median TTLP 29 months) and amputation could be 
avoided in 82% of the perfused limbs. 
Local toxicity of the procedure was mild to moderate in all cases and did not seem 
to be influenced by repeated ILPs or by previous radiotherapy. This is in accordance 
with previous observations in our institute in 26 patients treated with ILP after previ-
ous irradiation 29.
In the present series of patients with difficult-to-treat tumours, these observations 
show that TM-ILP can provide limb salvage in approximately four out of five pa-
tients. Because no treatment other than surgical excision has proven to be effective 
in extremity STS and because this option is not applicable in patients with multiple 
STS, TM-ILP has to be considered before scheduling a patient for amputation.
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ABSTRACT
Background
Recurrent extremity soft tissue sarcoma (STS) in a previously operated and irradi-
ated area can usually be managed only by amputation. Tumour Necrosis Factor-α 
(TNF) -based isolated limb perfusion (ILP) is an established alternative to achieve 
limb salvage but is assumed to require sufficient vasculature. Because radiotherapy 
is known to destroy vasculature, we wanted to evaluate retrospectively whether the 
outcome of ILP in patients with radiotherapy for their primary tumour nonetheless 
showed a benefit from TNF treatment.
Methods
We consulted a prospective database of TNF-based ILPs at the Erasmus MC - Daniel 
den Hoed Cancer Center in Rotterdam. Out of 342 TNF-based ILPs between 1991-
2003, 30 ILPs were performed in 26 patients with recurrent STS in the irradiated field 
after prior surgery and radiotherapy. Eleven patients (42%) had multiple tumours (n= 
2->20). All patients were candidates for amputation.
Results
We observed 6 complete responses (20%), 15 partial responses (50%), no change 
in 8 patients (27%), and progressive disease in 1 patient (3%). The median duration 
of response was 16 months (range 3 - >56 months), at a median follow-up of 22 
months (range 3 - > 67 months). The local recurrence rate was 45% in patients with 
multiple tumours and 27% in patients with single tumours. Ten patients (35%) died 
of systemic metastases. Limb salvage was achieved in 17 patients (65%). Regional 
toxicity was limited and systemic toxicity minimal.
Conclusions
TNF-based ILP can avoid amputations in the most patients with recurrent extremity 
STS in a prior operated and irradiated field.
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INTRODUCTION
The approval by the European Medicine Evaluation Agency of Tumour Necrosis Fac-
tor-α (TNF) in combination with melphalan in the setting of isolated limb perfusion 
(ILP) for the treatment of locally advanced extremity soft tissue sarcomas (STS), on 
the basis of the excellent limb salvage results of multicenter trials in Europe, has 
added an important treatment modality to avoid limb amputations 1-4. Patients with 
local recurrences in the limb after prior surgery and high dose radiotherapy and 
patients with multiple sarcomas are usually all candidates for amputation of the 
extremity.
In the early experience with the TNF-based ILP program for irresectable extremity 
STS, much attention was given to the post-ILP necrosis of the foot of a particular 
patient treated by TNF-based ILP after prior resections, high dose radiotherapy and 
prior ILP with cisplatin 5. It was then speculated that the high dose radiotherapy 
might have resulted in damage to the vasculature of the foot. This might have ren-
dered it susceptible to the toxic effects of the combination of high-dose TNF and 
melphalan, thus leading to complete necrosis of the healthy tissues, in contrast to the 
usually selective toxic effects on the tumour vasculature only. This observation led 
to hesitation to offer TNF-based ILP to patients when a local recurrence presented 
in a high-dose irradiated area. In an attempt to avoid amputation, we decided to 
offer TNF-based ILP in all cases where amputation was the only option, regardless 
of prior treatments. We performed 30 ILPs in 26 patients with tumour recurrences in 
irradiated limbs. Here we report on this unique experience.
PATIENTS AND METHODS
Between 1992 and 2003, 26 patients with recurrent STS initially treated with surgery 
and radiotherapy, were treated with ILP with melphalan and TNF. All patients were 
considered candidates for amputation at the time of referral because of extensive 
and/or irresectable disease. Irresectability was defined as the impossibility to per-
form an oncologically justified surgical resection without substantial function loss of 
the limb or complete loss of the limb.
The technique of the ILP with recombinant TNF and melphalan is in detail described 
elsewhere 2. Briefly, recombinant human TNF (Boehringer Ingelheim GmbH, In-
gelheim/Rhein, Germany) and the cytostatic drug melphalan, obtained as a sterile 
powder (100 mg) were dissolved aseptically using solvent and diluents (Burroughs 
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Welcome, London, UK). ILPs were performed with patients under general anaes-
thesia and normally took 2.5 to 4 hours. Isolation of the blood circuit of a limb was 
achieved by clamping the major artery and vein and by applying a tourniquet to 
compress the remaining collateral vessels. Perfusion was performed at the axillary, 
brachial, iliac, femoral, or poplitial level. ILP consisted of a 90-minutes perfusion 
with 1.5 to 3 mg (arm) or 2-4 mg (leg) of TNF and a 10 mg/l (leg) or 13 mg/l (arm) 
volume of melphalan at mild hyperthermia. Maximum tissue temperatures were 
39.5°C in the leg and 38.5°C in the arm. The composition of the perfusate was as 
follows: the priming volume of 700 to 850 ml consisted of 400 to 500 ml blood (50% 
RBCs, 50% plasma), 200 to 400 ml 5% dextran 40 in glucose 5% (Isodex; Pharmacia, 
Uppsala, Sweden), 10 to 30 ml 8.4% sodium bicarbonate, and 0.5 ml of 2500 to 5000 
IU heparin. TNF was injected as bolus into the arterial line provided that the limb 
tissue temperature was greater than 38°C. Melphalan was administered 30 minutes 
later at limb temperatures between 38°C and 39.5°C. At the end of the ILP, the limb 
was washed with 1 L (axillary) to 4 L (iliac perfusion) of physiologic saline solution 
and 6% dextran 70 (Macrodex; Pharmacia, Uppsala, Sweden).
Evaluation of response and toxicity
Tumour response was assessed at least twice between 4 and 12 weeks after perfu-
sion. Complete response was defined as the disappearance of all measurable disease 
in the limb for more than 4 weeks, partial response was defined as tumour size 
regression by greater than 50% for more than 4 weeks, no change was defined 
as regression of less than 50% or progression of less than 25% for longer than 4 
weeks, and progressive disease was defined as more than 25% disease progression. 
In patients in whom a resection of residual tumour, necrotic tissue mass, or both was 
performed after the ILP, a histological response rate was assessed by determining 
the percentage of necrosis. Clinical responses were standardized according to World 
Health Organization (WHO) criteria. 
Regional toxicity was graded according to Wieberdink et al. 6: grade 1, no toxicity; 
grade 2, redness and slight edema; grade 3, considerable edema or erythema with 
some blistering; grade 4, extensive epidermolysis or obvious damage to the deep 
tissues causing definite functional disturbances, or threatening or manifest compart-
mental syndrome; and grade 5, reaction requiring amputation. Systemic toxicity was 
graded according to Eastern Cooperative Oncology Group/World Health Organisa-
tion criteria.
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RESULTS 
Over the past 10 years, more than 340 patients with advanced melanoma or sarcoma 
were treated by using ILP with melphalan in combination with TNF in the depart-
ment of surgical oncology at the Erasmus MC - Daniel den Hoed Cancer Center. 
Twenty-six of these patients were previously treated with surgery and high dose 
radiotherapy (50-70 Gy) for their primary sarcoma and developed one or more ir-
resectable local recurrences. One patient had known distant metastases at the time of 
treatment. Patient and tumour characteristics are listed in tables 1 and 2. The group 
consisted of 15 men and 11 women, with a median age of 50 years (range 21-84 
years, mean 52 years). The median interval between treatment of the primary tumour 
and recurrence of disease was 19 months and ranged from 0 to 156 months. 
In all patients, systemic toxicity after ILP was mild to moderate and was easily 
manageable. More than 10% leakage was measured in five patients during perfusion, 
but this was without significant toxicity. When postoperative hypotension occurred, 
it responded immediately to fluid administration, and none of the patients required 
circulatory support with vasopressors. One patient experienced a fever higher than 
40oC after the ILP; this, however, was reversible within 24 hours. No patients en-
dured neurotoxicity after the ILP. 
A major tumour response was seen after 21 (70%) of 30 perfusions, with a partial 
response in 15 patients (50%) and a complete response in 6 patients (20%). Nine 
perfusions (30%) were not followed by any objective tumour response; four of these 
patients (patients 3, 4, 22, and 24) underwent an amputation of the limb. Two pa-
tients died of systemic disease with tumour present in the limb (patients 1 and 12). 
Patient 8 had a mixed response to the first perfusion, with 4 of 6 tumours showing 
a complete response but 2 tumours not responding at all, thus resulting in a no 
change score. The two remaining tumours responded well to the repeated perfu-
sion scheduled 13 months after the first ILP. However, the patient relapsed within 3 
months after the second perfusion and eventually underwent an amputation. Patient 
10 responded insufficiently on the first perfusion but showed a partial response after 
a second ILP, 7 months later. Because of a local recurrence, an amputation had to be 
performed after 10 months. In patient 20, the clinical response was insufficient for a 
partial response score. However, the tumour had shrunk enough to allow resection. 
Histological responses could be established in 11 patients who were treated with 
an additional tumour resection. In three patients, these responses showed much 
more necrosis in the tumour remnant than was clinically expected (patients 11, 16, 
and 26).
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In 17 (65%) of 26 patients, limb salvage could be achieved. The duration of re-
sponse was confined to the time from ILP until the first evidence of local recurrent 
disease and varied from 2 to 57 months (and ongoing), with a median of 12 months 
(mean 17 months). The median follow-up of patients was 22 months (range 3 to >61 
months, mean 29 months).
In 9 patients (11 perfusions), the tumour recurred locally after ILP: in 4 patients (4 ILPs) 
with a single tumour (24%) and in 5 patients (7 ILPs) with multiple tumours (54%). An 
amputation had to be performed to achieve local control in five patients, whereas in 
three patients no amputation was performed because of the poor short-term prognosis 
due to systemic metastases. In one patient (patient 5), a local recurrence occurred 43 
months after the perfusion, and it could primarily be resected. This patient died one 
year later as a result of lung carcinoma. Nine patients developed systemic metastases 
after ILP, of which they died. Overall survival is shown in figure 1. There was no sig-
nificant difference in response between low-grade or high-grade tumours. There was 
no correlation between tumour size and subsequent tumour response.
DISCUSSION
Our experience with 30 TNF-based ILPs in 26 patients with irresectable extremity 
STS recurrences in limbs previously treated with surgery in combination with high-
dose radiotherapy shows that even in this patient population, limb salvage can 
be achieved in most patients. Moreover, limb salvage was achieved in 65% of the 
patients even though multiple recurrences were present in 42% of the patients. Fur-
thermore, we have shown that TNF-based ILP in previously highly irradiated limbs is 
not associated with an increased local toxicity or complication rate. 
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Figure 1: Overall survival of 26 patients after isolated limb perfusion for previously irradiated recurrent sarcoma
X-axis: Time (months); Y-axis: Cumulative percentage
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In general, the management of extremity sarcomas has moved away from abla-
tive surgical procedures toward function-preserving surgery, which is often being 
combined with radiotherapy. As a result, more patients now incur locally recurrent 
sarcoma arising in previously irradiated areas. Amputation might be the most effec-
tive treatment option in this selected group of patients with local recurrences, but 
although this will improve local disease control it does not affect overall survival 
rates 7-10. Because amputation implies a significant decrease in quality of life, treat-
ment modalities that guarantee preservation of the extremity and good limb function 
have become more important. Surgical resection of recurrent tumour in a previously 
irradiated field is often impossible because it usually requires the resection of all tis-
sue exposed to a high radiation dose of 60 to 70 Gy. This can sometimes be handled 
by free transfer of vascularised tissue, but in most cases will require amputation.
Comparing our experience with data from the literature is difficult because compa-
rable series of patients with recurrent STS in an irradiated field are not at hand. More-
over, 42% of patients in our series had multiple tumours, and these cases are usually 
not present in series that discuss the application of single uses or combinations of 
re-operation and/or re-irradiation of the recurrent sarcoma. Thus, comparison with 
data from the literature is limited to cases with single tumour recurrences after prior 
surgery in combination with radiotherapy.
The results after re-irradiation are reported by Essner et al. 11 in a group of 32 
patients who received a second course of radiation for STS. In this group, 84% of 
patients showed benefit from preoperative radiotherapy in combination with subse-
quent surgery. Local excision of recurrent tumours followed by a second course of 
postoperative radiation resulted in a local failure in 8 (57%) of 14 patients and could 
not be recommended as a valuable therapy. 
The use of external beam therapy is restricted to patients with large tumours ly-
ing at least partially outside the previous treatment volume. When STS recur in a 
previously irradiated area, further external beam radiation is often not possible. 
Here brachytherapy allows a radiotherapeutic alternative in an attempt to reduce the 
risk of further local recurrence 12. Pearlstone et al. 13 reported on 26 patients who 
underwent resection and peri-operative brachytherapy in conjunction for recurrent 
STS. At a median follow-up of 16 months, they reported a 5-year local recurrence-
free survival rate of 52% and a 33% disease-free survival. This experience shows 
that in a series with single tumour recurrences, the local control rate is still far from 
optimal. In addition, 15% of all patients experienced major wound complications 
that warranted re-operation. Another study by Nori et al. 14 describes 40 patients 
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treated with brachytherapy, with a 5-year local control rate of 68% and a 12.5% 
severe wound complication rate. Catton et al. 15 advocate combined conservative 
surgery with re-irradiation as the primary salvage therapy for patients who experi-
ence treatment failure with combined therapy and who are suitable for conservative 
re-excision. In this highly selective patient population, local control for patients 
treated with conservative excision without radiation was only 36%, compared with 
100% for conservative surgery with re-irradiation. A very high proportion of patients 
(60%) experienced post-radiation complications. Obviously, this patient population, 
eligible for conservative surgery does not even resemble the patient population with 
single tumour recurrences that we have treated with TNF-based ILP, let alone the 
patients with multiple tumours. 
Up to now, trials with systemic neo-adjuvant chemotherapy have failed to achieve 
any significant improvement in the survival of patients with primary or recurrent 
STS 16. According to our findings, there are no data available in the literature up to 
now that describe the use of chemotherapy alone or in combination with the previ-
ously mentioned therapies for recurrent sarcoma in previously irradiated areas.
Regarding locoregional toxicity, no enhanced toxicity was observed as compared 
with TNF-based ILP in patients without prior surgery in combination with radio-
therapy. In essence, TNF-based ILP has no increased regional toxicity over ILP with 
melphalan alone 17. Regarding systemic toxicity, no toxicity of importance was ob-
served in this patient population. This was the case in patients without significant 
leakage as well in the few patients with significant leakage during the perfusion 
and is in line with earlier reports on our experiences in these patients 18, 19. This 
underscores our opinion that TNF-based ILP is safe and should be considered in all 
patients with limb-threatening tumours, irrespective of age, number of tumours or 
prior therapies 4, 20-22.
In conclusion, our experience clearly demonstrates that extremities should not be 
amputated without consideration of TNF-based ILP for limb salvage. In the described 
patient population with the extremely unfavourable characteristics of (multiple) 
limb-threatening sarcoma recurrences in an irradiated field after prior surgery and 
radiotherapy, the achievement of a 65% limb salvage rate clearly shows the efficacy 
of the TNF-based ILP approach to avoid amputations in what are often considered 
to be lost cases. 
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ABSTRACT H8
Background
Desmoid tumours are soft tissue sarcomas with local aggressive behaviour and a high 
rate of local recurrence after treatment. Although they do not tend to metastasise 
systemically, the local aggressiveness can lead to situations in which limb-preserving 
surgery cannot be performed without severe disability. As Isolated Limb Perfusion 
(ILP) with TNF and melphalan has proven to be extremely effective in the treatment 
of soft tissue sarcoma, we studied its potential in locally advanced extremity desmoid 
tumours.
Methods
Prospectively maintained database in a tertiary referral centre. Between 1991 and 
2003, 12 ILP procedures were performed in 11 patients for locally advanced desmoid 
tumours. Local surgical therapy with preservation of limb function was impossible 
in all patients due to large or multifocal tumours, multiple recurrences or extensive 
previous treatment. Perfusions were performed with 3 to 4 mg TNF and 10 to 13 
mg/L limb volume melphalan form leg and arm perfusions, respectively.
Results
Overall response rate was 75%: two complete responses were recorded (17%) and 
seven patients had a partial response (58%). Amputation could be avoided in all cas-
es. Local control was obtained after 10/12 ILPs and in the other two patients through 
repeat ILP and systemic chemotherapy, thus leading to an overall local control rate 
of 100%. Local toxicity was mild and systemic toxicity was absent in all patients.
Conclusions
ILP is a very effective treatment option in the multimodality treatment of limb des-
moid tumours. It should be considered in patients with aggressive and disabling 
disease where resection without important functional sacrifice is impossible.
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INTRODUCTION
Desmoid tumours are considered to be part of the soft tissue sarcoma (STS) family, 
although they do not tend to metastasise. The incidence is low, with an estimated 
three new cases per million per year, accounting for 3% of STS. Histologically, these 
tumours are fibroblastic proliferations arising from fascial or muscoloaponeurotic 
structures with benign histopathologic characteristics. However, when we focus 
on the extra-abdominal desmoids, they are also known as aggressive fibromatosis, 
which describes the aggressive local behaviour of the tumour with infiltration of 
surrounding tissue leading to pain, deformity and severe disability. Surgery is the 
mainstay primary treatment for desmoids, but despite adequate margins, extremely 
high local recurrence rates are reported of up to 77% at 10 years of follow-up. This 
behaviour leads in some cases to situations where surgery cannot be performed 
with preservation of a normal function of the limb. Several therapies can then be 
considered, ranging from radiotherapy to systemic chemotherapy, hormone therapy 
or just observation. As Isolated Limb Perfusion (ILP) with Tumour Necrosis Factor-α 
(TNF) and melphalan has shown to be an effective treatment option in the multimo-
dality-treatment of STS, this study was undertaken to assess the possible role of ILP 
in treating limb-threatening desmoid tumours.
PATIENTS AND METHODS
Patients
Between 1991 and 2003, out of 217 ILPs for soft tissue sarcoma of the limb, 12 ILPs 
in 11 different patients (7 females, 4 males) were performed for limb-threatening 
desmoid tumours. Median age of the patients at ILP was 32 years (mean 30.2 years, 
range 15-46 years). All patients had very large tumours, 10 ILPs were performed for 
recurrent disease and in seven patients the tumours were multifocal (n=3->20). In 
four patients, previous irradiation had taken place. Patient and tumour characteristics 
are listed in table 1. Local control through surgery was impossible in all cases, unless 
severe disabling operations or even amputations were performed.
Treatment
Patients underwent an ILP via the axillary (n=1), brachial (n=1), iliac (n=6), femoral 
(n=2) or popliteal (n=2) approach. ILP technique has been described previously 1, 2. 
Briefly, recombinant human TNF (Boehringer Ingelheim GmbH, Ingelheim/Rhein, 
Germany) and the cytostatic drug melphalan (L-PAM, Alkeran, Burroughs Wellcome 
Ltd., London, UK), obtained as a sterile powder, were dissolved aseptically using 
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solvent and diluents (Burroughs Wellcome Ltd., London, UK). Isolation of the blood 
circuit of a limb was achieved by clamping and canulation of the major artery and 
vein, connection to an oxygenated extracorporeal circuit, and application of a tour-
niquet to compress the remaining collateral vessels. TNF was injected as a bolus into 
the arterial line provided limb tissue temperature had reached 38°C. Melphalan was 
administered after 30 minutes at limb temperatures between 38°C and 39.5°C. The 
administration of melphalan changed during the studied period from injection as a 
bolus (1991-1996) to infusion by pump over a period of 20 minutes (1996-present), 
because of reports that melphalan peak concentration is correlated with regional 
toxicity 3. ILP consisted of a 90-minutes perfusion with 3 mg (arm) or 4 mg (leg) TNF, 
and a 10 mg/L (leg) or 13 mg/L (arm) volume of Melphalan at mild hyperthermia 
(tissue temperatures of maximally 39.5°C in the leg and 38.5°C in the arm). Median 
dose of Melphalan was 75 mg (mean 78.9 mg, range 25-121 mg); median dose of 
TNF was 4 mg (mean 3.8 mg, range 3-4 mg). In the first ILP for desmoid tumour, in-
terferon γ (IFN) was added to the schedule according to trial prescriptions consisting 
of the subcutaneous injection of 0.2 mg IFN on days –2 and –1 prior to the ILP and 
the injection of 0.2 mg IFN during the ILP procedure into the arterial line prior to the 
administration of TNF. During the procedure, continuous leakage monitoring was 
performed by using a precordial scintillation probe to detect leakage of radiolabelled 
albumen injected to the perfusion circuit. At the end of the ILP, the limb was washed 
out with at least 1 L (arm) up to 4 L (iliac perfusion) of physiologic saline solution 
and 6% dextran 70 (Macrodex Pharmacia, Uppsala, Sweden). ILPs were performed 
under general anaesthesia and normally took 2.5 to 4 hours. Median hospital stay of 
the patients was 8 days (mean 11 days, range 5-21 days).
Response evaluation and toxicity
Clinical response evaluation was performed 2, 4, 8 and 12 weeks after ILP and there-
after every 3 months for the first year both by clinical examination and by MRI (4 to 
6 and 8 to 12 weeks after ILP and hereafter every 3 to 6 months) 4, 5, and reported 
according to WHO-criteria. In 2 patients, histological response could be assessed by 
resection of the tumour remnants and in these patients response rates were adjusted 
if the pathological response (complete response (CR) if 100% necrosis, partial re-
sponse (PR) if 50-99% necrosis and no change (NC) if <50% necrosis) differed from 
clinical response. New lesions or growth of the tumour at first response evaluation 
is reported as progressive disease (PD), and if occurring during follow-up as local 
progression.
Acute local toxicity of the ILP procedure was classified according to Wieberdink et 
al. 6: (I) no reaction, (II) slight erythema or edema, (III) considerable erythema or 
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edema with some blistering, slightly disturbed motility permissible, (IV) extensive 
epidermolysis or obvious damage to the deep tissues, causing definite functional 
disturbance, and threatening or manifest compartmental syndrome, and (V) reaction 
that may necessitate amputation. Systemic toxicity is reported according to WHO 
criteria.
RESULTS
Overall response rate of the 12 performed ILPs for desmoid tumours was 75% with 
2 complete responses (17%) and seven partial responses (58%). In three patients, no 
response could be observed. Resection of the tumour was possible in five patients. 
In three patients with a single desmoid that did not respond to ILP (or insufficient 
for a PR score), a resection was performed accepting the functional loss that was 
associated with the resection in one patient (patient no. 4). No patient received 
adjuvant radiotherapy, neither after ILP alone nor after resection. Amputation was 
avoided in all patients. Partial responses usually were long lasting and no further 
surgical procedures were indicated in these patients as the biologic activity of the 
aggressive fibromatosis died out. Results of ILP are shown in table 1. Local control 
Table 2: Dose and toxicity
Patient no Leakage
(%)
Local Toxicity
(Wieberdink)
Limb 
function
Systemic 
toxicity
TNF dose
(mg)
Melphalan dose
(mg)
1 0 3 None 4 121
9,3 2 Perfect None 4 121
2 0 2 Perfect None 3 35
3 0 3 Perfect None 4 120
4 0 2
Mildly 
disturbed None 4 50
5 0 2 Perfect None 3 25
6 3 1
Mildly 
disturbed None 4 35
7 0 3 Perfect None 4 80
8 0 2 Perfect None 4 120
9 0 2
Mildly 
disturbed None 4 70
10 0 2 Perfect None 4 60
11 0 3
No further 
functional 
loss None 4 110
No = number, TNF = tumour necrosis factor, IFN = interferon
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of the tumour was obtained in 10/12 perfusions (83%). In 2 patients, the tumour re-
curred in the limb after 29 and 6 months, respectively. A second perfusion produced 
long-lasting local control in the first patient. The second patient received systemic 
chemotherapy (methotrexate and vinblastine), which led to prolonged local control 
as well. Thus, during a median time of follow-up of 31 months (mean 38 months, 
range 9-90 months), local control was maintained in all patients. Toxicity of the 
procedure was mild: local toxicity was limited to four patients having a Wieberdink 
grade III reaction. No systemic toxicity occurred. Limb function and toxicity of the 
procedure are listed in table 2.
DISCUSSION
The results of this study show that ILP is effective in obtaining local control in 
patients with locally advanced desmoid tumours. When primary resection of the 
tumour is impossible due to multifocality or previous therapies, excellent response 
on ILP can provide relief of symptoms. When the tumour is very large, adjacent to 
viable structures or in the vicinity of joints, ILP can provide tumour shrinkage to an 
extent that resection becomes a realistic option. Even a minor response, insufficient 
for a PR score as seen in three of the patients in the present series, can allow the 
surgeon to resect without severe morbidity.
It is hard to find comparable series of patients in literature, as all patients in the 
present study had unresectable disease. Lev-Chelouche at al. explored the use of ILP 
in six patients and reported a response rate of 83% 7. The only other report specifi-
cally dealing with patients in whom primary resection was impossible, is published 
by Lewis et al. 8. They followed 22 patients that had disease that was not resectable 
without amputation: seven patients underwent amputation, nine patients received 
radiotherapy and/or systemic therapy (chemotherapy, hormonal therapy, non-ste-
roidal anti-inflammatory drugs or a combination), and six patients received no treat-
ment at all. Of the nine patients receiving non-surgical therapy, only three (33%) 
showed a partial response. However, the most striking observation of this study was 
that none of the patients in whom no amputation was performed initially, required 
subsequent amputation during follow-up 8. This finding confirmed the results of an 
early study by Rock et al., who followed 68 desmoid patients with observation only 
and found that 60 of those patients remained stable and even that a shrinkage of the 
tumour occurred in six patients 9. All reports regarding response to therapy of the 
desmoid tumours, including the occasional reports on chemotherapy 10, hormonal 
therapy 11 but also the present study, should be viewed in this light.
122
C
ha
pt
er
 8
Surgery is regarded the cornerstone in therapy for primary desmoid tumours. As 
disease-specific death in desmoid patients is virtually negligible, especially in limb 
tumours, the primary goal of therapy is obtaining local control. The prognostic fac-
tors for local control after surgery are still under debate. Complete resection of the 
tumour certainly is the goal at surgery, but where in some reports a positive resec-
tion margin is a prognostic factor for local recurrence 12-15, in others this is not 16-18. 
The same discrepancy in literature exists regarding the prognostic value of presenta-
tion with primary versus recurrent disease on relapse-free survival. Most reports 
indicate multiple recurrences as a negative prognostic factor 12, 13, 17, 18, but some do 
not 14. Presentation with multiple tumours seems to be of negative prognostic value, 
but only small series exist 12. Adjuvant radiotherapy is recommended regardless of 
margin status 15, only after incomplete resection 12-14, 17, 19, or is not especially recom-
mended as in some series the selective use of adjuvant radiation did not effect the 
rate of local recurrence for margin-positive nor for margin-negative resections 16, 18. 
All in all, radiotherapy seems to increase the rate of local control after surgery, when 
selectively applied in patients with positive resection margins.
Many authors recommend radiotherapy as a primary treatment option in patients 
with unresectable disease 13, 17, 19. Spear et al. reported a series of 15 patients treated 
with radiotherapy alone. In six of them the tumour was located in the extremity and 
10 presented with recurrent disease. Although the overall local control rate was 93%, 
1 patient ultimately required below-the-knee amputation 13. Ballo et al. showed five 
relapses in 21 patients treated with radiotherapy alone (seven extremity, eight recur-
rent disease), thus a local control rate of 76%. A review by Nuyttens et al. combining 
the results of 22 studies including the two above-mentioned, revealed that in 102 
patients treated with radiotherapy alone (all locations, 26 recurrent disease), local 
control rate was 78% 15. The present study shows that ILP provides local control in 
83% of a patient population with very unfavourable characteristics since only 17% 
presented with primary desmoids, whilst 83% presented with recurrent disease, 58% 
presented with multifocal tumours and 33% had received surgery and prior radio-
therapy. Long-term complications of radiotherapy are fibrosis, paresthesias, edema 
and fracture 15, 17. Fibrosis, paresthesias and edema are also seen in ILP and were 
noted in 3 patients in our study leading to mild disturbance of limb function. The 
main advantage of ILP compared with radiotherapy in the treatment of desmoid tu-
mours, however, is the ability to apply different treatments after ILP. When a tumour 
recurs after ILP, a second ILP can provide prolonged local control as is shown in 
patient 1 in this study. When resection is performed after ILP and for some reason 
the resection margin is positive, adjuvant radiotherapy can be applied. Radiotherapy 
can only be applied once in sufficient dose to the same area. The impact of this 
TNF-based ILP for Desmoid Tumours 123
is reflected in the overall local control after multimodality treatment in this study, 
which reaches 100%.
In conclusion, ILP is a very effective treatment option in patients with desmoid tu-
mours where resection without important functional sacrifice is impossible. It seems 
more effective than systemic treatment and has important advantages over radio-
therapy. As observation is a realistic option in patients with unresectable disease, 
ILP should be reserved for symptomatic patients and for tumours that might be 
resectable after sufficient shrinkage. 
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INTRODUCTION
In the management of locally advanced extremity soft tissue sarcomas limb salvage 
has become all the more important in the light of evidence that amputations do not 
improve survival rates in patients with large (>5 cm) deep-seated high-grade sarco-
mas. Several studies have shown that marginal excisions with a high risk for local 
recurrence do not influence survival significantly 1-4. Of the 8680 new cases of STS 
diagnosed in the USA each year, about 5200 occur in the extremities and tumours are 
often large at the time of diagnosis 5. Treatment options for locally advanced extre-
mity STS may consist of an amputation or a limb-sparing extensive surgical procedu-
re followed by radiation therapy. This combination may mutilate and compromise 
limb function considerably. Preoperative therapies to improve limb salvage rates 
have been propagated. Preoperative radiotherapy alone or in combination with in-
tra-arterial or intravenous chemotherapy has been reported to improve resectability 
rates of extremity soft tissue sarcomas 6-8. Amputation may also be avoided and local 
control may be improved by combining a marginal resection with brachytherapy 
to the tumour bed 9. Isolated limb perfusion is another strategy to deal with locally 
advanced soft tissue sarcomas, and can also be applied in case of multifocal primary 
or multiple sarcoma recurrences in limbs, thereby expanding the patient population 
that can successfully be treated.
TNF- BASED ISOLATED LIMB PERFUSION FOR STS
Inadequate results in STS with ILP with chemotherapeutic drugs only
In contrast to the efficacy of melphalan-based ILP in patients with multiple in-transit 
melanoma metastases, results with ILP with melphalan, doxorubicin and a variety 
of other drugs for large soft tissue sarcomas were disappointing. After studies in the 
seventies and eighties with poor response rates, ILP for advanced STS was largely 
abandoned 10-14. Only recently, this was supported by a study from the MD Anderson 
Cancer Center that found no objective response and massive toxicity after ILP with 
doxorubicin alone 15. The reported studies are listed in table 1.
Results with ILP with TNF + melphalan trials leading to approval of TNF
Thanks to the pioneering work of Lejeune and Lienard, this situation changed dra-
matically with the application of high-dose TNF in the ILP setting 16. TNF-based 
ILP has been established as a highly effective new method of induction bioche-
motherapy in extremity soft tissue sarcomas with a 20% to 30% complete response 
(CR) rate and about a 50% partial response (PR) rate 17-22. On the basis of results in a 
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multicenter program in Europe, TNF was approved and registered in Europe for the 
sarcoma indication in 1998 22. The European TNF/ILP assessment group evaluated 
246 patients with irresectable STS enrolled in 10 years in four studies. All cases were 
reviewed by an independent review committee and compared with conventionally 
treated patients (often by amputation) of a population based Scandinavian STS data-
base. In short: there were 246 patients with locally very advanced disease: primary 
sarcomas in 55%, local recurrent sarcomas in 45%, multifocal primary or multiple 
local recurrences in 22 %. Overt concurrent metastatic disease in 15%. Tumours >10 
cm in 46%. Grade III tumours in 66%. Previous radiotherapy in 13%, chemotherapy 
in 15%. Patients underwent 1 ILP (222 patients) or 2 ILPs (24 patients) of 90 minutes 
at 39˚C to 40˚C with 2 to 4 mg TNF + melphalan (10-13 mg/L limb volume). The first 
56 patients also received IFNγg. A delayed marginal resection of the tumour remnant 
was usually (76%) done 2 to 4 months after ILP. Major responses were seen in 56.5% 
to 82.6% of the patients, thus making resection of the sarcoma possible. 
Limb salvage was achieved in 74% to 87% in these 4 studies and in 71% of the 196 
patients who had been classified by the independent review committees as cases 
that normally could only have been managed by amputation (87%) or by function-
ally debilitating resection + radiotherapy (13%). Comparison with the survival curves 
based on a matched control study with cases from the Scandinavian Soft Tissue Sar-
coma Databank showed that TNF had no negative effect on survival (p=0.96). It was 
concluded that the application of TNF in combination with melphalan in the setting 
of isolated limb perfusion represents a new and successful option in the manage-
ment of irresectable locally advanced extremity soft tissue sarcomas 22 (table 2). 
Confirmatory single-center studies
Lejeune et al. 23 reported a 17% CR and 64% PR rate in 22 STS patients treated for 
limb-threatening STS tumours, and achieved limb salvage in 77% of the patients. A 
Table 1: ILP with cytostatic drugs only for locally advanced STS
Drugs # 
Pts
CR PR NC/PD Limb 
Salvage
Year Author Ref #
Melphalan/Act-D/NH2 17 0% 35% 65% NS 1977 Krementz
10
Melphalan/Act-D/NH2/Various 51 6% 12% 82% NS 1985 Muchmore
11
Cisplatin 17 0% 18% 82% NS 1988 Pommier 12
Melphalan/Doxorubicin 13 7% 0% 93% 61% 1989 Klaase 13
Doxorubicin 22 0% 74% 26% 91% 1994 Rossi 14
Doxorubicin 14 0% 0% 100% 25% 2004 Feig 15
#Pts = number of patients, CR = complete response; PR = partial response; NC = no change; PD = progressive disease; Ref# = reference 
number, Act-D = Actinomycin-D, NH2 = Nitrogen mustard, NS = not stated
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similar limb salvage rate of 84% and excellent functional results were reported from 
the Berlin team regarding their experience in a series of 55 patients 24. The Am-
sterdam group reported somewhat less favourable results in their experience in 49 
patients (overall response rate 63%). The limb salvage rate of 57% was felt to reflect 
the selection of patients with particularly unfavourable characteristics 25. We recently 
reported the single-center study of the Rotterdam group on STS patients, in which 
we found an overall response rate of 75% and were able to achieve limb salvage in 
87% of the patients 26. All in all, these studies on the overall STS population show 
that overall response on TM-ILP varies between 63% to 91% and limb salvage that 
ranges from 58% to 94%. These studies are listed in table 2.
Table 2: Study reports of TNF-based ILP for Irresectable Soft Tissue Sarcomas
Drugs # Pts CR PR NC/PD Limb 
Salvage
Year Author Ref 
#
TNF+Melphalan¶ 8 100%1 0% 0% 64% 1993 Hill 17
TNF+IFN+Melphalan 55 18%1 64%1 18%1 84% 1996 Eggermont 18
36%2 51%2 13%2
TNF+Melphalan 10 70%1 20%1 10%1 89% 1996 Santinami 19
TNF+IFN+Melphalan 186 18%1 57%1 25%1 82% 1996 Eggermont 20
29%2 53%2 18%2
TNF+IFN+Melphalan 35 37%2 54%2 9%2 85% 1997 Gutman 21
TNF+IFN+Melphalan 246 28%3 48%3 24%3 76% 1999 Eggermont 22
196 17%3 48%3 35%3  71%4 
TNF+Doxorubicin 20 26%5 64%5 10%5 85% 1999 Rossi 27
TNF+IFN+Melphalan 22 18%2 64%2 82%2 77% 2000 Lejeune 23
TNF+IFN+Melphalan 55 NS NS NS 84% 2001 Hohenberger 24
TNF+IFN+Melphalan 49 8%2 55%2 37%2 58% 2003 Noorda 25
TNF+IFN+Melphalan 217 18%1 51%1 31%1 75% 2006 Grünhagen 26
26%2 49%2 25%2
TNF + Melphalan6¶ 72 49% 17% 34% 84% 2005 Bonvalot 29
35% 22% 43%
TNF+Doxorubicin¶ 21 5%1 57%1 38%1 71% 2005 Rossi 28
55%5 35%5 10%5
TNF+IFN+Melphalan¶ 48 38%2 31%2 29%2 85% 2005 Grünhagen 30
#Pts = number of patients, CR = complete response; PR = partial response; NC = no change; PD = progressive disease; Ref# = reference 
number, TNF = tumour necrosis factor, IFN = interferon gamma, ¶ = low dose (<4 mg for leg-ILP, <3 mg for arm-ILP), NS = not stated
1 = Objective Clinical Response Rate By WHO criteria.
2 = CR: clinical CR or 100% necrosis; PR: clinical PR or >50-99% necrosis
3 = CR only recognized by EMEA (European Medicine Evaluation Agency) when histopathology showed 100% necrosis.
4 = Independent committee recognised 196 patients as pure amputation candidates.
5 = No clinical response data; CR: >90% necrosis; PR: radiological and/or histopathological >50% necrosis.
6 = Different scoring system: upper panel: CR/PR: loss of vasculature on Ultrasound/MRI; lower panel CR: >90% necrosis on histopathology
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A point of discussion that has been studied in overall populations is whether high 
doses of TNF (3-4 mg) are necessary or whether lower doses (1 mg) suffice. An early 
clinical report by Hill and co-workers suggested that low doses of TNF (up to 1 mg) 
were sufficient, as in eight STS patients eight complete responses were observed 17. 
The small study sample, the concomitant use of high doses of corticosteroids and the 
fact that a different type of TNF was used did not allow for definitive conclusions. 
After the Italian studies on ILP with low-dose TNF in combination with doxorubi-
cin 27, 28, the French group reported recently on their experience in 72 patients. In a 
randomised phase II trial, utilizing various doses of TNF ranging from 0.5 mg to 4 
mg, they observed a 35% CR rate and an overall limb salvage rate of 84%. No sig-
nificant differences between the various TNF dosage groups were observed 29. Our 
own experience on low-dose ILP for STS confirms these data 30, although we know 
from our laboratory data that at very low TNF dose, all effect is lost 31. Low-dose TNF 
studies are listed in table 2.
Results with TNF + doxorubicin
Very similar results have been obtained by Italian perfusion groups with the drug 
doxorubicin in combination with TNF. Interestingly, similar response and limb sal-
vage rates are achieved while using lower doses of only 1 mg TNF instead of the 
usual doses of 2-4 mg used in combination with melphalan 27, 28 (table 2). The perfu-
sions were performed at much higher temperatures (40˚C-41˚C), which is associated 
with higher locoregional toxicity. Grade IV locoregional toxicity was reported in 
25% as opposed to only 5% in the large TNF+melphalan series 18, 22. We found that 
with melphalan ILPs, grade IV toxicity was clearly related to tissue temperatures of 
above 39˚C when melphalan was administered 32. Therefore we have only allowed 
for tissue temperatures to rise to 39˚C after melphalan has been added to the perfu-
sion circuit the last eight years and have hardly seen any cases with grade IV toxicity 
since, without a drop in response rates 22, 26. Most likely therefore the higher regional 
toxicity in the Italian experience with doxorubicin is primarily related to the hyper-
thermia, although doxorubicine may be responsible in part.
REPORTS ON SPECIAL PATIENT CATEGORIES
The results on TM-ILP in special STS patient categories are reported in table 3.
Patients with overt metastatic disease
Patients with overt metastatic disease and a limb-threatening tumour are a special 
category where tumour control can be relatively easily achieved, and thereby an 
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amputation avoided, by a palliative TNF-based ILP. A 77% response rate with a 89% 
limb salvage rate was reported in nine such cases 33, and we observed in 37 cases a 
84% response rate and a 97% limb salvage rate 34. This demonstrates that TNF-based 
ILP is an extremely attractive option in these patients.
Patients with multiple tumours in the extremity
Patients with multifocal primary tumours, such as Kaposi sarcomas 35, multiple 
lymphangio-sarcomas (Stewart-Treves Syndrome) 36, or with multiple primaries of 
various histologies or multiple recurrences after prior surgery 37, all present very 
difficult problems where TNF-based ILP is the ideal alternative to amputation. Re-
markably good results have been reported. We observed after 16 ILPs in 10 patients 
with Stewart-Treves Syndrome a 87% reponse rate and a 80% limb salvage rate. In 
our overall experience with patients with multiple tumours, we observed after 64 
ILPs a 77% response rate and a limb salvage rate of 82% 38. These results indicate that 
TNF-based ILP is very effective in this patient population.
Table 3: Study reports of TNF-based ILP for special STS patient categories
Drugs # 
Pts
CR PR NC/PD Limb 
Salvage
Year Author Ref 
#
TNF+IFN+M metastatic 9 44%2 33%2 22%2 89% 1998 Olieman 33
TNF+M multiple 13 38%2 54%2 8%2 92% 1999 Lev-Chelouche 37
TNF+M desmoids 6 33%1 50%1 17%1 100% 1999 Lev-Chelouche 40
TNF+M kaposi sarcoma 5 20%1 80%1 0%1 80% 1999 Lev-Chelouche 35
TNF+IFN+M Stewart Treves 16 56%2 31%2 13%2 80% 2002 Lans 36
TNF+IFN+M >75yrs 29 38%2 38%2 76%2 76% 2003 Van Etten 42
TNF+IFN+M multiple 64 42%2 45%2 13%2 82% 2005 Grünhagen 38
TNF+IFN+M in irradiated field 29 20%2 50%2 30%2 65% 2005 Lans 39
TNF+IFN+M metastatic 37 16%2 68%2 16%2 97% 2006 Grünhagen 34
TNF+IFN+M desmoids 12 17%2 58%2 25%2 100% 2005 Grünhagen 41
#Pts = number of patients, CR = complete response; PR = partial response; NC = no change; PD = progressive disease; Ref# = reference 
number, TNF = tumour necrosis factor, IFN = interferon gamma, M = melphalan
1 = Objective Clinical Response Rate By WHO criteria.
2 = CR: clinical CR or 100% necrosis; PR: clinical PR or >50-99% necrosis
Special patient categories:
Metastatic = patients with metastatic disease at presentation
Multiple = patients with multifocal disease
Desmoids = patients with desmoid tumours / aggressive fibromatosis
Stewart Treves = patients with Stewart Treves lymphangiosarcoma
>75 = patients older than 75 years
In irradiated field = patients with tumour located in previously irradiated area
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Patients with recurrent tumours in an irradiated field
We performed 29 ILPs in 26 such patients. In contrast to the believe that recurrent 
tumours in an irradiated field are unlikely to respond, we observed a response rate 
of 70% and a limb salvage rate of 65% 39, indicating that also in this very difficult 
patient category a TNF-based ILP is an attractive treatment option.
Patients with desmoid tumours and other histologies
Patients with desmoid tumours / aggressive fibromatosis often present with recurrent 
disease that is very difficult to treat surgically, with or without radiotherapy. Lev-
Chelouche et al. and our own study both report on very similar results in six and 12 
such cases. Response rates were 83% and 75 % respectively and the limb salvage rate 
was 100% in both reports, demonstrating the utility of the procedure 40, 41. 
Elderly patients > 75 years old
A very important message is given by the report on the Rotterdam experience with 
50 TNF-based ILPs in patients older than 75 years with limb-threatening tumours. Re-
sults were very favourable in the 34 perfusions for limb-threatening sarcomas, with 
a 38% CR and a 38% PR rate, achieving limb salvage in 76% of the patients. Equally 
good results were seen in 16 perfusions for bulky melanoma in-transit metastases 
in the elderly, as they resulted in a 75% CR and 25% PR rate. The procedure was 
proven safe in the elderly with the high reward of limb salvage, which is of overrid-
ing importance in this age group as amputations lead to loss of independency in the 
lives of the elderly 42. Moreover, we reported on the absence of toxicity in patients 
without leakage and the relatively easy management and relative lack of toxicity in 
patients with high leakage of TNF during ILP 43, 44. TNF-based ILPs are not associated 
with more regional toxicity than melphalan-based ILPs and do have less regional 
toxicity than doxorubicin-based ILPs 32.
TNF-based ILP active in many histologies
Since the tumour vasculature is the target of TNF and of the TNF+chemotherapy 
combination, it can be expected that this treatment is effective against a wide variety 
of tumour types as long as there is a well-developed vascular stromal component 
to the tumour. T.his is indeed the case. Apart from activity in some 20 different 
histological types of soft tissue sarcoma and activity in melanoma 45-49, the efficacy 
of TNF + melphalan ILP has also been demonstrated in various skin tumours 50 and 
bony sarcomas 51.
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VASCULOTOXIC MECHANISM OF TNF+CHEMOTHERAPY 
The target of TNF is the tumour-associated vasculature. This common denominator in 
all the well-vascularised tumours makes the use of TNF very attractive and explains 
its efficacy in combination with chemotherapy across all these different histologies. 
The selective destructive effects of TNF-ILP on tumour-associated vessels have been 
illustrated in previous publications by means of pre- and post perfusion angiograp-
hies 18. Moreover, in sarcoma patients’ magnetic resonance spectrometry studies we 
have clearly shown that the metabolic shut-down of the tumour is virtually complete 
within 16 hours after the perfusion, confirming the likelihood of TNF-α mediating its 
most important effects on the vasculature of the tumour 52. At the histopathological 
level, we have also studied these intravascular effects such as thrombocyte aggrega-
tion, erythrostasis, endothelial and vascular destruction already in the early and late 
stages after ILP 53, 54.
NEW INSIGHTS THROUGH LABORATORY MODELS
To create further insight in the mechanisms underlying the positive results obtained 
with ILP in humans, we developed extremity perfusion models using the BN175 
non-immunogenic fibrosarcoma in Brown Norway rats and the ROS-1 osteosarcoma 
in WAG rats. In both models, we could demonstrate that the tumour cells were 
resistant to TNF in vitro and that ILP in vivo with TNF alone had no major impact 
on tumour growth. In both models, a strong synergistic anti-tumour effect leading to 
CRs in some 60-70 % was observed after ILP with TNF+melphalan 55, 56. TNF alone 
only caused some central necrosis and no regression of the tumour was observed as 
has been reported for the clinical setting as well. Histopathologically haemorrhagic 
necrosis was most prominent after ILP with both drugs. Early endothelial damage 
and platelet aggregation in the tumour vessels are observed after ILP with TNF + 
melphalan and this is believed to lead to ischemic (coagulative) necrosis, which is 
in line with observations in patients. Our observations confirm that TNF-α has its 
major effect on larger tumours, with well-developed vasculature in contrast to small 
tumours (diameter < 3 mm) that lack a developed capillary bed. TNF may exert its 
effect mainly through the neovasculature of the tumour, which is more abundant in 
large tumours. Moreover, there are distinct similarities between tumour stroma gen-
eration and wound healing and observations by us that sites other than the tumour 
(recent wounds or skin overlying tumours only when invaded by tumour), which 
undergo angiogenesis, also become necrotic after ILP with TNF + melphalan, but not 
after ILP with melphalan alone.
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We have demonstrated a number of crucial elements in our rat tumour models iden-
tifying the mechanisms for the strong synergy between TNF and cytostatic drugs in 
ILP and have identified the prerequisites for an effective ILP:
Tumour vessel destruction
The vasculotoxic effects of the combination of TNF + melphalan leading to haemor-
rhagic and anoxic coagulative necrosis as described above.
Enhanced drug uptake by the tumour
We have recently demonstrated that the addition of high dose TNF to the perfusate 
results in a four- to sixfold increased uptake by the tumour of the cytostatic drug. 
For melphalan and for doxorubicin is was demonstrated that this uptake was tumour 
specific and that no increased uptake was noted in the normal tissues, thus empha-
sizing the relatively selective action of TNF on the tumour-associated vasculature 57. 
This increase in concentration was also observed with doxorubicin 58, but not in its 
liposomal form 59. Moreover, we have demonstrated that the effect correlates with 
the vascularity of the tumour. The more vascular the tumour, the better the synergis-
tic effect between TNF and the chemotherapeutic agent 60. Whether a TNF-mediated 
drop in interstitial pressure 61 in the tumour plays a role in this mechanism remains 
speculative.
Role of Leukocytes
We have shown that leukocytes play also an important role in the TNF-mediated 
anti-tumour effects. In rats that underwent total body irradiation and underwent 
an ILP at the time of absolute leukopenia, the anti-tumour effect of an ILP with 
TNF+melphalan was very similar to the effects of a perfusion with melphalan alone. 
In the leukopenic rat the TNF-effect was lost and the synergy between TNF and 
melphalan was no longer observed 62.
Dose range for TNF
We demonstrated that 10 micrograms of TNF (a fivefold reduction of the “standard 
dose of 50 microgram” was the threshold dose for activity of TNF in our rat tumour 
extremity perfusion model. At 2 micrograms, all TNF-effects were lost 31. This finding 
would suggest that also in the clinical setting dose reduction without loss of activ-
ity could be explored as has also been suggested by the clinical results of various 
studies 17, 27-30.
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Duration of ILP
As the pharmacokinetics of melphalan demonstrates that almost all melphalan up-
take occurs over 20-30 minutes, the minimal duration for an effective ILP should be 
30 minutes. Shorter perfusion times are associated with a drop in CR and PR rates 
whereas longer than 30 minutes ILPs do not seem to further improve the results 31.
Mild Hyperthermia
Temperatures of 38°C to 39°C were shown to be essential for obtaining a good anti-
tumour response without damage to the normal tissues in the limb. True hyperther-
mia (42°C-43°C) resulted in an increase of CRs but was associated with very severe 
damage to the normal tissues. All anti-tumour efficacy was lost when perfusions 
were performed at room temperature 31.
Hypoxia 
We demonstrated that hypoxia could enhance the anti-tumour effects of an ILP with 
either TNF alone or melphalan alone. Hypoxia did not further enhance the anti-
tumour efficacy of an ILP with TNF+melphalan as the synergy between these two 
agents “overrided” any minor enhancement mediated by hypoxia 31.
Interferon-gamma
In spite of many reports of the synergy between IFN-gamma and TNF both in vitro as 
well as in vivo in murine tumour models, the role of IFN-gamma was not very strong 
in our rat models. We demonstrated that about a 10% increase in CR rate and an 
increase of about 20% in overall response rate was observed in our animal models 63, 
which resembles the situation in the clinic 49.
Idiosyncratic toxicity
Interestingly unexpected interactions may lead to idiosyncratic reactions between 
TNF and certain cytostatic agents. Actinomycin D is commonly used in combination 
with melphalan in the clinical setting. When investigating whether TNF would en-
hance the efficacy of actinomycin D, we discovered that it did in an idiosyncratic and 
nondiscriminative way. The combination was more effective against the tumour than 
TNF+melphalan, but this advantage was annulled by the toxicity of TNF+actinomycin 
D to the normal tissues, resulting in the amputation of all extremities in these animal 
models. We sent out a strong warning to the clinic not to use TNF in combination 
with actinomycin D 64.
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Vasoactive drugs
Various vasoactive drugs have been and are being studied in our laboratory models. 
Nitric Oxide (NO) is an important molecule in the maintenance of both vascular 
tone and the integrity of the vascular wall and is highly produced in experimental 
and human tumours. We postulated that its inhibition could lead to hypoxia and an 
enhancement of the TNF-induced early vascular effects in the tumour. In our ILP 
BN175 rat model, we performed a response study with TNF in combination with 
the arginine analogues L-NAME and LNA, which inhibit NO synthase. In rats treated 
with TNF combined with L-NAME/LNA, important and immediate anti-tumour effects 
were observed and necrosis of the skin occurred at the tumour site. These effects are 
normally only observed when hypoxia or melphalan are added to TNF as described 
above. Typical TNF tumour response was observed when NO synthase was inhibited 
during ILP 65. Other vasoactive drugs are histamine and IL-2. Both these drugs have 
shown to have a clear synergy with melphalan in our tumour models 66, 67. These 
findings show the importance of agents that can change the pathophysiology of tu-
mour vasculature and rheologic conditions and thereby can improve drug uptake in 
tumours. Moreover, this underlines the importance of investigating how to modulate 
tumour physiology and the potential that this approach has to improve efficacy of 
various standard agents.
CONCLUSIONS
Isolated limb perfusion methodology provides us an excellent tool in the clinic to 
obtain local control and to avoid amputations of limbs in patients with limb-threat-
ening tumours. This has been largely achieved by the success of the antivascular 
TNF-based biochemotherapy in this setting. TNF, for the first time, has brought us an 
effective treatment against large, bulky tumours.
Moreover, isolated limb perfusion is a albeit somewhat exotic, but very interesting 
research model to develop and study agents that modify the pathophysiology of 
large tumours that blocks effective penetration of cytotoxic drugs into the tumour. 
We can now manipulate and study the tumour vascular bed in ways that will identify 
“new” drugs that can enhance the activity of “old” drugs. Moreover, it has proven to 
be a model system that may also facilitate the development of vector-mediated gene 
therapy and other innovative approaches.
Much of these developments have been initiated by the application of TNF in this 
setting. TNF-based isolated limb perfusion is a very successful treatment option to 
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achieve limb salvage in the management of advanced, multiple or drug-resistant 
extremity tumours. TNF-based ILPs are now performed in some 30 cancer centers 
in Europe with referral programs for limb salvage. TNF-based antivascular therapy 
of cancer is here to stay and its potential needs to be studied further 68. Other drugs 
will follow and we may well learn through this model how to use them systemically 
more effectively as well.
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ABSTRACT
Background
Isolated Limb Perfusion with TNF and melphalan (TM-ILP) is highly effective in the 
local treatment of advanced sarcoma and melanoma of the limb. The optimal dose 
of TNF for this procedure is not well established. The aim of this study was to assess 
the efficacy and toxicity of TM-ILPs with reduced TNF dose.
Methods
Largest single institution prospective database on TNF-based ILP. Out of 339 TM-ILPs 
performed between 1991 and 2003, 64 procedures were performed with reduced 
TNF dose (<3 mg in arm perfusions, <4 mg in leg perfusions). Response rates and 
toxicity of the procedure and outcome of the patients are evaluated.
Results
Complete response in melanoma patients after reduced-dose ILP was 75% vs. 69% af-
ter standard-dose ILPs (overall response 94% vs. 95% respectively); overall response 
in non-melanoma patients was 69% (reduced) vs. 74% (standard). Response rates 
and outcome were comparable with the procedures performed with standard-dose 
TNF (p=NS for response, local/systemic progression and survival after multivariate 
analysis, both in melanoma and in non-melanoma patients). Systemic and local tox-
icity did not differ statistically between reduced- and standard dose TM-ILPs.
Conclusions
Provided doses at 1 mg or higher are used, TM-ILP with TNF dose reduction for 
both melanoma and non-melanoma patients seems to be as effective as the standard 
dose procedure in terms of response rate and patient outcome. Numbers to formally 
confirm or reject this hypothesis are too large for such a non-inferiority trial to be 
conducted in patients with these rare conditions.
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INTRODUCTION
The use of Isolated Limb Perfusion (ILP) in the treatment of patients with exten-
sive melanoma in-transit metastases and of patients with limb-threatening soft tissue 
sarcoma, has earned more and more appreciation in the last decade. Although the 
technique of ILP was described already in 1958 by Creech and co-workers 1 and used 
with great success in melanoma patients, patients with larger tumours (especially soft 
tissue sarcomas) did not profit from this technique because of poor and inhomoge-
neous drug uptake in these tumours. A breakthrough for this patient category came 
in the early 1990s when Tumour Necrosis Factor-α (TNF) was introduced as co-drug 
for ILP 2. Excellent response rates could be obtained by this two-drug regimen 3. 
This led to the approval of TNF in Europe for the treatment of irresectable extremity 
soft tissue sarcoma 4. The use of TNF has some major implications for the centers 
in which ILP with TNF and melphalan (TM-ILP) is performed: the administration of 
TNF can lead to potentially lethal toxicity if there is important leakage of TNF to 
the systemic circulation. Moreover, the high cost of TNF and the fact that TNF is not 
commercially available worldwide, makes the procedure even more delicate. The 
approved dose of TNF used in the ILP procedure is 3 mg for ILP of the arm and 4 
mg for ILP of the leg. As the experience with melphalan revealed that in regional 
application using ILP, drug concentrations 10 times higher than systemically tolerated 
were well tolerated in the limb, this same proportional translation was made for 
TNF 2. This translation is not necessarily correct, as TNF in the ILP setting is known 
to be an enhancer of the melphalan effect (by immediate increased melphalan up-
take in the tumour 5 and by eradication of the tumour associated vasculature) rather 
than having a direct anti-tumour effect itself. The optimal TNF dose in ILP for the 
synergistic effect with melphalan has never been properly determined. However, 
both preclinical 6 and clinical studies 7-9 suggest that TNF dose reduction to 1 mg 
might be as effective as the now standardly used TNF dose of 3 mg for arm- and 4 
mg for leg-ILPs. 
As in our institution over 300 TNF-based ILPs were performed since 1991, we retro-
spectively studied our procedures in order to assess whether ILPs performed with 
reduced dose TNF are comparable to the standard dose ILPs in terms of response to 
ILP, clinical outcome and local and systemic toxicity.
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PATIENTS AND METHODS
Patients
Between 1991 and 2003, 339 TNF and Melphalan (TM)-ILPs were performed in 
patients with multiple in-transit melanoma metastases (n=99), soft tissue sarcomas 
(n=217) or other tumours (n=23) in the limb. Sixty-four ILPs were performed with 
reduced dose (<4 mg TNF for leg-ILPs, <3mg TNF for arm-ILPs). Dose reduction 
was applied in a non-randomised manner. Reasons for dose reduction were leakage 
problems prior to the administration of TNF especially when this happened in frail 
elderly patients with a cardiovascular compromised status. Moreover, the knowl-
edge of the Italian experience with 1 mg TNF in combination with doxorubicin 10, 11 
and the observations on the lack of impact of a four-fold TNF dose-reduction in 
our laboratory 6 influenced our attitude. Demographic data, disease presentation at 
time of ILP and ILP characteristics were obtained from a prospectively maintained 
database. 
Treatment
All patients underwent an ILP of the upper (n=74) or lower (n=265) limb. The 
method of ILP is described in detail previously 3, 4. In short: isolation of the limb is 
achieved by clamping and canulation of the major artery and vein, connection to an 
oxygenated extracorporeal circuit, ligation of collateral vessels and application of a 
tourniquet proximal to the site of perfusion. Once tissue temperature has reached 
38°C, recombinant TNF (Boehringer Ingelheim GmbH, Ingelheim/Rhein, Germany) 
is administered via the arterial line. Tissue temperatures are stabilized between 38-
39.5°C and leakage monitoring is performed by using a precordial scintillation probe 
to detect leakage of radiolabelled albumen injected to the perfusion circuit 12. After 
10-30 minutes, Melphalan (L-PAM, Alkeran, Burroughs Wellcome Ltd., London, UK) 
is added to the perfusate in a dose of 10 mg/L for leg- and 13 mg/L for arm perfu-
sions. The administration of Melphalan changed during the studied period from 
injection as a bolus (1991-1996) to infusion by pump over a period of 20 minutes 
(1996-present), because of reports that melphalan peak concentration is correlated 
with regional toxicity 13. In the first 50 ILPs, performed between 1991 and 1994, 
interferon γ (IFN) was added to the schedule according to trial prescriptions. This 
consisted of the subcutaneous injection of 0.2 mg IFN on days –2 and –1 prior to the 
ILP and the injection of 0.2 mg IFN during the ILP procedure into the arterial line 
prior to the administration of TNF. At the end of the perfusion period, a washout 
procedure using 2-4 litres of a dextrane and/or electrolyte solution is performed. In 
patients undergoing an iliac perfusion for melanoma, an iliac lymph node dissection 
is performed; an axillary lymph node dissection is performed in patients undergoing 
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an axillary ILP. In melanoma patients with palpable nodal disease in the groin, an 
ilio-inguinal lymph node dissection is performed in the same operative session as the 
ILP but prior to executing the ILP.
Evaluation of response and toxicity
Clinical response evaluation was performed 2 to 4 weeks and 8 weeks after ILP by 
clinical examination, and after that at 3 months regular intervals for the first 2 years 
and a longer intervals hereafter. For non-melanoma ILPs, response evaluation by 
MRI was performed after 4 to 6 and 8 to 12 weeks after ILP, and thereafter every 
3-6 months. Response rates were reported according to World Health Organisation 
(WHO) criteria 14. Histological response could be obtained in 136 non-melanoma 
ILPs either by resection of the tumour remnant or by histological biopsy. In these pa-
tients, final outcome was adjusted if the pathological response (necrosis percentage: 
complete response (CR) if 100% necrosis, partial response (PR) if 50-99% necrosis, 
no change (NC) if <50% necrosis) differed from the clinical response. Recurrence of 
tumour within the extremity after a CR, or progression of the lesions and the appear-
ance of new lesions after a PR or after NC, is reported as local progression. 
Acute local toxicity of the ILP procedure was classified according to Wieberdink et 
al. 15: (I) no reaction, (II) slight erythema or edema, (III) considerable erythema or 
edema with some blistering, slightly disturbed motility permissible, (IV) extensive 
epidermolysis or obvious damage to the deep tissues, causing definite functional 
disturbance, and threatening or manifest compartmental syndrome, and (V) reaction 
that may necessitate amputation. As Wieberdink grade I-II reactions are completely 
reversible local reactions with no implications on long-term outcome 16, and grade 
IV-V normally require surgical intervention in the postoperative period, these grades 
of local toxicity are combined for analysis.
Systemic toxicity is reported if any grade of neurogenic, hepatic, renal or haemato-
logic toxicity as defined by the WHO 14 occurred, or if a drop in vascular resistance 
necessitated the use of vasopressors.
Statistical evaluation
Survival estimates of overall survival (OS), time to local progression (TTLP) and time 
to systemic progression (TTSP) were made using the method of Kaplan and Meier. 
We evaluated the prognostic value of some baseline factors for these three endpoints 
(TTLP, TTSP and OS) using the log-rank test. Because demographics were not bal-
anced between the reduced dose and the normal dose group, a multivariate model 
using Cox regression was designed. This model includes for melanoma patients, 
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besides TNF dose, MD Anderson stage of disease, size of the largest lesion and age 
of the patient (known to be the prognostic factors for survival in ILP treatment for 
melanoma 17). For non-melanoma patients, we included age of the patient, size of 
the tumour, recurrent disease at presentation and resection after ILP in the multivari-
ate model 4, 18. Difference between two binary variables was tested using the Fisher’s 
exact test. Furthermore, a logistic regression was performed to evaluate the effect of 
dose reduction on toxicity with adjustment for diagnose and gender of the patient 19. 
All tests were done at a significance level of 5%.
RESULTS
Sixty-four TM-ILPs with reduced TNF dose were performed in melanoma (n=16) 
or non-melanoma (n=48) patients. Median age of the patients treated with reduced 
dose ILP was 64 years (range 12-91 years); patients with normal dose ILP had a 
median age of 55 years (range 15-84 years, p=0.011). All patients were amputation 
candidates. Patient and tumour characteristics are listed in table 1. 
Response rate and outcome
Melanoma patients
In 16 ILPs with reduced TNF dose in melanoma patients, CR rate was 75% versus 
69% for ILPs with traditional dose (p=0.770). There was no statistical difference 
between 5-year local (30% vs. 30%), or 5-year systemic recurrence-free survival (22% 
vs. 29%) between the reduced dose and the normal dose ILPs. Overall 5-year sur-
vival rate was 16% for reduced dose patients versus 36% for patients treated with 
Figure 1. 
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Figure 1: Overall survival in melanoma patients, reduced versus normal TNF dose
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standard dosage (hazard ratio 1.83, p=0.056) (table 2, figure 1). In multivariate analy-
sis including MD Anderson stage, age of the patient and size of the largest lesion, 
the hazard ratio of OS of patients treated with TNF dose reduction with respect to 
standard dose patients was 1.42 (p=0.336), indicating that the shift in unfavourable 
prognostic characteristics in the low dose group is so important that the effect of 
dose is not an independent factor by itself and that the true p-value for dose effect 
is non-significant (p=0.336).
Non-melanoma patients
The response rate of 48 ILPs with dose reduction for non-melanoma patients was 
38% CR, 31% PR, 25% NC, 4% PD and was not assessed in 1 patient. This differed 
from the response rates in normal dose ILPs, as the CR and PR rate in the latter group 
was 21% and 53% respectively (p=0.022). Overall response rate (CR+PR) did not 
differ statistically between the groups (p=0.468). Limb function could be assessed in 
43/48 treated limbs; amputation could not be avoided in seven cases. No statistical 
difference could be detected between patients treated with normal and reduced 
Table 1
Patient and tumour characteristics
Melanoma Non-melanoma
reduced normal reduced normal
n=16 n=83 n=48 n=192
Gender F 11 58 26 93
M 5 25 22 99
Age ≤ 60 3 43 25 119
>60 13 40 23 73
Site Arm 1 4 13 56
Leg 15 79 35 136
No of lesions 1 0 0 29 143
2 - 10 6 37 9 31
>10 10 46 10 18
Size largest lesion ≤ 40 mm 3 44
>40 mm 13 39
Grade 1 7 32
2 11 51
3 24 101
NA 6 8
Stage IIIA 7 37 Primary 26 86
IIIAB 7 34 Recurrent 16 74
IV 2 12 Metastasized 6 32
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dose TNF in terms of TTLP, TTSP or OS (table 2, figure 2). Adjustment for known 
prognostic factors for survival showed that although size of the tumour (HR=1.6 for 
tumours >10cm, HR=3.0 for tumours >20 cm), tumour recurrence at time of presenta-
tion (HR=2.2 for recurrent tumours, HR=0.45 for re-recurrent tumours) and resection 
of the tumour remnant after ILP (HR 0.58) all are significantly contributive, this had 
no influence on the lack of effect of TNF dose reduction on survival of non-mela-
noma patients in the multivariate model (HR=1.27, p=0.423). 
Leakage and Toxicity
In 339 ILPs, 84 procedures had systemic leakage of 1% to 64%. Twenty-five ILPs were 
performed with systemic leakage between 10% and 20% without leading to severe 
Table 2
Effect of TNF dose reduction on Response Rate and Outcome  
  Melanoma p Non-melanoma p
  reduced normal  reduced normal  
  n=16 n=83  n=48 n=192  
Response CR 12 57  18 41  
 PR 3 22  15 101  
 NC 1 4  12 46  
 PD    2 3  
 NA   0,80 1 1 0,02
TTLP 5-yrs 30% 30% 0,94 44% 59% 0,27
TTSP 5-yrs 22% 29% 0,32 45% 50% 0,58
Survival 5-yrs 16% 36% 0,06 36% 47% 0,69
CR = complete response, PR = partial response, NC = no change, PD = progressive disease, NA = not available, TTLP = time to local 
progression, TTST = time to systemic progressionFigure 2. 
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Figure 2: Overall survival in non-melanoma patients, reduced versus normal TNF dose
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systemic toxicity. Six procedures were complicated by systemic leakage of >20% 
(21-23-25-29-34-64%). The procedure with 64% leakage was discontinued after 35 
minutes, just after administration of the melphalan because the tourniquet snapped. 
The other 5 ILPs were terminated when the accumulative leakage passed 20%, but 
melphalan circulation time was at least 45 minutes in all procedures. No systemic 
toxicity could be detected in patients with these high-leakage ILPs. There was no 
difference in systemic toxicity between the normal and reduced dose ILPs (p=0.622). 
Local toxicity in 339 ILPs according to Wieberdink was grade I - II in 76%, III in 
21% and IV -V in 3%. Overall, the Fisher’s exact test for comparison between groups 
revealed a borderline difference in local toxicity in favour of the reduced dose 
procedures compared with the normal dose ILPs (p=0.135, table 3), which remained 
after adjustment for gender of the patient (odds ratio 2.0, p=0.065). 
Table 3: Systemic and local toxicity
Systemic toxicity    
  Reduced (N=64) Normal (N=275)
N N
Neurol absent 61 255
 grade 1 2 18
 grade 2 1 1
 grade 3  1
Liver absent 64 271
 grade 3-4  4
Renal absent 64 274
 grade 3-4  1
Haem absent 64 272
 grade 3-4  3
Shock absent 63 272
 present 1 3
P-value 0.62
Local toxicity   
Wieberdink 1-2 54 202
 3 8 64
 4-5 2 9
P-value  0.14
Neurol = neurologic, Haem = haematologic
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DISCUSSION
This retrospective non-randomised study of 64 ILPs performed with TNF dose reduc-
tion shows that both in melanoma and in non-melanoma patients, overall response 
rates are not affected. Toxicity of TM-ILPs in normal dose procedures is mild and 
easily manageable in virtually all cases and is not further reduced by the use of lower 
dose TNF.
Response
The use of TNF in melanoma ILPs is favoured in Europe since 1994, as a multicenter 
report on TM-ILPs showed a significant increase in CR rate up to 90% compared to 
the 52% CR rate in these 4 centers for melphalan-only ILPs 20. Especially in bulky 
melanoma in-transit metastases, the use of TNF seems of extra value 21. The pres-
ently reported CR rate of 75% for reduced-dose ILP in melanoma patients with bulky 
disease compares both to our own data on normal-dose ILPs and to data from the 
literature 17, 22, 23. Importantly, it is far better than the reported CR rates for melphalan-
only ILPs 24, indicating that the additional effect of TNF is still present at lower dose. 
These observations are sustained by the recent report of Rossi and co-workers, who 
find a CR rate of 70% in 20 melanoma patients treated with 1 mg TNF 8. In non-
melanoma patients with extensive limb disease unsuitable for resection, TM-ILP has 
proven to render excellent overall response and high limb salvage rates 3, 25, 26. The 
overall response rate of 69% in this study is in line with these results and with the 
limited data available on low-dose TM-ILPs 7, 11. The relatively high CR rate in the 
reduced dose population is partly explained by the fact that 5/16 ILPs for Stewart-
Treves lymphangiosarcoma and 5/7 ILPs for Kaposi sarcoma, both tumours known 
to have better responses on ILP than other STS 27, 28, were performed with low-dose 
TNF. Reduction of the TNF dose in both melanoma- and non-melanoma-ILPs does 
not seem to have negative impact on response rates.
Toxicity
Systemic toxicity in a locoregional treatment procedure as ILP is, is determined by 
the amount of systemic leakage of the (bio-)chemotherapeutics to the systemic cir-
culation. Although systemic leakage of melphalan should be avoided (systemic side 
effects consist of immediate postoperative nausea and vomiting and occasionally 
transient bone marrow depression 29), systemic toxicity attributable to melphalan is 
often limited. Typical TNF related systemic toxicity consists of hypotension, fever 
and chills (“shock-like syndrome”) 30 and occasionally of transient leukopenia, hepa-
tobiliary or renal toxicity, or pulmonary complications. Because of these serious side 
effects at low dose already (maximum tolerated dose ± 400 µg/m2 31, 32), systemic ad-
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ministration of TNF has been abandoned. Leakage of this cytokine should therefore 
be minimized by adequate isolation of the limb and a thorough washout procedure, 
and should be carefully monitored during the procedure. Dose reduction of TNF 
in the ILP setting will only have an effect on systemic toxicity in case of significant 
leakage. At present, however, the ILP technique is capable of providing leakage-free 
procedures. Moreover, adequate fluid management in the immediate postoperative 
period shows to prevent TNF-related hypotension and makes vasopressor support 
virtually unnecessary. Systemic toxicity of TNF-ILP is therefore not essentially dif-
ferent from melphalan-ILPs 33, even in high-leakage ILPs 30, and is not likely to be 
further reduced by TNF dose reduction, as is confirmed by the data of the present 
study.
Local toxicity in the total of 339 ILPs performed in our institute was mild to moder-
ate in virtually all cases, with only 2 treatment-related amputations. One case of 
Wieberdink V local toxicity necessitating an amputation concerned a patient with 
melanoma in-transit metastases of the lower leg who developed extensive rhabdo-
myolysis of the upper leg after a 4 mg TNF-ILP at the iliac level. The other patient 
underwent an ILP for Ewing sarcoma in the upper leg 10 days after systemic chemo-
therapy (DIME, 6th cycle) and developed extensive necrosis of the whole leg, most 
probably due to systemic vascular damage caused by the systemic chemotherapy. 
Whether TNF increases local toxicity compared to a melphalan-only ILP is still under 
debate. Initial reports explicitly state that no increased local toxicity was observed 
in a triple drug (TNF, melphalan, IFN) regimen 2, 34. However, in a TNF dose escala-
tion study with TNF doses up to 6 mg, Fraker et al. report that local toxicity was 
significantly related with TNF dose 23. The authors speculate that the reason for this 
observation is the increased uptake of melphalan in the tissue, as experimental ILPs 
with TNF only revealed no local toxicity at all. The one study specifically addressing 
the local toxicity of TM-ILP, showed a significant increase of local toxicity with TNF 
compared to melphalan-only ILPs 19. The confounding factor here however was that 
the patients in that study participating in the TNF-ILP protocol were, due to trial 
prescriptions, exposed to higher temperatures during melphalan circulation. This 
difference might in part be the explanation of the observed difference in toxicity. 
Second, the local toxicity as a whole was mild to moderate and no grade IV-V toxic-
ity was recorded. These results compare with the data shown in the present study: 
local toxicity was higher in the standard dose ILPs compared to the ILPs performed 
with TNF dose reduction, although not statistically significant. 
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Optimal dose
The standard dose of TNF used in the ILP setting (4 mg for the leg, 3 mg for the 
arm) was originally chosen by Lienard and Lejeune based on the experience with 
melphalan that a 10-fold increase of the systemically tolerable dose could be safely 
used 2. Ever since, the only clinical study about the TNF dose was the dose escala-
tion study by Fraker et al. using 4 to 6 mg of TNF, showing no increased response 
but dose limiting local toxicity 23. A dose finding study for TNF is never reported 
in humans, but there are some studies reporting excellent results with lower dose 
TNF 7-9, even for TNF doses as low as 125 µg 7. A dose finding study performed in 
a rat model at our institution revealed that the TNF dose could be reduced five- to 
tenfold compared to the standard dose used in the rat without affecting the response 
rates 6. However, further reduction of the TNF dose caused complete loss of the syn-
ergy of TNF and melphalan 6. The present study was not designed to determine the 
optimal TNF dose, but the results confirm the conclusions of the above-mentioned 
studies that the standard dose of TNF used might be higher than strictly necessary. 
To definitely establish the optimal dose, a non-inferiority study would be the most 
appropriate, although we realize that due to the already low toxicity of ILP, this study 
would require such accrual that it will never be performed. 
In conclusion, the ILP procedures performed in our institution with TNF dose reduc-
tion for both melanoma and non-melanoma patients seem to be as effective as the 
standard dose procedures. Each milligram of TNF reduced implies a cost reduction 
of R2300 for the entire procedure. We therefore state that the standard dose of 4 mg 
TNF for the leg and 3 mg for the arm might be higher than necessary for achieving 
the maximal synergy between TNF and melphalan. Lowering TNF dose reduces 
the costs of the ILP procedure and seems to affect local toxicity and is therefore 
preferable. Although the effect of lowering TNF dose on the survival of patients 
could not be fully addressed due to the non-randomised setting of this study, these 
data suggest that OS is not inferior to the survival rate of patients receiving normal 
dose TNF.
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ABSTRACT
Background
Both patients with soft tissue sarcoma (STS) and patients with melanoma have lim-
ited treatment possibilities once the tumour has metastasised systemically. In patients 
with extremity STS or bulky melanoma in-transit metastases, the local tumour burden 
may be so problematic that, even in patients with systemically metastasised disease, 
an amputation may be inevitable. Isolated Limb Perfusion (ILP) has proven to be an 
excellent, local, limb-saving treatment option in patients with locally advanced ex-
tremity tumours. In this study, the authors investigated the palliative value of the ILP 
procedure to avoid amputation in patients who had stage IV STS and melanoma.
Methods
From 1991 to 203, of 339 tumour necrosis factor-α (TNF)-based ILPs, 51 procedures 
were performed for either stage IV STS (n=37 patients) or stage IV melanoma (n=14 
patients). All patients underwent an ILP with TNF and melphalan of the upper (n=4 
patients) or lower limb (n=47 patients) with 26 to 140 mg melphalan and 2 to 4 mg 
TNF. 
Results
The overall response in patients with stage IV STS was 84%, and their median sur-
vival was 12 months after ILP. Limb salvage could be achieved in 36 of 37 patients, 
with 1 patient undergoing amputation due to treatment toxicity. In the patients with 
stage IV melanoma, the complete response rate was 43%. All melanoma patients 
preserved their limb during a median survival of 7 months.
Conclusions
TNF-based ILP is an excellent procedure that provided tumour control and limb sal-
vage for the short survival of patients with metastasised, very bulky, limb-threatening 
tumours of the extremity.
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INTRODUCTION
Soft Tissue Sarcoma (STS) has a high mortality rate of up to 50% due to the propen-
sity of the tumour to develop distant metastases 1. Patients with metastatic sarcoma 
(TNM stage IV) have a median survival of only 1,5 years 1, 2 and survival rates have 
not improved in the last decades 3. For patients with non-metastasised STS, standard 
therapy consists of surgical resection of the tumour, often combined with radiothera-
py. When large or multiple tumours make this treatment option impossible, Isolated 
Limb Perfusion (ILP) with Tumour Necrosis Factor-α (TNF) and melphalan (TM-ILP) 
has proven to be effective as a limb-salving therapeutic option 4-6. 
Patients with distant melanoma metastases (stage IV) have very poor survival expec-
tations, with a median survival that barely exceeds 1 year. In-transit metastases in the 
extremities occur in 5-8% of patients with high-risk melanoma, and these patients 
cannot be treated surgically. ILP has shown to be an excellent treatment option in 
this patient category 7, 8.
A minority of patients with stage IV STS or patients with stage IV melanoma may 
present with combined problems of systemic metastases and locally very advanced 
tumour (recurrences) or in-transit metastases. The local situation may be disabling 
and very difficult to handle because of the poor sensitivity of these tumours to 
systemic therapies. Radiotherapy options also may be absent or very limited in these 
patients because of prior treatments, the tumour size and the multiplicity of tumours 
in the extremity. In general, we offer these patients with severe local disability and 
no other palliative treatment options a TNF-based ILP. This study was undertaken 
to evaluate the value of the TM-ILP procedure in patients with stage IV STS and 
melanoma with a short life expectancy. 
PATIENTS AND METHODS
Patients
Of 217 TM-ILPs for STS performed in the Daniel den Hoed Cancer Center between 
1991 and July 2003, 37 patients were treated with systemically metastasised extremity 
STS. During the same period, 14 patients with American Joint Committee on Cancer 
/ The University of Texas M. D. Anderson stage IV melanoma (distant metastases 
present) underwent an ILP for local control of disease in the limb. There were 14 
females and 23 males in the STS group with a median age of 55 years (range 17-86 
years), and the melanoma group consisted of 5 females and 9 males with a median 
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age of 61 years (range 25-78 years). Histological classification of the tumours is sum-
marized in table 1. All patients with STS were candidates for amputation, because 
primary surgical resection was impossible either because of the size and location or 
because of the multifocality of the tumours. All patients with melanoma had large 
and multiple tumours in the limb (the size and number of the lesions prevented pri-
mary surgery), which caused severe local discomfort. In total, 51 patients underwent 
ILP for metastasised tumours. The patient and tumour characteristics are summarized 
in table 2.
Table 1: Histological classification of 51 TM-ILPs for metastasised tumours
Histology N
Synovial sarcoma 7
MFH / High grade pleiomorf sarcoma 5
Osteosarcoma 4
Liposarcoma 4
Clear-cell sarcoma 4
(Extraskeletal) Ewing sarcoma 3
Hemangiopericytoma 2
Other STS 8
Melanoma 14
MFH = malignant fibrous histiocytoma, STS = soft tissue sarcoma
Table 2: Patient and tumour characteristics of 51 TM-ILPs for metastasised tumours
Patient and tumour characteristics of 51 TM-ILPs for metastasised tumours
Stage IV sarcoma Stage IV melanoma
N=37 % N=14 %
Gender F 14 38% 5 36%
M 23 62% 9 64%
Age ≤60 24 65% 7 50%
>60 13 35% 7 50%
Site Arm 4 11% 0 0%
Leg 33 89% 14 100%
Primary/Locally recurrent Primary 18 49%
(Re)recurrent 19 51%
Previous treatment* None 16 43% 6 43%
XRT 7 19% 3 21%
CT 17 46% 4 29%
ILP 2 5% 3 21%
* = 5 STS and 1 melanoma patients received both XRT and CT, 1 melanoma patient received both XRT and prior ILP.
F = female, M = male, XRT = radiotherapy, CT = chemotherapy, ILP = isolated limb perfusion
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Treatment
Patients underwent an ILP via the axillary (n=1), brachial (n=3), iliac (n=29), femoral 
(n=16) or popliteal (n=2) approach. The ILP technique has been described previ-
ously 5, 9. Briefly: recombinant human TNF (Boehringer Ingelheim GmbH, Ingelheim/
Rhein, Germany) and the cytostatic drug melphalan (L-PAM, Alkeran, Burroughs 
Wellcome Ltd., London, UK), which was obtained as a sterile powder, were dis-
solved aseptically using solvent and diluents (Burroughs Wellcome Ltd., London, 
UK). ILPs were performed under general anaesthesia and normally took from 2.5 
hours to 4.0 hours. Isolation of the blood circuit of a limb was achieved by clamping 
and canulation of the major artery and vein, connection to an oxygenated extracor-
poreal circuit, and application of a tourniquet to compress the remaining collateral 
vessels. ILP consisted of a 90-minutes perfusion with 1 to 3 mg TNF (arm) or 3-4 mg 
TNF (leg), and a 10-mg/L volume (leg) or 13-mg/L volume (arm) of melphalan at 
mild hyperthermia (tissue temperatures of maximally 39.5°C in the leg and 38.5°C in 
the arm). The median dose of melphalan was 60 mg (mean 68.7 mg, range 26-140 
mg); median dose of TNF was 4 mg (mean 3.3 mg, range 2-4 mg). In the melanoma 
group, all patients underwent lower extremity ILP and received a median dose of 90 
mg melphalan (mean 90.4 mg, range 50-120 mg) and a median dose of 4 mg TNF 
(mean 3.7 mg, range 2-4 mg). TNF was injected as a bolus into the arterial line pro-
vided limb tissue temperature had reached 38°C. Melphalan was administered after 
10-30 minutes at limb temperatures between 38°C and 39.5°C. During the procedure, 
continuous leakage monitoring was performed by using a precordial scintillation 
probe to detect leakage of radiolabelled albumen injected to the perfusion circuit. At 
the end of the ILP, the limb was washed out with at least 1 L (arm) up to 4 L (iliac 
perfusion) of physiologic saline solution and 6% dextran 70 (Macrodex; Pharmacia, 
Uppsala, Sweden). In patients with melanoma who underwent iliac perfusion, an 
iliac lymph node dissection was performed, and patients who had palpable nodal 
disease in the groin underwent an ilio-inguinal lymph node dissection in the same 
operative session as the ILP but prior to the ILP.
Response evaluation and toxicity
Clinical response evaluation in patients with STS was performed 2 weeks, 4 weeks, 
8 weeks and 12 weeks after ILP and every 3 months thereafter for the first year both 
by clinical examination and by magnetic resonance imaging 4-6 weeks after ILP, 8-12 
weeks after ILP and every 3-6 months thereafter. Response evaluation in patients with 
melanoma was performed 2-4 weeks and 8 weeks after ILP by clinical examination, 
and after that at regular 3- month intervals for the first 2 years and at longer intervals 
thereafter. Responses are reported according to World Health Organisation (WHO) 
criteria 10. When histological response could be assessed in patients with STS, the 
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final outcome was adjusted if the pathological response (based on the percentage of 
necrosis: complete response (CR) if 100% necrosis, partial response (PR) if 50-99% 
necrosis, no change (NC) if <50% necrosis) differed from the clinical response. 
Acute local toxicity of the ILP procedure was classified according to Wieberdink et 
al. 11, as follows: (grade I) no reaction, (grade II) slight erythema or edema, (grade 
III) considerable erythema or edema with some blistering, slightly disturbed motil-
ity permissible, (grade IV) extensive epidermolysis or obvious damage to the deep 
tissues, causing definite functional disturbance, and threatening or manifest compart-
mental syndrome, and (grade V) reaction that may necessitate amputation. Systemic 
toxicity is reported according to WHO criteria.
RESULTS
Response
STS
A clinical CR after ILP in 37 patients with metastasised extremity STS was observed 
in 8%. A PR occurred in 65%, NC was observed in 24% and clinical response was not 
determined in 1 patient (3%). Eighteen patients underwent resection of the tumour 
remnant after shrinkage, and patients with multiple tumours underwent a biopsy for 
response assessment (median time after ILP 3 months, range 0.4-7.4 months), which 
showed 100% necrosis in 4 patients, 50-99% necrosis in 12 patients and 0-50% necro-
sis in 2 patients. In 6 patients, histological response differed from clinical response (3 
patients were reclassified from NC to a PR, and 3 patients were reclassified from a PR 
to a CR), resulting in a final 16% CR rate, a final 68% PR rate, and a final 16% NC rate. 
The overall response rate of TM-ILP in patients with stage IV sarcoma (84%) did not 
differ significantly from our ILP experience in treating patients with nonmetastatic 
disease (overall response rate 71%, p=0.11). 
Melanoma
Among the patients with stage IV melanoma, a CR was observed in 6 patients (43%), 
a PR was observed in 7 patients (50%) and NC was observed in 1 patient (7%). The 
response in patients with stage IV melanoma differed significantly from the respons-
es obtained in patients treated in our institution with stage IIIA disease (in-transit 
metastases only) or IIIAB disease (in-transit metastases and lymph node metastases; 
84% and 63%, respectively, p-values=0.004 and 0.184, respectively).
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Outcome and toxicity
Overall survival of the 37 patients with STS after ILP was 53% at 1 year and 15% 
at 2 years. The median survival after ILP was 12 months, and death was related to 
the disease in all cases. In patients with melanoma, the median time of survival 
was 7 months: Thirty-nine percent of the patients still were alive after 1 year, but 
no patients survived for 2 years. Local control of the disease for the full duration 
of life, which is the main objective of ILP for patients who have stage IV disease, 
was obtained in 33 patients with STS and in 11 patients with melanoma. In seven 
patients, continued control was not achieved: Four patients with STS and three pa-
tients with melanoma experienced local progression of the disease in the limb after 
an initial response. Because of their initial responses and the ongoing progression 
of their distant metastases, the local control achieved in these patients lasted long 
Figure 1 
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Figure 1: Overall survival (OS) and time to local progression (TTLP) after ILP in patients with stage IV sarcoma
X-axis: Time (months); Y-axis: Cumulative percentageFigure 2 
Overall Survival and Time to Local Progression in stage IV melanoma patients 
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Figure 2: Overall survival (OS) and time to local progression (TTLP) after ILP in patients with stage IV melanoma
X-axis: Time (months); Y-axis: Cumulative percentage
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enough to avoid a situation in which an amputation was required. Overall survival 
and time to local progression are shown in figure 1 (STS) and figure 2 (melanoma). 
The toxicity of TM-ILP was very mild, consistent with prior reports. Local toxicity 
was mild (grade 1-2) to moderate (grade 3) in 35 patients with STS who underwent 
ILP and in all patients with melanoma who underwent ILP. One patient developed 
pain in the lower leg without the symptoms of compartment syndrome (Wieberdink 
grade IV). In one other patient, there was extensive necrosis of the tumour after ILP 
that developed in a secondary infection. Eventually, an amputation was inevitable 
in the postoperative period, which is considered a grade V local toxicity of the ILP 
procedure. This was the only amputation that had to be performed in the described 
patient population. Limb function of the other 36 patients with STS was excellent in 
27 patients; mildly disturbed in 5 patients, and severely affected (leading to the use 
of crutches) in 4 patients. All patients with melanoma had excellent limb function 
after perfusion. Systemic toxicity was absent or mild, with only 1 patient who had 
Table 3: Local and systemic toxicity of 51 TM-ILPs for metastasised tumours
Local toxicity
Grade I Grade II Grade III Grade IV Grade V
Wieberdink 10 31 8 1 1
Systemic toxicity
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Neurologic* 47 4 0 0 0
Liver* 50 0 1 0 0
Renal* 50 0 1 0 0
Haematologic* 49 1 0 0 1
<38°C 38-39°C 39-40°C >40°C, <24 hrs >40°C, >24 hrs
Temperature 24 13 11 2 1
Absent Present
Shock& 51
Hrs = hours, * = WHO criteria13, & = support of vasopressors needed
Table 4: Outcome of 51 patients after ILP for metastasised tumours
Outcome of 51 patients after ILP for metastasised tumours
STS Melanoma
N=37 N=14
OS 1-yr 53% 39%
2-yrs 15% n.a.
LPFS 2-yrs 86% 78%*
LS 96% 100%
STS = soft tissues arcoma, OS = overall survival, LPFS = local progression free survival, LS = limb salvage, n.a. = not applicable, * =estimated
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STS developing a fever >40°C for >24 hours and with 1 patient who had melanoma 
developing a grade IV leucopenia, which lasted only for 1 day and that did not 
require any type of intervention (table 3). Median hospital stay for the 51 patients 
was 10 days. Outcomes of the patients are summarized in table 4.
DISCUSSION
The present data show that ILP can provide excellent local control and salvage of the 
limb in patients with stage IV STS or melanoma in combination with limb-threatening 
local tumours.
STS
The overall response rate (84%) in this study was relatively high compared both 
with data in literature (63-91% 5, 6, 12) and with our own experience in nonmetastatic 
disease (71%). However, this high overall response rate was largely attributable to 
the proportion of patients who had a PR (68%). Especially in patients with metastatic 
disease, any response that leads to local control and prevents amputation is worth 
the effort in light of the limited life expectancy.
The median survival of the patients after ILP was 12 months. This corresponds well 
with data from other studies, which have reported a survival of 11-26 months 1, 2, 13, 14 
in patients with metastatic disease, taken into account that there is a lead-time bias 
effect in the current study, because survival was calculated from the date of ILP.
Melanoma
The overall response rate in the 14 patients with stage IV melanoma was 93% with 
a CR rate of 43%. This is remarkably good for a stage IV melanoma population, 
because the results reported from ILP in patients with melanoma usually deal only 
with stage IIIA or IIIAB disease. The responses with TM-ILP achieved in our patients 
with stage IV melanoma who had bulky disease were as good as the reported results 
reported from melphalan-only ILPs in patients who had stage IIIA/IIIAB disease 15, 
but they were markedly lower than the results reported from TM-ILP in patients who 
had stage IIIA/IIIAB disease 8, 16, 17. Reasons for this reduced response rate are un-
known, but we speculated previously that in these patients with stage IV melanoma, 
all of whom had very bulky disease in the limbs, a reduced immunocompetence in 
stage IV melanoma may play a significant role, along with an increased aggressive-
ness of the melanoma itself 17. However, further research will be needed to explain 
properly this decreased response rate, which has been found universally in this and 
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other (melphalan-based) studies 8, 18, 19. Survival in patients with stage IV melanoma is 
extremely poor and reportedly is only 41-59% at 1 year, depending on the site of the 
metastases 20, which is in line with the 39% 1-year survival rate in this study, again 
taking into account the lead-time bias effect. 
Toxicity
Systemic toxicity from TM-ILP virtually was absent in the procedures performed. This 
is a very important observation, because, in general, a palliative procedure should be 
relatively free of side effects. The dreaded, shock-like symptoms of (high-leakage) 
ILP with TNF could be avoided easily in the postoperative phase, because we know 
from the extensive experience in our institution that generous fluid management and 
the use of indomethacin in the immediate postoperative period prevents the symp-
toms of fever and the transient drop in blood pressure 21. Local toxicity was severe 
(grade IV or V) in 2 patients in the study population and led to amputation of the 
limb in 1 of these patients. This is a severe, adverse, therapy-related effect, despite 
the fact that an amputation of the limb in this patient was inevitable if no treatment 
was offered. In our experience with TM-ILP in nearly 350 procedures for patients 
with melanoma and non-melanoma tumours, only 2 treatment-related amputations 
(Wieberdink grade V) had to be performed. 
The rationale for palliative treatment of patients with stage IV disease by a locore-
gional treatment procedure deserves further discussion. For both systemically me-
tastasised STS and melanoma, the reported effectiveness of systemic chemotherapy 
is very poor. In patients with STS, no effect of systemic chemotherapy on survival 
could be demonstrated either in the adjuvant setting after resection of the primary 
tumour 22, or in patients who already had metastatic disease 23. In fact, a recent study 
from the Memorial Sloan-Kettering Cancer Center has shown that, despite improved 
insight into the tumour biology of sarcoma, the prognosis for patients with STS has 
not improved in the last 20 years 3. For patients with melanoma, the same problem 
is encountered: although some treatment regimens seem to increase response rates, 
none of the treatment schedules has been able to prolong overall survival 24. These 
data indicate that in both patients with STS and patients with melanoma who have 
distant metastases, the objective of treatment should be improving quality of life 
during the terminal phase. Previous studies have demonstrated that ILP could of-
fer palliation in both patients with melanoma 25 and patients with STS 26 who have 
advanced disease. The 51 patients presented in the current study all had locally 
advanced tumour activity for which amputation of the limb was inevitable. Their pre-
ILP limb function was very poor and especially in patients with melanoma, necrosis 
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of the tumours resulted in socially disabling conditions. TM-ILP preserved the limb 
in 50 of 51 patients with excellent limb function in 31 patients.
The currently series of 51 patients showed that TM-ILP can offer important benefits 
to patients with metastasised melanoma and sarcoma, with low treatment-related 
morbidity. When surgical resection of the tumours is impossible or is possible only 
at the cost of severe disability, a TNF-based ILP can offer limb salvage in 98% of the 
patients, which means important improvement in patient mobility during the last, 
often short, period of life. Therefore, we recommend considering TM-ILP for patients 
in this category as soon as the local situation of the limb prompts for action.
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SUMMARY AND CONCLUSIONS
Isolated limb perfusion (ILP) with melphalan is effective in the treatment of small 
multiple melanoma in-transit metastases and is utilized widely for this indication. 
The technique achieves regional drug concentrations 15–25 times higher than sys-
temic administration and is without systemic side effects 1, 2. However, the treatment 
is much less effective against bulky melanoma metastases and has uniformly failed in 
the treatment of irresectable extremity soft tissue sarcomas. The addition of tumour 
necrosis factor-alpha (TNF-α) to this treatment approach has changed this situation 
dramatically and has greatly expanded the successful application of ILP. TNF-based 
ILP (TM-ILP) can avoid amputations regardless of the tumour size and type.
TNF-BASED ILP FOR MELANOMA PATIENTS 
For patients with extensive melanoma in-transit metastases (IT-mets), treatment op-
tions are often limited. Surgical excision of IT-mets is chosen when size and number 
permits this approach. Treatment by carbon dioxide laser therapy or external beam 
radiotherapy is only possible in highly selected patient categories. Immunotherapy 
through vaccination has not yet produced satisfactory results and the response per-
centage of systemic chemotherapy for melanoma is such disappointing, that it should 
only be used in the palliative treatment of systemically metastasised patients 3. It 
must be realized that amputation is seldom if ever indicated and does not improve 
survival 4. Due to the lack of effective treatment options for patients with extensive 
melanoma IT-mets of the extremity, ILP is a very attractive treatment modality in 
this patient population. ILP with melphalan alone is reported to achieve about 50 
% CR rate and 80% overall response rate 5. The introduction of TNF-α in this setting 
led to an increase in CR rates to 70–90% and overall response rates to 95–100% 6. 
These results encouraged us to start a series of TM-ILPs for patients with melanoma 
IT-mets.
In chapter 2, we report about 100 consecutive TM-ILPs in 87 melanoma patients 
using a 1–4 mg TNF-α dose. Of these, 45 ILPs were performed for stage IIIA (IT-mets 
without positive lymph nodes), 41 ILPs for stage IIIAB (IT-mets with positive nodes) 
and 14 ILPs for stage IV (IT-mets plus distant metastases) disease. Most patients had 
bulky disease (0–10 lesions in 43 patients, 11–50 in 32 patients, and over 50 lesions 
in 25 patients) and/or failed multiple prior treatments. In 21 patients, a second or 
third TM-ILP was performed because patients failed to respond to a prior M-ILP or 
TM-ILP. The overall response rate was 95% with 69 CRs (69%), 26 PRs (26%) and 5 
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stable diseases (5%). The CR rates differed significantly according to disease stage: 
82% in Stage IIIA; 63% in Stage IIIAB and 43% in Stage IV. In 50% of patients with 
a CR, local recurrences occurred. Mean time to recurrence / progression in CR pa-
tients was 22 months (3–129+ months), versus 6 months in the other patients. There 
were 71 patients with metastatic disease at or after ILP and the mean time to distant 
metastases was 14 months. At a median follow up of 22 months (1–132+ months), 
overall 5-year survival was 32% and 10-year survival was 17%. The outcome of pa-
tients after ILP is determined by the stage of the disease, which is a reflection of the 
aggressiveness of the melanoma. However, within each stage of disease, a complete 
response on ILP selects those patients with relatively favourable characteristics. The 
local toxicity of the procedure was mild and no grade 3–4 systemic toxicity was 
observed, not even in the eight patients with high leakage (10–32%). The CR rate in 
the first 50 ILPs was 80% versus 58% in the last 50 ILPs (p=0.017). This difference 
in CR reflects a change in policy, whereby TM-ILP was offered only to patients with 
bulky disease and or multiple recurrences after multiple surgical interventions and/
or after vaccine-therapy trials, to which many patients were first entered. This patient 
category with highly unfavourable characteristics, still showed a superior response 
rate compared with the historical group of patients treated with M-ILP without such 
an unfavourable patient selection 6 and it is similar to the observations in the US in 
an interim analysis of a randomised trial by Fraker et al. 7. Thus, TM-ILP results in 
high response rates in patients with melanoma IT-mets, and is of special value in 
patients with bulky disease. 
In chapter 3, we report about our study of 25 ILPs with a 1–4 mg TNF-α for recur-
rences in the limb after previous ILP treatment. The overall response rate of repeat 
ILP was 96% (CR 76%, PR 20%) and there was no change in 4%. This did not differ 
from the primary ILPs in our series and no increased toxicity was observed. This 
observation underscores the efficacy of a TNF-based ILP in the repeat-ILP setting and 
thereby its indication for this difficult clinical problem.
Chapter 4 is an outline of possible treatment modalities in patients with melanoma 
IT-mets and determines the place of ILP in this gamut. For patients with extensive 
IT-mets of the limb that cannot be treated by local techniques, a regional technique 
is able to achieve drug concentrations in the affected limb that are sufficient to yield 
tumour response. It seems that patients with multiple small lesions can be treated ef-
fectively by melphalan-only techniques, whether that is Isolated Limb Infusion (ILI) 
for lesions in the distal part of the limb, or the traditional melphalan-only ILP. TM-ILP 
however, has shown to be more effective in terms of response rates. Due to the 
vasculotoxic effect of TNF, it is likely that large tumours with their own vasculature 
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profit the most from addition of this cytokine. Preclinical studies, various single-
center reports, our own experience with 100 TM-ILP procedures for melanoma, and 
the interim analysis of a randomised controlled trial 7, all confirm this hypothesis. For 
patients with bulky melanoma metastases of the limb and those patients who failed 
prior ILP treatment, TM-ILP seems to be the most efficacious therapy to obtain local 
control and achieve limb salvage.
TNF-BASED ILP FOR SOFT TISSUE SARCOMA PATIENTS
Achieving limb salvage is a key element in the management of locally advanced 
soft tissue sarcomas (STS) of the extremities, because there is ample evidence that 
limb-preserving surgery is equal to amputation in terms of overall survival 8-10. This 
improved the interest in neoadjuvant treatment options that could reduce the size 
of the tumours and hence make function-preserving surgery possible. In contrast to 
the efficacy of melphalan-based ILP for small melanoma in-transit metastases, results 
with ILP using melphalan, doxorubicin, or any other drug for large STS have been 
very disappointing. The introduction of TNF in the ILP setting in an initial report of 
4 TM-ILPs in locally advanced STS changed this situation as it showed impressive 
and very rapid responses 11. Multicenter trials confirmed that TNF-based ILP was a 
highly effective new method of induction biochemotherapy for extremity STS with a 
20–30% complete remission (CR) rate, a ~ 50% partial remission (PR) rate and a limb 
salvage percentage of ~80% 12, 13. Rotterdam was the leading institute of the pivotal 
multicenter trials of the application of TM-ILP for locally advanced STS.
In chapter 5, the 217 consecutive TM-ILPs in 197 patients for limb-threatening STS 
performed in Rotterdam between 1991 and 2003 are analysed. Primary sarcomas 
were perfused in 61% of patients, local recurrent sarcomas in 39%, multifocal pri-
mary or multiple local recurrences in 29%, and overt concurrent metastatic disease in 
16%. Tumours >10 cm were found in 42% of patients; most tumours were high grade, 
with 81% showing grade II-III tumours. A major response after therapy was observed 
in 75% of the patients (26% complete responses, 49% partial responses). Limb sal-
vage was achieved in 87%. Although on theoretical grounds it can be expected that 
high-grade tumours respond better to ILP, as they are usually more vascularized, this 
could not be confirmed in this study, and only ILP for Stewart-Treves lymphangio-
sarcoma or Kaposi sarcoma was associated with significantly better response. At a 
median follow-up period of 22 months (range 0.1-130+ months), actuarial overall 
5-year survival was 49% with a median survival time of 57 months. Trojani grade and 
the presence of multiple tumours were negative prognostic factors for survival. The 
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excellent results of TM-ILP in locally advanced STS have established a permanent 
role of TM-ILP in the multimodality treatment arsenal for these tumours.
REPORTS ON SPECIAL PATIENT CATEGORIES
Patients with multiple tumours in the extremity
TNF-based ILP is the ideal alternative to avoid amputation in patients with multifocal 
primary tumours, who are difficult to treat, such as Kaposi sarcomas 14 and multiple 
lymphangiosarcomas (also known as Stewart Treves Syndrome) 15. Chapter 6 de-
scribes the experience of our group in patients of STS patients with multiple primaries 
of various histologies or multiple recurrences after prior surgery. Remarkably good 
results were reported, as we observed an 87% response rate and 82% limb salvage 
rate in 64 patients with multiple tumours. These results indicate that TNF-based ILP 
is very effective and can prevent amputation in this patient population.
Patients with recurrent tumours in an irradiated field
We performed 30 ILPs in 26 patients with recurrent tumours in an irradiated field, 
which is reported in chapter 7. In contrast to the belief that such tumours are 
unlikely to respond, we observed a 70% response rate and 65% limb salvage rate, 
indicating that in this very difficult patient category a TNF-based ILP approach is an 
attractive treatment option. 
Patients with desmoids
Patients with desmoid tumours and aggressive fibromatosis often present with recur-
rent disease, which is very difficult to treat surgically with or without radiotherapy. In 
chapter 8, our group observed an overall response rate of 75 % and a limb salvage 
rate of 100%, demonstrating the utility of this procedure in achieving local control 
in this tumour type. 
The results obtained in Rotterdam on TM-ILP for STS, both in the overall population 
and in patients with specific problems such as multifocality, previous radiotherapy 
and recurrent desmoid tumours, are compared to the literature in chapter 9. As 
TNF-α targets the vasculature-vasculature, which is a common denominator in all 
these tumour types, the use of TNF is very attractive and it explains its efficacy in 
combination with chemotherapy across these numerous histologies. No other neo-
adjuvant treatment option in STS produces the response rates obtained with TM-ILP, 
which leads to the conclusion that a TM-ILP should be considered standard of care 
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in each patient with locally advanced STS where an amputation, or a resection with 
severe functional loss, is the only surgical option. 
GENERAL QUESTIONS IN ISOLATED LIMB PERFUSION
An aspect that has been studied in overall populations is whether high doses of 
TNF-α (e.g. 3–4 mg) are necessary or whether lower doses (e.g. 1 mg) suffice. An 
early clinical report by Hill and co-workers suggested that low doses of TNF-α were 
sufficient 16. The small study size, the concomitant use of high doses of corticoste-
roids, and the fact that a different type of TNF-α was used, meant that definitive 
conclusions were not possible. Confirmative reports came from the Italian studies of 
1 mg TNF-α in combination with doxorubicin 17 and the French randomised phase 
II trial in 100 patients on four TNF-α doses (0.5, 1.0, 2.0 and 4.0 mg) 18. Chapter 
10 describes our analysis of 240 ILPs in which the TNF-α doses varied between 1.0, 
2.0, 3.0 and 4.0 mg. A reduction of TNF dose up to 1 mg is not correlated with an 
inferior response to therapy, nor does it affect toxicity rates. This is consistent with 
findings from our laboratory, which indicate that doses of 1 mg TNF-α are sufficient, 
but further dose reduction results in complete loss of activity 19.
In patients who have overt metastatic disease and a limb-threatening tumour a pal-
liative TNF-based ILP could possibly induce tumour control and avoid amputation. 
In chapter 11, the results of 51 ILP procedures performed in patients with stage IV 
disease are presented. True local control was achieved in 33/37 STS patients and 
in 11/14 melanoma patients, and the remaining patients showed an initial response 
with ongoing progression of their metastatic disease. Only one amputation had to be 
performed in this patient category. Although this amputation was due to treatment 
toxicity, the overall toxicity of the 51 procedures was very low, both on the local and 
on the systemic level. This demonstrates that TNF-based ILP is an attractive option 
in these patients with a short life expectancy.
CONCLUSIONS AND FUTURE DIRECTIONS
ILP methodology provides us an excellent tool in the clinic to obtain local control 
and avoid amputations of limbs in patients with limb-threatening tumours. This 
has been largely achieved by the success of the antivascular TNF-based biochemo-
therapy in this setting. TNF-based ILP is a very successful treatment option to achieve 
limb salvage in the management of advanced disease and multiple or drug resistant 
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extremity tumours. TNF-based ILPs are now performed in 35 cancer centers in Eu-
rope with referral programs for limb salvage. TNFα-based ILP is a well-established 
treatment to avoid amputations and represents an important example of tumour 
vascularity-modulating combination therapy and should be offered in large volume 
tertiary referral centers. In the field of isolated perfusion, newly discovered vaso-ac-
tive drugs await evaluation in preclinical research projects and future clinical trials. 
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SAMENVATTING EN CONCLUSIES
Geïsoleerde extremiteitsperfusie (ILP) met melphalan is een effectieve behandeling 
voor multipele kleine melanoom in-transit metastasen en wordt hiervoor dan ook 
veelvuldig toegepast. De techniek maakt het mogelijk om locoregionaal een medi-
cijnconcentratie te bereiken die 15-25 keer hoger is dan bij systemische toediening, 
zonder dat dit gepaard gaat met systemische toxiciteit 1, 2. Toch is deze behandeling 
veel minder effectief gebleken voor grote melanoommetastasen en is voor de behan-
deling van irresectabele weke delen sarcomen van de extremiteit niet bruikbaar. Het 
toevoegen van tumor necrose factor-alpha (TNF-α) aan het perfusaat heeft hierin 
echter een dramatische verandering gebracht waardoor de succesvolle toepassing 
van ILP enorm kon worden uitgebreid. ILP met TNF (TM-ILP) kan amputaties voor-
komen bij patiënten met tumoren van elke grootte en elk type.
ILP MET TNF VOOR MELANOOMPATIËNTEN 
Voor patiënten met uitgebreide in-transit metastasen (IT-meta’s) van het melanoom 
zijn de behandelingsmogelijkheden vaak beperkt. Chirurgische excisie van de IT-
meta’s wordt verricht als de grootte en het aantal dit toelaat. Een behandeling met 
CO2 laser therapie of met radiotherapie is alleen mogelijk bij een geselecteerde 
patiëntengroep. Immunotherapie in de vorm van vaccinatie heeft nog onvoldoende 
bevredigende resultaten opgeleverd en de responspercentages op systemische che-
motherapie zijn dusdanig laag, dat dit alleen overwogen moet worden als palliatieve 
behandeling van systemisch gemetastaseerde patiënten 3. Ook moet men zich reali-
seren dat amputatie van een extremiteit bij een melanoompatiënt zelden of nooit is 
geïndiceerd en niet tot een betere overleving leidt 4. Door het gebrek aan effectieve 
behandelingen voor patiënten met uitgebreide IT-meta’s van het melanoom op de 
extremiteit is ILP een erg aantrekkelijke behandelingsmodaliteit voor deze patiën-
tengroep. Van ILP met melphalan alleen zijn complete respons (CR) percentages 
bekend van rond 50% en totale respons percentages van 80% 5. De introductie van 
TNF-α in het ILP model heeft deze percentages echter doen stijgen tot 70-90% voor 
CR en tot 95-100% voor de totale respons 6. Deze resultaten hebben ons gestimuleerd 
om een serie behandelingen met TM-ILP te starten voor patiënten met IT-meta’s van 
het melanoom.
In hoofdstuk 2 beschrijven we de resultaten van 100 opeenvolgende TM-ILPs bij 
87 melanoompatiënten waarbij TNF-α doseringen werden gebruikt tussen 1-4 mg. 
Van deze procedures werden 45 ILPs uitgevoerd voor stadium IIIA ziekte (IT-me-
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ta’s zonder positieve lymfklieren), 41 ILPs voor stadium IIIAB ziekte (IT-meta’s met 
lymfkliermetastasen) en 14 ILPs voor stadium IV ziekte (IT-meta’s plus afstandsme-
tastasen). De meeste patiënten hadden multipele grote afwijkingen (1-10 laesies bij 
43 patiënten, 11-50 bij 32 patiënten en meer dan 50 laesies bij 25 patiënten) en/of 
hadden niet gereageerd op meerder voorafgaande behandelingen. Bij 21 patiënten 
werd een tweede of derde perfusie uitgevoerd omdat eerdere melphalan (M)-ILP of 
TM-ILP geen of onvoldoende effect had gehad. Het totale respons percentage was 
95% met 69 CRs (69%), 26 partiële responses (PR, 26%) en 5 keer stabiele ziekte 
(5%). Het CR percentage verschilde significant per ziektestadium: 82% in stadium 
IIIA, 63% in stadium IIIAB en 43% in stadium IV. Bij 50% van de patiënten met een 
CR ontwikkelde zich een lokaal recidief. De mediane duur tot aan het ontwikkelen 
van een recidief respectievelijk progressie van de laesies was 22 maanden (3-129+) 
bij patiënten met een CR versus 6 maanden bij de overige patiënten. In totaal had-
den of kregen 71 patiënten metastasen op afstand na een mediane duur van 14 
maanden. Bij een mediane follow-up van 22 maanden (1-132+ maanden) bleek de 
5-jaars overleving 32% en de 10-jaars overleving 17%. Het lot van patiënten na een 
ILP wordt bepaald door het stadium van de ziekte, hetgeen een weerspiegeling is 
van de agressiviteit van het melanoom. Toch selecteert een CR na ILP, binnen elk 
ziektestadium, die patiënten met relatief gunstige tumorkenmerken. De lokale toxici-
teit van de procedure was mild, wat blijkt uit het ontbreken van graad 3-4 toxiciteit, 
zelfs bij de acht patiënten met veel (10-32%) lekkage. Het CR percentage in de eerste 
50 ILPs was 80%, tegen 58% in de 2e 50 ILPs (p=0.017). Dit is een gevolg van een be-
leidsverandering waardoor TM-ILP alleen werd aangeboden aan patiënten met zeer 
uitgebreide ziekte en/of multipele recidieven na eerdere chirurgische interventie 
en/of na vaccinatietherapie studies waaraan vele patiënten primair hadden deelge-
nomen. Deze patiëntencategorie met zeer ongunstige kenmerken bleek nog altijd 
te reageren op TM-ILP met betere responspercentages dan een historische groep 
patiënten die met M-ILP was behandeld en die deze ongunstige kenmerken miste 6. 
Dit responspercentage is gelijk aan de resultaten die worden gemeld door Fraker et 
al. 7 in een interim-analyse van een gerandomiseerde studie in de Verenigde Staten. 
Concluderend resulteert TM-ILP in hoge responspercentages bij patiënten met me-
lanoom IT-meta’s, en is het van buitengewone waarde bij patiënten met uitgebreide 
ziekte.
In hoofdstuk 3 melden wij de resultaten van onze studie van 25 ILPs met 1-4 mg 
TNF-α voor melanoomrecidieven in de extremiteit na eerdere ILP behandeling. Het 
totale respons percentage van de herhaalde ILPs was 96% (CR 76%, PR 20%) en 
4% bereikte stabiele ziekte. Deze resultaten verschilden niet van de primaire ILPs 
in onze serie, noch bleek er sprake van verhoogde toxiciteit. Deze bevindingen 
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onderstrepen de effectiviteit van TM-ILP als herhalingsbehandeling en daarmee de 
indicatie voor dit lastige klinisch probleem.
Hoofdstuk 4 is een uiteenzetting van de mogelijke behandelingsvormen voor pa-
tiënten met melanoom IT-meta’s en bepaalt de plaats van ILP in dit scala. Voor 
patiënten met uitgebreide IT-meta’s van de extremiteit die niet met lokale behande-
lingen kunnen worden behandeld, blijkt deze regionale techniek in staat om medi-
cijnconcentraties in het aangedane gebied te bewerkstelligen die hoog genoeg zijn 
om een tumor respons te induceren. Patiënten met multipele kleine laesies kunnen 
effectief worden behandeld met technieken die alleen melphalan gebruiken, of dit 
nu geïsoleerde extremiteitsinfusie (ILI) is voor laesies in het distale deel van de ex-
tremiteit, of de traditionele melphalan-ILP. TM-ILP heeft echter bewezen effectiever 
te zijn als het gaat om responspercentages. Doordat TNF toxisch is voor tumor-
vasculatuur is het aannemelijk dat juist de tumoren met een eigen vasculatuur het 
meest profiteren van de toevoeging van dit cytokine. Preklinische studies, meerdere 
single-center studies, onze eigen ervaringen met 100 TM-ILP procedures voor me-
lanoom en de interimanalyse van een gerandomiseerde trial 7, bevestigen alle deze 
hypothese. Voor patiënten met uitgebreide melanoommetastasen in de extremiteit 
en voor patiënten die onvoldoende hebben gereageerd op eerdere ILP-behandeling, 
lijkt TM-ILP de meest effectieve therapie om lokale controle te verkrijgen en om de 
extremiteit te behouden.
ILP MET TNF VOOR WEKE DELEN SARCOOM PATIËNTEN
Extremiteitsbehoud is een belangrijke doelstelling van de behandeling van lokaal 
uitgebreide weke delen sarcomen (WDS) van de ledematen, gezien het ruim aanwe-
zige bewijs dat extremiteitssparende chirurgie een even goede overleving oplevert 
als amputatie 8-10. Dit heeft de interesse in neoadjuvante behandelingsmogelijkheden 
vergroot, die in staat zijn om tumoren te doen slinken en daarmee functiebehou-
dende chirurgie mogelijk te maken. In tegenstelling tot de effectiviteit van melpha-
lanperfusies voor kleine in-transit metastasen van het melanoom, zijn de resultaten 
van ILP met melphalan, doxorubicine of willekeurig welk ander medicament zeer 
teleurstellend bij de behandeling van het WDS. De introductie van TNF in het ILP-
model maakte een eind aan deze situatie door in een eerste studie van vier lokaal 
uitgebreide WDS patiënten een indrukwekkende en snelle respons te laten zien 11. 
Multicentrische studies bevestigden dat ILP met TNF een zeer effectieve nieuwe 
methode van inductie biochemotherapie was voor het WDS van de extremiteit, met 
20-30% complete respons (CR) percentages, ~50% partiële respons (PR) percentages 
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en extremiteitsbehoud in ~80% van de patiënten 12, 13. Rotterdam was de initiatiefne-
mer van de eerste multicentrische studies naar de toepassing van TM-ILP voor het 
lokaal uitgebreide WDS.
 
In hoofdstuk 5 worden de 217 opeenvolgende TM-ILPs bij 197 patiënten met ex-
tremiteitsbedreigend WDS geanalyseerd die van 1991 tot 2003 in Rotterdam zijn 
uitgevoerd. In 61% van de patiënten werd de perfusie uitgevoerd voor een primair 
sarcoom, in 39% voor een recidief, in 29% voor multifocale primaire tumoren of mul-
tipele lokaalrecidieven, en in 16% voor stadium IV ziekte (met afstandsmetastasen). 
Tumoren groter dan 10 cm waren bij 42% van de patiënten aanwezig; de meeste 
tumoren waren hooggradig met 81% graad II en III tumoren. Bij 75% van de patiën-
ten kon een duidelijke respons op therapie worden bereikt (26% complete respons, 
49% partiële respons). In 87% kon de extremiteit worden behouden. Hoewel op 
theoretische gronden van hooggradige tumoren verwacht mag worden dat ze beter 
responderen op perfusie omdat ze over het algemeen beter gevasculariseerd zijn, 
kon dit niet door deze studie worden bevestigd. Slechts ILPs voor Stewart-Treves 
lymfangiosarcomen en Kaposi sarcomen waren gerelateerd aan significant betere 
responspercentages. Gedurende een mediane follow-up van 22 maanden (0.1-130+ 
maanden) was de berekende totale 5-jaars overleving 49% met een mediane overle-
vingsduur van 57 maanden. De Trojani gradering van de tumor en de aanwezigheid 
van multipele tumoren bleken negatieve prognostische factoren voor overleving. De 
uitstekende resultaten van TM-ILP voor het lokaal uitgebreide WDS van de extremi-
teit maakt dat deze behandeling zich een permanente plaats heeft verworven in de 
behandeling van deze tumor.
STUDIES BIJ APARTE PATIËNTENCATEGORIEËN
Patiënten met multipele tumoren in de extremiteit
ILP met TNF is het ideale alternatief om amputatie te voorkomen bij patiënten met 
moeilijk behandelbare multifocale primaire tumoren zoals het Kaposi sarcoom 14 en 
multipele lymfangiosarcomen (beter bekend als het Stewart Treves Syndroom) 15. 
Hoofdstuk 6 beschrijft de ervaringen van onze groep bij WDS patiënten met multifo-
cale primaire tumoren met verschillende histologische kenmerken en met multipele 
recidieven na eerdere chirurgische interventies. De gerapporteerde resultaten zijn 
opmerkelijk goed bij deze groep van 64 patiënten met multipele tumoren, bij wie 
een responspercentage werd gezien van 77% en een percentage extremiteitsbehoud 
werd bereikt van 82%. Deze resultaten laten zien dat ILP met TNF een zeer effectieve 
therapie is om amputatie te voorkomen bij deze patiëntenpopulatie. 
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Patiënten met recidief tumoren in bestraald gebied
Wij voerden 30 perfusies uit bij 26 patiënten met recidief tumoren in het bestralings-
veld, zoals gepresenteerd in hoofdstuk 7. In tegenstelling tot de veronderstelling 
dat deze tumoren nauwelijks zouden reageren, vonden wij een responspercentage 
van 70% en een percentage extremiteitsbehoud van 65%. Dit laat zien dat voor 
deze zeer gecompliceerde patiëntencategorie een ILP met TNF een aantrekkelijke 
behandelingsmogelijkheid is. 
Patiënten met Desmoïd Tumoren
Patiënten met desmoïd tumoren en agressieve fibromatose presenteren zich vaak 
met recidieven van de ziekte, die moeizaam te behandelen zijn door middel van chi-
rurgie met of zonder radiotherapie. In hoofdstuk 8 zag onze groep totale respons-
percentages van 75% en 100% extremiteitsbehoud in de groep van twaalf patiënten 
met deze aandoening. Dit demonstreert de bruikbaarheid van de ILP procedure om 
lokale controle te verkrijgen over deze tumoren. 
De verkregen resultaten in Rotterdam met TM-ILP voor het WDS, zowel in de totale 
populatie als bij patiënten met specifieke problemen zoals multifocaliteit, vooraf-
gaande radiotherapie en recidieven van desmoïd tumoren, worden vergeleken met 
de resultaten uit de literatuur in hoofdstuk 9. Omdat TNF-α aangrijpt op tumor 
vasculatuur, is het gebruik van TNF aantrekkelijk en verklaart het de effectiviteit in 
combinatie met chemotherapie voor al deze verschillende histologische subtypen. 
Geen andere neo-adjuvante therapie voor het WDS is in staat de responspercentages 
van ILP te evenaren. Dit leidt tot de conclusie dat TM-ILP als standaard therapie zou 
moeten worden beschouwd bij elke patiënt met lokaal uitgebreid WDS bij wie een 
amputatie, of een resectie met aanzienlijk functieverlies, als enige chirurgische optie 
wordt gezien.
ALGEMENE VRAGEN IN GEÏSOLEERDE EXTREMITEITSPERFUSIE
Eén van de aspecten die veelvuldig is bestudeerd als deelaspect in algemene stu-
dies, is of hoge doses TNF-α (3-4 mg) noodzakelijk zijn of dat lage doses (1 mg) 
volstaan. Een vroege klinische studie door Hill et al. suggereerde dat lage doses 
TNF-α voldoende zouden zijn 16. Het feit dat het een studie betrof met kleine patiën-
tenaantallen, dat er gelijktijdig hoge dosis corticosteroïden werd toegediend en dat 
een variant type TNF-α werd gebruikt, maakt dat hier geen definitieve conclusies 
uit getrokken konden worden. Bevestigende berichten kwamen echter uit Italiaanse 
studies waarbij 1 mg TNF-α werd gebruikt in combinatie met doxorubicine17, en de 
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Franse gerandomiseerde fase II studie bij 100 patiënten met vier verschillende doses 
TNF-α (0.5, 1.0, 2.0 and 4.0 mg) 18. Hoofdstuk 10 beschrijft onze analyse van 240 
ILPs waarbij de dosis TNF varieerde tussen 1.0, 2.0, 3.0 en 4.0 mg. Een reductie van 
de TNF dosis tot 1 mg is niet gecorreleerd met een slechtere respons op perfusie, 
maar is ook niet van invloed op toxiciteit. Dit is consistent met onze bevindingen uit 
het laboratorium die aangeven dat een TNF-α dosis van 1 mg voldoende is, maar dat 
verdere reductie leidt tot een compleet verlies van effectiviteit 19.
Bij patiënten met gemetastaseerde ziekte en een extremiteitsbedreigende tumor zou 
een palliatieve ILP met TNF lokale tumorcontrole kunnen induceren en daarmee 
amputatie kunnen voorkomen. In hoofdstuk 11 worden de resultaten van 51 ILP 
procedures gepresenteerd die werden uitgevoerd bij patiënten met stadium IV ziek-
te. Daadwerkelijke lokale controle kon worden verkregen bij 33/37 WDS patiënten 
en 11/14 melanoompatiënten, en in de overige gevallen werd een initiële respons 
gezien bij voortgaande progressie van de gemetastaseerde ziekte. Het bleek slechts 
voor één patiënt noodzakelijk om een amputatie uit te voeren. Hoewel deze ampu-
tatie wegens toxiciteit van de behandeling moest worden verricht, was de algemene 
toxiciteit van de 51 procedures zeer gering, zowel lokaal als systemisch. Dit toont dat 
ILP met TNF een zeer aantrekkelijke optie is voor de behandeling van deze patiënten 
met een korte levensverwachting.
CONCLUSIES EN VERWACHTINGEN VOOR DE TOEKOMST
De ILP methode verschaft ons een uitstekende mogelijkheid in de kliniek om lokale 
controle te verkrijgen en amputatie te voorkomen bij patiënten met extremiteitsbe-
dreigende tumoren. Dit is grotendeels bereikt door de toepassing van antivasculaire 
biochemotherapie op basis van TNF-α in deze procedure. ILPs met TNF-α worden 
momenteel in 35 kankercentra in Europa uitgevoerd. ILP met TNF-α is een zeer 
succesvolle en inmiddels gevestigde behandelingsmogelijkheid om amputaties te 
voorkomen en vertegenwoordigt een belangrijk voorbeeld van therapie gericht op 
modulatie van tumorvasculatuur. De behandeling zou in tertiaire, hoog-volume ver-
wijscentra aangeboden moeten worden. Op het terrein van de geïsoleerde perfusie 
wachten nieuwe vaso-actieve medicijnen op hun evaluatie tijdens preklinische on-
derzoeksprojecten en toekomstige klinische trials. 
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NAWOORD
‘The Rotterdam Experience’ is de ondertitel van dit proefschrift en is tegelijkertijd 
een term die de sfeer weergeeft waarin dit proefschrift tot stand gekomen is. Vanaf 
het moment dat ik via een email aan Hans de Wilt solliciteerde naar een keuze 
co-assistentschap in de Daniel den Hoed Kliniek en deze mail binnen tien minuten 
positief werd beantwoord, zijn de gedrevenheid en het enthousiasme van het team 
chirurgische oncologie een buitengewone stimulans geweest. Niet alleen voor het 
schrijven van dit proefschrift, maar ook voor het uitoefenen van mijn werk als chirurg 
in opleiding. De energie en werklust van mijn promotor, professor Lex Eggermont, 
is inmiddels legendarisch en ligt ten grondslag aan alle artikelen die dit proefschrift 
vormen. Mijn co-promotor, Hans de Wilt, is met hetzelfde virus besmet en heeft 
de afgelopen jaren zowel op wetenschappelijk als op klinisch terrein op mij een 
bijzondere invloed gehad. Ook Bert van Geel en Kees Verhoef, co-auteurs van dit 
proefschrift, Marian Menke en alle fellows in de Daniel den Hoed Kliniek dragen bij 
aan de stimulerende omgeving. De statistische bewerkingen in dit proefschrift zijn 
gedaan door Wilfried Graveland, volledig in de Rotterdamse traditie: snel, accuraat 
en vrijwel altijd beschikbaar. Deze termen gaan zeker ook op voor het secretariaat 
chirurgische oncologie, met name Marja van Wijngaarden, Marinka Eijsberg en Nelly 
Haazebroek. Kortom: ‘The Rotterdam Experience’ staat voor enthousiasme en daad-
kracht. Het is een voorrecht om daar deel van uit te maken.
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